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 Inpatient gout flare is a common problem which could lead to longer length of 
hospital stay and higher hospital cost. However, factors associated with inpatient gout 
flare are not well understood. 
Objectives 
 This thesis has three objectives: (1) to identify the predictors of inpatient gout 
flare in people with comorbid gout, (2) to explore the relationship between the 
predictors of inpatient gout flare and the length of hospital stay, and (3) to develop and 
validate a clinical tool to identify people who are at high risk of developing gout flare 
during hospital stay. 
Methods 
 Three studies were conducted to address each of the objectives. The first study 
collected data from a retrospective cohort of people with comorbid gout admitted to 
three hospitals in the Wellington region in 2017. Fifty-two candidate variables were 
explored, with inpatient gout flare (yes/no) as the dependent variables. A prediction 
model was built using clinical knowledge-guided variable selection followed by logistic 
regression with shrinkage. The second study used data from a population-based cohort 
of people with comorbid gout admitted to New Zealand public hospitals in 2017. The 
association between 19 gout flare-related variables and the length of hospital stay was 
explored using a generalized linear model. In the third and final study, a prediction rule 
for inpatient gout flare was developed from the set of predictors identified in the first 
study. The prediction rule was then validated in an independent cohort of hospitalized 
people with comorbid gout (validation cohort) prospectively recruited from a hospital 
in Thailand. 
Results  
The first study (N =625) identified nine predictors of inpatient gout flare: (1) 
pre-admission serum urate >0.36 mmol/L, (2) tophus, (3) no pre-admission urate-
lowering therapy (ULT), (4) no pre-admission gout prophylaxis, (5) ULT adjustment, 
(6) gout prophylaxis started/increased, (7) diuretic adjustment, (8) acute kidney injury 
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and (9) surgery. In the second study (N =36,047), regular pre-admission ULT and urate 
testing were found to be associated with a shorter length of hospital stay. Loop 
diuretics, potassium-sparing diuretics and surgery were found to be associated with a 
longer length of hospital stay. People with multiple factors associated with longer 
length of stay were estimated to add at least four days to their hospital stay. In the third 
study, a prediction rule for inpatient gout flare was developed, containing four items; 
(1) no pre-admission GOut prophylaxis, (2) no pre-admission ULT, (3) Tophus and (4) 
pre-admission serum urate >0.36 mmol/L (the GOUT-36 rule). The presence of two or 
more items indicates that the person is at high risk of developing gout flare during 
hospital stay. In the validation cohort (N =184), the GOUT-36 rule has a sensitivity of 
0.74, specificity of 0.69 and AUC of 0.71. 
Conclusion 
 The thesis identified nine predictors of inpatient gout flare, as well as the 
association between some of the predictors and the length of hospital stay. The GOUT-
36 prediction rule for inpatient gout flare was sensitive, intuitive and user-friendly. All 
four items in the GOUT-36 rule are assessable on the first day of admission, allowing a 
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Chapter 1 Introduction 
1.1 Background: a clinician’s perspective 
From 2015 to 2017, I practiced as a clinician in the field of rheumatology based 
in a public teaching hospital in Thailand. My clinical work involved both outpatient and 
inpatient care for individuals with joint and autoimmune conditions. Since gout is one 
of the most common inflammatory arthritides, I had the opportunity to treat many 
people with gout. Though not inherently life-threatening, I saw that gout had significant 
negative impact to the livelihood and work productivity of my patients. Despite 
advances in the treatment of gout making it possible to gain good control of the disease, 
the real-world clinical experience had shown me that gout was still perceived as a less 
important problem by both clinicians and patients. Its initial intermittent nature could 
be deceptive as this created the illusion that gout would go away on its own and that it 
was not worth committing to long-term treatment. Gout also typically coexisted with 
other medical conditions, such as cardiovascular diseases, kidney diseases and 
metabolic disorders, making it less likely that gout would get the attention it deserved. 
As a result, many people with gout were not properly diagnosed, treated and monitored.  
Hospitalized people with gout, in particular, did not gain much attention from 
either clinicians or researchers. There was a dearth of studies looking into this 
population, despite the fact that they were a vulnerable group and sometimes difficult to 
manage. Recognition and confirmation of gout flare were often delayed as pain and 
signs of inflammation could easily be confused with other coexisting conditions. 
Inpatient gout flare must also be differentiated from other hospital acquired 
complications, leading to extensive and sometimes invasive investigations. Clinicians 
also faced further challenges after gout flare had been diagnosed, as many therapeutic 
options might be contraindicated. All these challenges could result in delayed hospital 
discharge, over investigations, more medications and, most importantly, greater 
suffering for the patients.  
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Clinicians had been dealing with inpatient gout flare in a passive manner. It 
could be said that we mostly neglected gout, treating it as a minor comorbid disease 
until it caused trouble in the hospital. By that time, it was too late. The most logical 
solution to this problem was to prevent gout flare during a hospital course. But that 
would not be possible unless we understand what factors contribute to inpatient gout 
flare and who may be at high risk. Most of the existing studies and guidelines on gout 
were conducted among outpatient gout populations, so they overlooked the unique 
challenges that hospitalized people, and attending doctors had to face.  
In this research, I will look for the predictors of inpatient gout flare and explore 
their relationships with a hospital outcome (length of hospital stays). Then, I will 
develop a simple clinical tool to help clinicians identify people at high risk of 
developing inpatient gout flare. Once we know which persons are at high risk, we 
might be able to take appropriate actions to prevent or at least to minimize the burden 
of inpatient gout flare. 
1.2 Rationale 
Gout is the most common inflammatory joint disease, with especially high 
prevalence among Māori and Pacific people. Gout has negative impact on quality of 
life, work productivity and healthcare cost. Observational studies suggested that people 
with comorbid gout were hospitalized more frequently and were more likely to 
experience gout flare during hospital stay. Factors associated with the risk of inpatient 
gout flare have not been evaluated in a large controlled study of hospitalized people 
with comorbid gout.(1) There is also no standard tool to assess the risk of inpatient gout 
flare, nor how to prevent it. 
This thesis will identify predictors of inpatient gout flare, using a population of 
hospitalized people with comorbid gout. I will then examine the relationships of these 
predictors to a hospital outcome (length of stay) using data from national data 
collections. Finally, I will develop a clinical tool to help clinicians and health 
professionals identify the people who are at high risk of developing inpatient gout flare. 
Such knowledge could potentially influence how clinicians assess and manage people 
with comorbid gout in the hospital setting. It could also lead to further research on 
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preventive intervention in certain high risk inpatient populations, which might 
subsequently result in better hospital outcomes. 
1.3 Overarching aim 
The overarching aim of the thesis is to develop a clinical tool to identify people 
at high risk of developing inpatient gout flare. The clinical tool should be simple, 
sensible and sufficiently accurate.  
1.4 Thesis structure 
The thesis is divided into five sections: literature review (Chapter 2), the first 
study looking for predictors of inpatient gout flare (Chapter 3), the second study 
exploring the association between the predictors of inpatient gout flare and the length of 
hospital stay (Chapter 4), the third study developing and validating a clinical tool for 
the prediction of inpatient gout flare (Chapter 5), and the concluding chapter (Chapter 
6). The literature review describes knowledge of gout and gout flare with a focus on 
inpatient gout flare. Each of the three studies’ chapters contains rationale, objectives, 
methodology, results and discussion. The final chapter brings all the thesis sections 





Chapter 2 Literature review 
2.1 Gout 
2.1.1 Introduction 
Gout is the most common inflammatory arthritis in men and it affects 1 to 4% of 
the general population in high income countries.(2) Increase in gout prevalence and 
incidence have consistently been shown over recent decades, according to reports from 
the United Kingdom,(3) United States,(4) Canada,(5) and the Nordic countries.(6) Gout 
negatively impacts the patients’ health-related quality of life, work productivity and 
mortality.(7, 8) Gout also leads to very large economic burden and healthcare resource 
utilization.(9) People with comorbid gout were admitted to hospital more frequently 
compared to people without gout(10) and were four times more likely to experience 
gout flare during their hospital stay,(11) leading to poor hospital outcomes. 
The characteristic pathology of gout is the progressive deposition of 
monosodium urate (MSU) crystals in the joints and surrounding tissues as a 
consequence of long-standing hyperuricemia.(12) Acute clinical manifestations of gout 
result from an inflammatory response to the presence of MSU crystals, while chronic 
features including tophi, chronic arthropathy and bone erosion are the consequences of 
high crystal burden.(13) The primary goal of gout treatment is the dissolution of MSU 
crystal by long term maintenance of serum urate level below its saturation point. Sub-
saturation serum urate concentration can also lead to reduction of tophus and 
elimination of future gout flares.(14) In the past decade, advances have been made on 
the understanding of gout pathogenesis, disease burden, diagnostic assessments, urate-
lowering treatment and outcome measures. 
Despite the increasing prevalence of gout and the burden of gout hospitalization 
in New Zealand, as well as other countries,(15-17) little research has been done 
regarding gout among people hospitalized for other reasons. The inpatient setting is 
fundamentally different from outpatient care, where most gout trials are based, making 
it difficult to rely on the existing body of literature for management of inpatient gout. 
6 
 
Gout flares are a significant concern as these events are common and usually lead to a 
more complicated hospital course. Few studies have examined the factors associated 
with inpatient gout flare in people with comorbid gout. Identification of factors 
associated with inpatient gout flare would be beneficial for the patients’ risk 
stratification and potentially for preventive intervention. 
2.1.2 Pathophysiology 
2.1.2.1 Hyperuricemia 
The definition of hyperuricemia depends on the context. The definitions used in 
epidemiological studies range from 0.42 to 0.46 mmol/L in men and 0.34 to 0.39 
mmol/L in women. The statistical definition based on serum urate concentration higher 
than two standard deviation (SD) above the population mean level varies between 
different populations.(18) Based on physiochemical properties of sodium urate, the in 
vitro limit of solubility at physiological pH and temperature is 0.40 mmol/L. However, 
the saturation point is 0.36 mmol/L at 35⁰C, which could explain the propensity of gout 
to occur at cold peripheral locations like the toes.(19) In a routine clinical setting where 
patient cooperation is paramount, a therapeutic threshold of 0.36 mmol/L, as 
recommended by most guidelines, maybe most practical.(20, 21) 
Serum urate level is the function of uric acid production (endogenous purine 
metabolism and dietary intake) and uric acid elimination. Uric acid is a weak acid that 
mainly exists as urate in physiological pH. Purine metabolism consists of de novo and 
salvage pathway, with the final steps relying on xanthine oxidase enzyme to generate 
urate from hypoxanthine and xanthine.(22) With the absence of uricase enzyme in 
humans, uric acid is excreted as urate rather than as allantoin. Two thirds of urate is 
eliminated by the kidneys through a series of reabsorption and secretion processes 
along the proximal tubules, which results in approximately 10% of urate filtered 
through glomeruli being excreted. These events are facilitated by multiple reabsorptive 
transporters such as urate anion transporter 1 (URAT-1) and glucose transporter 9 
(GLUT-9), and secretory transporters including organic anion transporters (OAT1, 
OAT2, OAT3), ATP-binding cassette subfamily G member 2 (ABCG2) and multidrug 
resistance protein 4 (MRP4). The remaining one third of urate is eliminated by the 
gastrointestinal tract.(22) The majority of hyperuricemia is caused by renal 
underexcretion.(23) Nevertheless, hyperuricemia can also result from extra-renal 
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underexcretion of urate, overproduction from hepatic metabolism or increased cell 
turnover conditions or a combination of mechanisms.(24) 
2.1.2.2 Crystal formation and deposition 
Only 25% of people with hyperuricemia have ultrasonographic evidence of 
MSU crystal deposition in the first metatarsophalangeal (MTP) joint,(25) suggesting 
hyperuricaemia and additional factors are required for MSU crystal deposition.  MSU 
crystal formation requires three steps: decreased solubility, crystal nucleation and 
crystal growth.(26) Multiple factors exert influence on these steps: urate concentration, 
other ion concentrations, temperature, pH, mechanical stress, serum and synovial fluid 
factors.(26, 27) Structural factors could also facilitate crystal formation. A study of 
tissues found that the fiber organization at tendon insertion and cartilage may act as 
template for crystal deposition and further growth.(28)  
2.1.2.3 Tophus and joint damage 
Tophus is an organized chronic granulomatous inflammatory response to MSU 
crystals, typically found during physical examination.(29) Tophi typically appear as 
chalky white nodules of variable size and shape, including irregular, nodular, plaque-
like, cauliflower, fungiform, exophytic and multilobular appearance. The consistency of 
tophus range from firm to gelatinous.(30) Tophi are comprised of a packed MSU 
crystal core surrounded by a cellular layer consisting mostly of macrophages and 
plasma cells (corona zone) and the outermost fibrovascular zone. Both pro-
inflammatory and anti-inflammatory cytokines are found in the tophus, suggesting 
cycles of chronic inflammation and attempted resolution.(31) Neutrophil extracellular 
traps (NETs) have been shown to be integral in tophus formation.(29) MSU crystals 
have the ability to induce formation and aggregation of NETs by granulocytes, 
especially neutrophils.(32) These aggregated NETs can degrade pro-inflammatory 
factors and suppress neutrophil recruitment. Furthermore, NET-like features were 
found in tophi supporting their roles in tophus formation.(32, 33) The presence of MSU 
crystals alters bone remodeling, leading to net results of osteoclastic bone resorption 
and reduced osteoblast activities.(34) A dual-energy computed tomography (DECT) 
study of people with tophaceous gout found MSU crystal deposition within bone 
erosion only when there were also cortical breaks, confirming that bone erosion 
occurred by an outside-in manner.(35) 
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2.1.3 Risk factors for incident gout 
Hyperuricemia has been established as the key risk factor for the development 
of gout in a time- and concentration-dependent manner, with strongest association 
observed in men.(36-39) In a recent analysis of 18,889 participants from four large 
published cohorts, the 15-year cumulative incidence (95% confidence interval [CI]) 
ranged from 1% (0.9 to 1.4) for serum urate <0.36 mmol/L to 49% (30.5 to 66.6) for 
serum urate ≥0.60 mmol/L. The adjusted hazard ratio (HR) (95%CI) compared to 
serum urate <0.36 mmol/L ranged from 2.7 (2.0 to 3.6) for serum urate between 0.36 
and 0.41 mmol/L to 64.0 (42.5 to 96.2) for serum urate ≥0.60 mmol/L.(40) Most other 
factors that have been associated with incident gout also contribute to the rise of serum 
urate level. These factors can be simply categorized into non-modifiable and modifiable 
factors. 
2.1.3.1 Non-modifiable factors 
Men have a higher prevalence of gout. Though hyperuricemia increases the 
incidence and risk of gout in both genders, the effect is smaller in women compared to 
men with similar serum urate level.(36, 39) Women also develop gout later than men, 
with mean age of gout onset 9.7 years greater in female compared to male patients in 
one study.(41) This could be explained by the uricosuric effects of oestrogen, which 
reduce the risk of hyperuricemia and gout in women of pre-menopausal age.(42) 
Prevalence of gout and hyperuricemia is positively associated with increasing age. A 
study of administrative claims found an overall increase of prevalence by 2 cases per 
1,000 individuals per year over a period of 10 years, with the >75 years age group 
showing greatest increase from 21 per 1,000 individuals in 1990 to 41 per 1,000 in 
1999.(43) This study also found that men had greater gout burden in every time point of 
the study period. Difference in the prevalence of gout among various ethnic groups has 
also been described.(44-46) The most relevant example is the high prevalence of gout 
among Māori and Pacific people in New Zealand compared to those of European 
descent.(47)  
Genome-wide association studies (GWAS) have identified several genetic 
variations associated with hyperuricemia and gout, most of which involve renal 
handling of urate. The most prominent genes are SLC2A9, ABCG2 and 
SLC22A12.(48) SLC2A9 encodes GLUT-9 which plays an important role in 
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reabsorption of urate from renal proximal tubules.(49) Its effect on variance of serum 
urate level is more pronounced in women compared to men (6% vs. 1%).(50) ABCG2 
encodes ABCG2 transporter, a transporter that mediates urate secretion on the apical 
membrane of the proximal tubules. ABCG2 has stronger effect in men (51) and may 
also be associated with tophaceous gout.(52) SLC22A12 encodes URAT-1 which 
regulates tubular reabsorption of urate.(53) Nevertheless, these genetic variations 
collectively account for approximately 6% variance in serum urate level, implying the 
complex nature of gout and the impact of environmental factors(48)  
2.1.3.2 Modifiable factors 
Alcohol consumption increases serum urate concentration through multiple 
mechanisms: decreased renal urate excretion,(54) increased adenosine triphosphate 
(ATP) turnover leading to urate production(55, 56) and purine loading with 
consumption of beer.(57) Serum urate level increases with larger amounts of alcohol 
intake.(58) The link between alcohol intake and incident gout has been established, 
with multivariate relative risk (RR) and 95%CI ranging from 1.3 (0.99 to 1.75) for 
alcohol intake 10.0 to 14.9 g/day to 2.5 (1.73 to 3.70) for ≥50 g/day. Beer consumption 
conferred the greatest RR among different types of alcoholic drinks.(59)  
Fructose increases ATP degradation to adenosine monophosphate (AMP) and 
subsequently uric acid. In addition, fructose phosphorylation depletes phosphate, limits 
regeneration of ATP from adenosine diphosphate (ADP), which in turn becomes 
substrate for uric acid production.(60) Consumption of fructose-rich beverages (sugar-
sweetened soft drinks or soda and orange juice) increases the risk of incident gout in a 
dose-dependent manner in both men and women in two large prospective cohort 
studies.(61, 62) Major sources of fructose include foods containing corn syrup, maple 
syrup, honey and table sugar (as part of disaccharide sucrose). Among the purine-rich 
foods, red meat and seafood have shown associations to the risk of incident gout, with 
the multivariate RR (95%CI) for men in the highest quintile of intake of 1.4 (1.07 to 
1.86) and 1.5 (1.17 to 1.95), respectively.(63) 
Greater body mass index (BMI) is associated with the risk of incident gout.(64) 
In the Health Professional Follow-up Study, which had 12 years of follow up, the 
multivariate RR of incident gout increased with BMI. Men who had gained 30 lb. (13.6 
kg) or more since age 21 years had RR (95%CI) of 1.9 (1.49 to 2.66), compared to 
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those who had maintained their weight.(65)  Other comorbid diseases that have been 
linked to incident gout are chronic kidney disease,(66) psoriasis and psoriatic 
arthritis.(67) Loop and thiazide diuretics have been linked to incident gout, with the use 
in combination having the highest odds ratio (OR) (95%CI) of 4.7 (3.51 to 6.16).(68) 
Other medications known to increase the risk of gout include beta blockers, angiotensin 
converting enzyme inhibitors, non-losartan angiotensin II receptor blockers and 
cyclosporine.(69, 70) 
2.1.4 Clinical manifestations 
The clinical stages of gout can be divided into asymptomatic phase, consisting 
of asymptomatic hyperuricemia and hyperuricemia with crystal deposition, and 
symptomatic phase which includes periods of intermittent episodes of gout flare and 
advanced gout.(71) 
2.1.4.1 Asymptomatic hyperuricemia and crystal deposition 
Prolonged asymptomatic hyperuricemia typically precedes clinical gout for 
decades. Positive correlation between serum urate level and the likelihood of 
developing gout has long been established.(37) Using pooled data from multiple 
cohorts, the 15-year cumulative incidence of gout among those with serum urate level 
≥0.60 mmol/L was 49%.(40) With the adoption of ultrasonography (US) and DECT for 
joint assessment, a number of studies have demonstrated the presence of intra-articular 
monosodium urate crystals, tophus, subclinical synovitis and bony erosion in people 
with asymptomatic hyperuricemia.(25, 72-74) This emphasizes the natural history of 
gout as a chronic progressive disease that occurs long before the first clinically evident 
arthritic episode.  
2.1.4.2 Episodes of acute inflammation 
Acute inflammatory episodes or flares are the clinical hallmark that usually 
bring patients to medical attention. The affected joint typically becomes swollen, warm 
and extremely painful so that the person can no longer tolerate weight bearing or 
function in usual roles. Some people experience a tingling sensation or mild discomfort 
of the joint (aura) that precedes the arthritis episode. Redness of the overlying skin is 
common and may extend beyond joint line, making it difficult to differentiate from 
cellulitis. Typical sites of gout flares include the first MTP joint (also known as 
podagra), followed by midfoot, ankle and knee.(75) Podagra is the most common first 
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presentation, with prevalence of 54 to 74% of patients.(76, 77) While the estimated 
prevalence of first MTP arthritis at any point during disease course was 73%.(78) Joints 
of the upper extremities and axial joints can also be affected, more frequently in people 
with advanced gout. Although debilitating oligoarticular or polyarticular attacks may 
occur in advanced cases, gout flares usually affect a single joint. Maximum 
inflammation is often reached within 24 hours and resolved completely within two 
weeks, regardless of medical treatment. As the disease advances, the symptom-free 
interval between inflammatory episodes (intercritical period) becomes shorter. 
Systemic manifestation such as fever and malaise may occur especially in polyarticular 
attacks. Episodes of acute inflammation can also affect other synovial lined structures 
with MSU crystal deposition including bursae and tendons.(13)  
2.1.4.3 Advanced gouty arthritis 
Without optimal control of serum urate level, the patient may progress to 
advanced gout. This stage usually occurs after 3 to 40 years (mean duration of 12 years) 
after first episode of acute arthritis.(79) Advanced gout is characterized by several 
persistent manifestations; palpable tophi, chronic arthritis, joint limitation and, in 
extreme cases, deforming arthropathy.(13) On examination, tophi are usually firm in 
consistency and painless. Ulceration and exposure of chalk-like material may occur. 
Common locations are peripheral areas and areas exposed to friction including fingers, 
toes, auricular helix, medial and lateral malleolus and olecranon bursa.(80) Urate 
deposition in and around the joints may result in limited joint mobility. Persistent joint 
swelling is the result of chronic granulomatous inflammation of synovial membrane. 
Advanced imaging studies such as ultrasonography can raise the sensitivity in detection 
of subclinical synovitis and tophi not captured by physical examination. A high burden 
of tophi and urate deposition can also lead to bony erosion and joint deformity. 
2.1.4.4 Comorbidities 
Gout often coexists with other conditions which further complicate the overall 
management and prognosis. An estimated prevalence of comorbid diseases in people 
with gout based on the US National Health and Nutrition Examination Survey 
(NHANES) 2007-2008 showed hypertension as the most common comorbidity (74%), 
followed by chronic kidney disease (CKD) stage ≥2 (71%), obesity (53%), diabetes 
mellitus (26%), nephrolithiasis (24%), myocardial infarction (14%), heart failure (11%) 
and stroke (10%). The prevalence of comorbidities tended to be higher in those who 
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had higher serum urate level.(81) People are also at higher risk of developing new 
comorbidities after gout diagnosis, compared to controls, especially cardiovascular 
diseases, kidney diseases, diabetes mellitus and hyperlipidemia.(82) A large 
prospective study demonstrated high all-cause mortality among men with gout, 
primarily due to coronary heart disease.(83) High serum urate level and presence of 
subcutaneous tophi, representing poorly controlled advanced gout, have been linked to 
increased risk of mortality.(8) On the other hand, as urate has a neuroprotective 
antioxidant properties, people with comorbid gout may have lower risk of Parkinson’s 
disease, Alzheimer’s disease and other neurodegenerative disorders.(84, 85) 
2.1.5 Diagnosis 
Identification of MSU crystals in the synovial fluid or tissue aspirates under 
compensated polarized microscopy is the gold standard for gout diagnosis. Joint 
aspiration is safe and thus should be performed in all patients presenting with acute 
arthritis suspected of gout if not otherwise contraindicated.(86) MSU crystals appears 
as needle-shaped, 2 to 20 µm long, negatively birefringent crystals which can be 
intracellular or extracellular.(87) Synovial fluid is typically turbid, yellow and low in 
viscosity with abundant neutrophils which could exceed 50,000 cells/mm3.(88)  
During gout flare, serum urate level alone is not reliable as a tool of gout 
diagnosis. In a study of 339 people with comorbid gout, over 14% had serum urate 
level ≤0.36 mmol/L and 32% had serum urate level ≤0.48 mmol/L during gout 
attacks.(89) Acute phase responses, including leukocytosis, elevated erythrocyte 
sedimentation rate (ESR) and elevated C-reactive protein (CRP), are common but not 
specific to gout.(90) Specific radiological findings of gout in conventional radiography, 
namely punched-out bony erosion and overhanging edge, are only found in advanced 
disease. Ultrasonography can assist gout diagnosis by demonstrating urate deposition 
on the articular cartilage (double-contour sign), tophus and crystals aggregates in 
synovial fluid (snowstorm appearance).(91, 92) DECT is highly sensitive in the 
detection of urate deposition in and around the joint.(93) However, these imaging 
studies should be interpreted in conjunction with clinical manifestations, as abnormal 




When joint aspiration and crystal identification are not feasible, clinicians may 
use clinical clues from existing classification criteria to support their clinical diagnosis of gout. 
The most recent criteria by the American College of Rheumatology (ACR) and 
European League Against Rheumatism (EULAR) incorporates clinical, laboratory and 
radiological data for the primary purpose of clinical trials recruitment (Table 2-1).(94) 
The criteria has been shown to perform well in researches based in both primary care 
and tertiary care settings.(95, 96) 
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Table 2-1 American College of Rheumatology/European League Against 
Rheumatism (ACR/EULAR) Gout Classification Criteria(94) 
Entry criterion At least 1 episode of swelling, pain, or 
tenderness in a peripheral joint or bursa 
Sufficient criterion Presence of MSU crystals in a 
symptomatic joint or bursa or tophus 
Classification 8 or more points or MSU crystal (+) 
Criteria  Categories (score) 
Pattern of joint involvement (as part of 
mono or oligoarthritis) 
Ankle or midfoot (1) 
MTP1 joint (2) 
Characteristics of the episode 
• Joint erythema 
• Can’t bear touch or pressure 
• Difficulty with walking or 
inability to use affected joint 
One characteristic (1) 
Two characteristics (2) 
Three characteristics (3) 
 
Time course of episode: presence of ≥2 
• Time to maximal pain < 24 hours 
• Resolution in ≤14 days 
• Complete resolution 
One typical episode (1) 
Recurrent typical episodes (2) 
Clinical evidence of tophus :  Present (4) 
Serum uric acid level <0.24 mmol/L (-4) 
0.36 to <0.48 mmol/L (2) 
0.48 to <0.60 mmol/L (3) 
≥0.60 mmol/L (4) 
Synovial fluid analysis  MSU crystal negative (-2) 
Imaging evidence of urate deposition 
or joint damage 
 
Ultrasonographic double-contour sign or 
DECT demonstrating urate deposition (4) 
Erosion and overhanging edge in 
conventional radiography of the hands 




2.1.6 Principles of management  
A combination of short- and long-term management strategies are essential to 
effectively control gout which is a chronic disease that typically displays remitting 
acute manifestations. Treat-to-target strategy using urate lowering therapy (ULT) is 
central to the management aiming for dissolution of MSU crystals, the main 
pathological component of gout.(14, 97) This principle is endorsed by most 
rheumatology associations including the ACR,(20, 98) EULAR(21) and Australia and 
New Zealand.(99) Other supplementary managements include treatment of flare, 
prophylaxis of gout flare, lifestyle modification and control of comorbid diseases. 
However, controversially the guidelines recently published by the American 
College of Physician (ACP) took a less intensive stance regarding the use of urate-
lowering medications. The ACP guidelines recommend using ULT to avoid recurrent 
gout flares rather than the treat-to-target strategy. Furthermore, the guidelines did not 
recommend any specific therapeutic serum urate threshold, treatment duration or urate 
monitoring strategy.(100)  
2.1.6.1 Treat-to-target urate-lowering therapy 
Long term maintenance of serum urate level <0.36 mmol/L, a concentration 
below saturation threshold of urate, leads to dissolution of MSU crystals and reduction 
of tophi.(101, 102) Sub-saturation level of serum urate also suppresses the future 
recurrence of gout flares.(103, 104) Recent updated EULAR guidelines recommend a 
target of serum urate <0.36 mmol/L for all people with indication for use of ULT and 
<0.30 mmol/L for severe gout with high crystal burden (defined as having tophi, 
chronic arthropathy and frequent flares).(21) According to the EULAR 
recommendations, ULT should be initiated in people with gout who had frequent gout 
flares (two or more flares per year), tophus, urate arthropathy and/or renal stone. In 
addition, ULT should be considered in people presenting at ages younger than 40 years, 
or with serum urate level >0.48 mmol/L and/or comorbidities (renal impairment, 
hypertension, ischaemic heart disease, heart failure).(21) In comparison, the indications 
for ULT in the latest ACR guidelines are frequent flares (two or more flares per year), 
one or more tophi, and radiographic joint damage attributed to gout by any imaging 
modality.(98) Serum urate level should be regularly monitored, optimally every two to 
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five weeks, during titration of urate-lowering agent. Once the target level is achieved, 
serum urate should be monitored every six months.(20)  
Several urate-lowering agents are currently available (Table 2-2).(12) 
Allopurinol, a xanthine oxidase inhibitor, is the first line agent in most 
recommendations and guidelines due to its efficacy, availability and cost efficiency.(20, 
21, 98, 99, 105) Allopurinol should be initiated at low dose (50 to 100 mg daily) and 
then slowly titrated until target serum urate is reached. Despite the belief that a urate-
lowering agent should be commenced a few weeks after gout flares, studies have shown 
that it can be initiated during gout flare as long as the flare episode is adequately 
treated.(106, 107) Febuxostat and uricosuric agents (probenecid and benzbromarone) 
are second line drugs to be considered when target serum urate level could not be 
achieved with appropriate dosage of allopurinol or when allopurinol is not tolerated. 
Combination of a xanthine oxidase inhibitor and uricosuric agent is recommended 
when target serum urate level is not reached using monotherapy at an appropriate 
dosage. Pegloticase is considered in people with debilitating advanced gout when all 
other options fail.(21) Recent randomized trials showed that an emerging uricosuric 
agent, lesinurad, combined with allopurinol was superior to allopurinol alone in 
reducing serum urate in individuals with inadequate response to standard-of-care 
allopurinol.(108, 109) Lesinurad is however no longer available in the market. 
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Table 2-2 FDA approved urate-lowering agents(12) 
Drugs  Mechanism  Dosage Cautions  
Allopurinol  Xanthine 
oxidase 
inhibitor 
50 to 800 
mg daily 






40 to 120 
mg daily 
Ischemic heart disease, heart 
failure, abnormal liver function 
Probenecid  Uricosuric 500 to 1000 
mg twice a 
day 
Kidney stone, blood dyscrasias, 
drug interaction (aspirin, 
methotrexate) 
Benzbromarone  Uricosuric  50 to 200 
mg daily 
Kidney stone, liver disease, drug 
interaction (warfarin, fluconazole, 
phenytoin, rifampicin) 
Pegloticase  Recombinant 
uricase 







2.1.6.2 Prophylaxis of flare 
It has been well established that introduction of urate lowering therapy increases 
the risk of gout flares for several months due to rapid change of serum urate 
concentration and crystal dissolution.(110-112) Currently, prophylaxis with low dose 
colchicine or non-steroidal anti-inflammatory drugs (NSAIDs) is recommended for the 
first three to six months of the treatment with urate-lowering agent.(21, 98, 113) Low 
dose prednisone (≤10 mg daily) may be considered in those with contraindication to 
colchicine and NSAIDs. Frequent evaluation of risk and benefit of prolonged 
corticosteroid use is encouraged as the risk of gout flare diminishes over time after 
starting urate-lowering agent.(113) 
2.1.6.3 Non-pharmacological management 
All people with comorbid gout should be screened and treated accordingly for 
the following common comorbidities and cardiovascular risk factors; renal impairment, 
coronary heart disease, heart failure, stroke, peripheral arterial disease, obesity, 
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hyperlipidemia, hypertension, diabetes and smoking.(21) Patient education on the 
nature of gout, goal and treatment strategy is essential to ensure long term adherence, 
especially when there is no apparent pain. A recent randomized trial of nurse-led gout 
management which prioritized patient education and patient engagement was found to 
be superior to the usual care over two years; 95% of people receiving nurse-led care 
achieved serum urate target of below 0.36 mmol/L, compared to only 30% in people 
who received usual care.(114) Lifestyle modification should be advised, especially 
weight loss, exercise, smoking cessation and limitation of diets known to increase risk 
of gout or gout flare: alcohol, high-purine diet and high-fructose corn syrup.(20, 98) 
2.1.7 Gout in New Zealand 
Compared to the prevalence of gout in adult population from most high income 
countries which ranged from 1 to 4%,(2) New Zealanders have a relatively high 
prevalence of gout, especially among Māori and Pacific people. According to an 
analysis of the national databases (Aotearoa New Zealand Health Tracker (ANZHT) 
and HealthStat), in which gout cases were identified by hospital discharge diagnosis 
coding or allopurinol and colchicine dispensing claims, the overall prevalence of gout 
in population ≥20 years of age was 4%. However, when analyzed by ethnicity, gout 
prevalence was 3% in European New Zealanders, 6% in Māori and 8% in Pacific 
people. The prevalence reached over 25% in Māori and Pacific men aged 65 years and 
older.(47) Among Māori adults, 11-year incidence rates of gout were reported at 10% 
in men and 4% in women.(115) The high prevalence of hyperuricemia and gout in 
Māori and Pacific people are believed to be the results of multiple factors, including  
genetic predisposition and life-style changes, especially exposure to diet high in purine 
and fructose.(116) In addition, prevalence of gout has been shown to be rising across 
ethnic groups. The prevalence of gout rose from 11% in 2012 to 14% in 2018 among 
Māori men, and rose from 6% in 2012 to 8% in 2018 among non-Māori/non-Pacific 
men.(117)  
Despite the high burden of gout, studies in New Zealand population have shown 
that current gout management remains suboptimal.(118) An analysis of the national 
health datasets revealed that 57% of people with gout received at least one dispensing 
of allopurinol and only 39% received allopurinol in at least three of four quarters in a 
year. Māori and Pacific people were less likely to have received regular allopurinol. 
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Only 34% of those who received at least one dispensing of allopurinol had serum urate 
level testing within six months following the dispensing.(119) Adherence to urate-
lowering medication is also suboptimal. A survey among 732 individuals who received 
at least one 90-day supply of allopurinol showed that 22% had suboptimal adherence 
(medication possession ratio [MPR] 0.88).(120) Gout management in New Zealand 
faces several physician and patient barriers, many of which revolve around perception 
of gout. A qualitative study among primary care physicians identified several potential 
barriers: perception of gout as an acute rather than chronic disease, time constraints for 
adequate patient education, physician’s emphasis on diet control which could lead to 
patients’ feeling of being stigmatized and cultural difference between physicians and 
patients.(121) A patient survey by Martini et al. demonstrated some misconception or 
suboptimal knowledge: 52% of people with gout knew ULT should be taken daily, 63% 
knew prednisone, diclofenac, and colchicine should be used during gout flares and 47% 
did not know if they had serum urate level regularly tested.(122)  
2.1.8 Gout in Wellington region 
Prevalence of gout and total population in Wellington region categorized by 
District Health Boards are shown in Table 2-3.(117) The first study in this thesis 
recruited people with comorbid gout from Wellington and Kenepuru hospitals (Capital 
& Coast District Health Board, CCDHB) and Hutt hospital (Hutt Valley District Health 
Board, HVDHB). The prevalence of hospitalization among people with comorbid gout 
has not been determined. However, when assuming that 18% of people with gout are 
hospitalized each year,(10) the estimated annual number of admissions with comorbid 
gout from CCDHB and HVDHB is 3,630 admissions.  










Estimated number of 
admissions with comorbid 
gout (per annum) 
Capital & Coast 4.1% 306,700 2,264 
Hutt Valley 5.2% 145,900 1,366 




2.2 Gout flare 
2.2.1 Mechanism of acute inflammation 
Gout flare is the result of a cascade of inflammatory response to MSU crystals. 
Activation of the innate immune system is the main mechanism of acute gout 
inflammation, with macrophages and neutrophils as key cellular components. 
Following the release or appearance of MSU crystals in the joint, resident macrophages 
act as the first responders via nucleotide-binding domain, leucine-rich-containing 
family, pyrin domain-containing-3 (NLRP3) inflammasome activation and thus begins 
the inflammatory cascade.(123) 
Activation of the inflammasome requires two signals; (1) the priming of cells 
and (2) the activation of inflammasome.(124) The priming of cells promotes expression 
of necessary components for inflammasome assembly and activation. This signal is 
mediated by surface receptors of the innate immune systems, especially toll-like 
receptor 2 and 4 (TLR2, TLR4), with possible support from complement C5a and 
granulocyte-macrophage colony-stimulating factor (GM-CSF). The second signal 
drives NLRP3 inflammasome assembly. Intracellular MSU crystals induce NLRP3 
inflammasome activation by causing alteration of intracellular ion balance, most 
prominently potassium efflux and calcium influx. The activation results in recruitment 
and oligomerization of caspase-1, which subsequently cleaves pro-interleukin-1β (pro-
IL-1β) and pro-IL-18 into their respective active forms, IL-1β and IL-18. A major 
inflammatory mediator in gout, IL-1β further causes release of matrix-degrading 
enzymes, vasodilation and neutrophils recruitment. 
After their encounter with MSU crystals, neutrophils further propagate 
inflammation by several mechanisms; release of chemoattractants resulting in further 
neutrophil accumulation and release of pro-inflammatory products namely reactive 
oxygen species (ROS), matrix metalloproteinases (MMPs), IL-1, IL-8, lysosomal 
enzymes and eicosanoids.(125) Conversely, neutrophils also play an important role in 
spontaneous resolution of inflammation in gout through the formation of NETs.(33) 
NETs formation occurs at high concentration of neutrophils and is dependent on the 
presence of ROS. Aggregated NETs trap and degrade proinflammatory cytokines and 
chemokines, leading to termination of inflammation. MSU crystals are also trapped by 
AggNETs and packed together with extra-cellular DNA (forming tophus), effectively 
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preventing the MSU crystals from further triggering inflammation.(126) Other anti-
inflammatory cytokines that promote the resolution of inflammation includes 
transforming growth factor β1 (TGFβ1), AMP-activated kinase (AMPK), IL-1 receptor 
antagonist (IL-1Ra) and IL-10.(127) 
2.2.2 Factors associated with gout flare 
Among people with gout, baseline serum urate level is associated with the risk 
of developing flare in a dose-dependent manner. A study using a medical claims 
database from the United States found that the hazard ratios (95%CI) over two years for 
the risk of gout flare compared to baseline serum urate of <0.30 mmol/L were: 1.7 
(1.46 to 1.97) for serum urate 0.36 to <0.40 mmol/L, 2.2 (1.87 to 2.50) for serum urate 
0.40 to <0.48 mmol/L, 2.9 (2.49 to 3.31) for serum urate 0.48 to <0.54 mmol/L and 3.9 
(3.35 to 4.42) for serum urate ≥0.54 mmol/L.(128) 
Sudden decreases in serum urate level lead to rapid MSU crystal dissolution and 
shedding into the joint. Exposure of resident macrophages to MSU crystals 
subsequently triggers an inflammatory response. The most well established example of 
this principle is the high rates of flares following initiation of ULT in people with 
gout.(129) Post-surgical status may trigger gout flares presumably through exposure to 
large volume of fluids, leading to transient decline in serum urate level,(130) or 
transient period of dietary restriction or dehydration.(131) Another possible trigger is 
consumption of whiskey, which has been shown to lower serum urate level by its 
uricosuric property(132, 133). Acute systemic inflammation has also been shown to 
lower serum urate level, though these data come from a study including participants 
who do not have gout.(134)  
It is unclear how rapid rise of serum urate level can trigger gout flare, as 
formation and growth of MSU crystals is a slow process.(135) However, several factors 
that could raise serum urate level have been associated with an increased risk of flare.  
In an online case-crossover study, recent exposure to diuretics increased the risk of gout 
flare, with OR and 95%CI of 3.6 (1.4 to 9.7).(136) An online survey of gout patients 
linked the use of low-dose aspirin to the risk of recurrent gout flare,(137) although 
evidence on the effect of low-dose aspirin on urate level remained conflicting.(138, 
139) Episodic alcohol intake, especially within 24 hours, can trigger gout flares through 
rise of serum urate from high purine content and hepatic breakdown of ATP.(140) The 
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risk of flare also increases at higher quantity of alcohol consumption.(141) Finally, 
consumption of purine from animal sources within the previous 48 hours was 
associated with the risk of developing gout flare, with the highest OR observed among 
those who consumed the highest quantity of purine-rich food (OR 4.8, 95% CI 3.37 to 
6.74).(142) 
2.2.3 Impact of gout flare 
Gout flare poses significant negative impact to the patients’ quality of life, daily 
activity and work productivity. In a survey using Medical Outcomes Short Form 12 
(SF-12) questionnaire among people with gout in the United States and Europe (France, 
Germany and the United Kingdom), having four or more flares in the past year was 
associated with decreased health-related quality of life (HRQOL) which encompassed 
mental and physical component summary score and SF-6D health utility.(143) . In this 
study, the physical component score for people with four or more flares in the past year 
was 37 points, compared to 43 points in people without flare (minimally important 
difference of 3 points). Similarly, the SF-6D utility values for people with at least four 
flares in the past year was 0.64, compared to 0.73 for people without flare (minimally 
important difference off 0.03).(143) The same study also found that people with gout 
who reported one or two flares in the past year had significant activity limitations 
compared to those without flare, as measured by Work Productivity and Activity 
Impairment (WPAI) questionnaire. The negative effect of flare frequency to people 
with gout’s quality of life and daily activity has been demonstrated by a number of 
studies conducted among different ethnic groups.(144-146). In a prospective study of 
working age people with chronic uncontrolled gout, the mean number of flares was 
eight times per year and the average work day loss was three days for each episode of 
flare. In addition, 52% and 54% of people with gout reported at least one flare per year 
that impaired self-care and social activity, respectively.(147)  
Having frequent gout flares contributes to higher healthcare expenditure. A 
study of administrative claims from the United States reported higher gout-specific 
healthcare costs among those having three or more annual flares, compared to those 
with less than three annual flares (889 vs 210 USD).(148) The economic burden has 
also been shown to increase with higher frequency of gout flare. In a study by Jackson 
et al., adjusted annual gout-related costs were 1,804 USD in people with gout who 
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reported one or no flare per year, 3,014 USD in people with two flares per year and 
4,363 USD in people with three or more flares per year.(149) Similar results were 
found in another study, with gout-related medical costs in people with gout who had six 
or more yearly flares of 12,046 USD, compared to 5,477 USD in those who had three 
or more yearly flares.(150) 
2.2.4 Management of gout flare 
After patient education and discussion, treatment for gout flares with anti-
inflammatory agents should be initiated as soon as possible. Drugs first considered for 
treatment of gout flares are NSAIDs, cyclooxygenase (COX)-2 inhibitors, colchicine, 
injected corticosteroids or systemic corticosteroids.(21) Monotherapy is usually an 
adequate strategy, although may result in inadequate response, which is defined as 
<20% improvement within 24 hours or <50% after 24 hours. In such case, switching to 
or adding another medication is encouraged. Initial combination of agents may be 
considered in severe flares, defined as patient reported pain score of 7 or more, multiple 
large joint involvement or having polyarthritis.(113) 
Besides the efficacy of medication in suppressing inflammation, safety issues 
are also a major challenge. Older people with gout tend to have multiple comorbidities 
and can be frail. As a result, choice of medication is not only based on the severity, but 
is also dictated by each person’s existing contraindications.(21, 113) Of note, the 
prevalence of contraindications to gout medications among people with comorbid gout 
have been estimated to be very high in a large cohort which included both inpatient and 
outpatient subjects; >90% for NSAIDs and glucocorticoids, and >50% for 
colchicine.(151)  
2.3 Inpatient Gout 
2.3.1 Epidemiology of inpatient gout 
Currently, there are limited data available for the true prevalence of hospital 
admission and inpatient gout flare in people with comorbid gout. A survey among 
United States veterans, albeit with low response rates, found that 18% of people with 
comorbid gout were hospitalized annually, a rate higher than that in people without 
gout.(10) An upward trend of hospital admission with gout as a primary diagnosis has 
been observed from a number of population-based administrative data studies (Table 
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2-4).(15-17, 152, 153) This trend is in line with the rising prevalence of gout observed 
in high income countries.(2) An Australian database study has also shown a steady rise 
in the number of admissions with gout as a complicating diagnosis, with total increase 
of 18% between 2009 and 2014 (4,429 and 5,248 admissions, respectively) and 
annualized increase of 4%.(15)  
Hospitalization in and of itself is a major risk factor for gout flare, posing a 
four-fold (OR 4.1, 95%CI 1.78 to 9.19) increase of gout flare risk in a community-
based online survey by Dubreuil et al.(11) Although inpatient gout flare is commonly 
encountered in clinical practice, few studies have reported the prevalence of such 
events among people with comorbid gout hospitalized due to non-gout conditions 
(Table 2-5). A single-center study from Australia analyzed case record data of 251 
hospital admissions which received administrative gout ICD-10 coding between 2005 
and 2006. The study found that 134 (53%) admissions had gouty arthritis, in which 
64% had gout as secondary diagnosis. Based on this study, the estimated prevalence of 
inpatient gout flare among people with comorbid gout was 34%.(154) Another 
retrospective chart review study from the United States identified 184 people with 
comorbid gout by ICD-9 coding. Seventy-nine (43%) people had acute arthritis, with 
15 of 79 people receiving gout as primary diagnosis. The estimated prevalence of 
inpatient gout flare among people with comorbid gout from this study was 35%.(155) 
Of note, people from these two studies were identified by hospital discharge ICD 
coding. This could lead to selection bias as clinicians were more likely to document 
gout as a discharge diagnosis only when there were inpatient flare requiring specific 
medical attention. Depending on the hospital’s administrative protocols, the clinical 
coders who interpret the physician’s discharge summary could potentially cause 
additional selection bias. A recent study from the United States reported the rate of 85 
flares per 100 person-year of inpatient, compared to 8.5 per 100 person-year of 
outpatient follow up (relative risk 10.2, 95%CI 6.8 to 14.5).(156) 
Many studies in the inpatient setting instead focused solely on people who had 
gout flare either as primary or complicating diagnosis, but did not assess those with 
comorbid gout who did not have flare during admission. Overall, these studies 
suggested that the majority of gout flares in hospitalized people were complications 
occurring after admission rather than the primary cause of admission (Table 2-5). A 
study reviewing records of 235 admissions diagnosed with gout flare in Christchurch 
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Hospital found that 95 (40%) admissions had gout flare as primary diagnosis, leaving 
140 (60%) admissions having gout flare as complicating diagnosis.(157) Another report 
from New Zealand describing 90 admissions with gout flare in 2012 found that 66% of 
cases had gout as a complicating diagnosis.(158) A survey of 126 hospitalized people 
with gout flare from a Malaysian hospital between 2011 and 2012, 109 (87%) were 
admitted due to other medical or surgical causes.(159) Similarly, 65% of gout flare 
episodes recorded in a Canadian study(160) and 71% of episodes in an Australian 
study(161) occurred after admission. 
In summary, the existing literature suggested that (1) people with comorbid gout 
were hospitalized at a higher rate compared to people without comorbid gout, (2) rates 
of admissions with gout as primary and complicating diagnosis were increasing and (3) 
over two-third of all gout flares observed in hospitalized patients occurred during 
hospital stay and were not present at admission. The prevalence of inpatient gout flare 
in people with comorbid gout admitted due to non-gout condition is not certain. 
Table 2-4 Summary of studies on the trends of hospital admission with gout as 
primary diagnosis(15-17, 152, 153) 
Countries  Years studied Prevalence of hospital 
admission for gout as 
primary diagnosis  
Change 
(%) 
Sweden 1998 to 2000 vs. 
2013 to 2015 
10.5 vs. 20.8 per 100,000 +98 
Sweden 2002 vs. 2012 9.5 vs. 16.7 per 100,000 +76 
Canada  2000 vs. 2011 3.8 vs. 7.6 per 100,000 +100 
Australia and New 
Zealand 
2009 vs. 2014 AUS 0.10 vs. 0.12 per 1,000 
NZ 0.30 vs. 0.33 per 1,000 
+20 
+10 
New Zealand and 
England 
1999 to 2000 vs. 
2008 to 2009 
NZ 700 vs. 1,130 admissions 
















Gout flare as 
complicating 
diagnosis 
Gnanenthiran SR, 2011 ICD-10 251 134 (66%) 86 (34%)* 
Petersel D, 2007 ICD-9 184 79 (65%) 64 (35%) 
Barber C, 2009† Hospital records NA 135 (100%) 90 (65%) 
Kamalaraj N, 2012† ICD-10 NA 207 (100%) 148 (71%) 
Teh CL, 2014† Prospective 
recruitment 
NA 126 (100%) 109 (87%) 
Kennedy NJ, 2016† ICD-10 NA 90 (100%) 59 (66%)* 
Wright S, 2017† ICD-10 NA 235 (100%) 140 (60%) 
*Only the percentage was reported, number shown were estimated from percentage. 
†The cohort included only patients with flare. 
NA, not available 
 
2.3.2 Characteristics of inpatient gout flare 
In a Korean study, the mean±SD of time period between admission and the 
occurrence of gout flare was 4.2±3.1 days.(130) Gout flares developed after mean 
duration of 6.5 days in another study from Taiwan, with 87% of flares occurring within 
the first nine days of admission.(162) Similar to typical episodes of gout flare in an 
outpatient setting, symptoms of inpatient gout flare usually include pain, tenderness and 
swelling resulting in difficulty to bear touch or inability to utilize the joints. The usual 
pattern of articular involvement is to be expected, typically monoarticular arthritis of 
the lower extremities, especially the first MTP joint. However, a higher proportion of 
oligoarticular and polyarticular arthritis have been observed in the inpatient 
populations, compared to those seen in outpatient clinics. Previously reported 
prevalence of inpatient gout flare affecting more than one joint was 41 to 51%.(130, 
161, 163) In comparison, the prevalence was only 9% from a large survey of outpatient 
gout managed by general practitioners and office-based rheumatologists.(164) 
Physicians also face additional challenge in detecting and diagnosing gout flare in 
patients who were unable to communicate the occurrence of joint pain, e.g., intubate 
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patients. Without recognition of joint inflammation, signs of systemic inflammation in 
hospitalized people, such as fever and leukocytosis, usually lead to suspicions of life 
threatening causes other than gout flares.(165, 166) As a result, diagnosis delay is 
common in this particular setting, with prevalence of 16% (ranging between 2 and 14 
days) in one report.(163) 
Hospitalized people with comorbid gout not only are complicated by the acute 
illness that was the primary cause of admission but also by their comorbidities, most 
common of which are hypertension, kidney failure, cardiovascular diseases and 
diabetes mellitus.(157, 158) These comorbidities could also contribute to the 
occurrence of gout flare, interfere with existing gout medications and complicate the 
management of inpatient gout flare. 
2.3.3 Impact of inpatient gout flare 
Gout leads to significant inpatient healthcare cost. A study utilizing health 
claims database of 300,000 employees in the United States reported annual expenditure 
for inpatient care of 1,371 USD per person with gout, compared to 615 USD for those 
without gout.(167) In another study of health claims data from North America, annual 
inpatient cost for people with gout who had six or more gout flares a year (10,775 
USD) was significantly higher than those with three or more flares a year (6,776 USD) 
and those without gout (924 USD).(150) A recent systematic review indicated that the 
healthcare cost was higher among people with gout who had more severe disease, 
defined by flare frequency, the presence of tophus, and higher serum urate level.(9)  
Hospitalized people who experience gout flare require more investigations, 
specialist consultations and pharmacological interventions, all of which potentially lead 
to worse hospital outcomes. Gout flare contributes to an additional six days of hospital 
stay in a study conducted in Australia.(168) Another study reported an additional three 
days of hospital stay occurring among acute stroke patients who had gout flares.(162) 
Treatments required for inpatient gout flare, especially NSAIDs and colchicine, may 
increase risk of adverse events as hospitalized people are often frail and complex.  A 
survey from the United States found that over 80% of people with acute gout given 
colchicine or NSAIDs had impaired renal function.(155) 
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2.3.4 Risk factors of inpatient gout flares 
Although hospitalization can increase the risk of gout flare,(11) only a few 
controlled studies have determined the factors associated with the flare event (Table 
2-6).(130, 162, 169) A Korean study compared 67 people with comorbid gout who 
developed flares after surgery to 67 people with comorbid gout without postsurgical 
gout flare. Using multivariate analysis, three-day pre-surgical serum urate ≥0.54 
mmol/L and cancer surgery were identified as risk factors for postsurgical flare, with 
OR (95%CI) of 8.2 (2.23 to 30.54) and 6.2 (1.92 to 19.90), respectively. From the same 
study, receiving colchicine prophylaxis was identified as a protective factor, with OR 
(95%CI) of 0.2 (0.04 to 0.61). Pre-surgical intake of allopurinol and gastrointestinal 
surgery showed a significant association only in univariate analysis. In this study, the 
authors speculated that infusion of fluid low in sodium content might have caused rapid 
drop of serum urate after surgery, leading to dissolution of urate crystal deposits and 
intra-articular crystal shedding.(130) Another retrospective study from China examined 
474 surgical patients with comorbid gout, of whom 191 (40%) had postsurgical flare. 
Factors associated with postsurgical gout flare were previous flare at the ankle (OR 5.6, 
95%CI 1.63 to 19.41), postsurgical decrease of serum urate by ≥0.13 mmol/L (OR 19.7, 
95%CI 8.13 to 47.89), and abdominal surgery (OR 3.4, 95%CI 1.18 to 9.62). 
Colchicine prophylaxis was found to be protective for postsurgical gout flare, with OR 
(95%CI) of 0.1 (0.01 to 0.60).(170) 
A Taiwanese study conducted in people hospitalized due to acute stroke (60 
gout flares vs. 860 non-gout control) found that having history of gout (OR 14.3, 
95%CI 6.75 to 30.18), higher in-admission serum urate level (OR 1.5, 95%CI 1.26 to 
1.78), and hypercholesterolemia (OR 2.0, 95% CI 1.06 to 3.83) were associated with 
inpatient gout flare. Of note, renal insufficiency was found to be associated with gout 
flare only in univariate analysis, and no association was found between gout flare and 
discontinuation of urate-lowering agents, alcohol and exposure to diuretics.(162) A 
recent study from Olmsted County, Minnesota, evaluated multiple potential predictors 
of inpatient gout flare, including male gender, ULT use at admission, ULT withdrawal 
at/during admission, in-admission diuretic use, kidney disease and serum urate at gout 
diagnosis. The study did not find any association between these potential predictors and 
inpatient gout flare. However, this study recorded only 23 inpatient gout flare episodes, 
which might not have enough power to detect the association, if existed.(156) 
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Several other factors commonly present during hospitalization could rapidly 
alter the level of serum urate and thus theoretically could trigger gout flare.(1) 
Dehydration, acidosis and renal impairment could interact with renal handling of urate, 
leading to hyperuricemia and crystal formation. On the other hand, exposure to new 
urate-lowering agent, volume overload and systemic inflammatory response could 
lower the level of serum urate, promote urate crystal dissolution and promote crystal 
release. Nevertheless, associations of these factors with inpatient gout flare have not 
been confirmed in any controlled study. 
 
Table 2-6 Factors associated with the risk of inpatient gout flare according to 
existing studies (130, 162, 169, 170)  
Factors Odds ratio  95% CI 
Risk factors  
History of gout* 14.28 6.75 to 30.18 
Previous flare at the ankle 5.63 1.63 to 19.41 
Increasing serum urate* 1.50 1.26 to 1.78 
Hypercholesterolemia* 2.01 1.06 to 3.83 
Pre-surgical (3-day) serum urate ≥0.54 mmol/L  8.25  2.23 to 30.54 
Postsurgical decrease in serum urate ≥0.13 
mmol/L 
19.73 8.13 to 47.89 
Abdominal surgery 3.37 1.18 to 9.62 
Cancer surgery 6.19 1.92 to 19.90 
Protective factors 
Colchicine prophylaxis 0.16 0.04 to 0.61 
Colchicine prophylaxis 0.07 0.01 to 0.60 
Pre-admission active smoking 0.64 0.59 to 0.68 






Gout is a common inflammatory arthritis with especially high prevalence 
among Māori and Pacific peoples. Long standing hyperuricemia plays a major role in 
the deposition of urate crystal in and around the joint. Gout flare occurs as a result of 
acute inflammatory response to urate crystals in the joint. People with gout are 
frequently hospitalized and they are at higher risk of developing gout flare during 
admission. People who had inpatient gout flare stayed in the hospital longer than those 
who did not. Many variables were believed to increase the risk of developing inpatient 
gout flare, but evidence from controlled study is still lacking. Currently, there is no 
standard recommendation on how to stratify the risk of gout flare in hospitalized people 




Chapter 3 Predictors of inpatient gout flare 
(Study 1) 
3.1 Summary 
Inpatient gout flare is a common occurrence but its predictors are not well 
understood. This chapter describes a retrospective cohort study of 625 people with 
comorbid gout admitted in three hospitals in the Wellington Region during the 2017 
calendar year. To identify the predictors of inpatient gout flare, a prediction model was 
built, with inpatient gout flare (yes/no) set as the primary outcome. For model 
development, three approaches were employed: (model A) a clinical knowledge-driven 
model using clinical knowledge for variable selection and standard regression analysis 
for coefficient derivation, (model B) a statistics-driven model using the least absolute 
shrinkage and selection operator (LASSO) procedure and (model C) a tree-based 
machine learning model using chi-square automatic interaction detector (CHAID) 
algorithm. Appropriate shrinkage techniques were applied to the first two models to 
minimize potential over-optimism. Model performance was assessed using C-statistics 
and calibration slope. The clinical knowledge-driven model was ultimately chosen for 
its superior performance and practicality. The final model consisted of nine predictors: 
no pre-admission urate-lowering therapy (ULT), ULT adjustment, no pre-admission 
gout prophylaxis, gout prophylaxis started or increased, diuretic adjustment, acute 
kidney injury, surgery, tophus and pre-admission serum urate >0.36 mmol/L. Internal 
model validation with bootstrap procedure showed adequate optimism-corrected 
discrimination and calibration. The nine-item prediction model will serve as a basis for 
the following chapters, which will explore its relationship to the hospital outcome, as 




3.2.1 Chapter structure 
This chapter describes the first study of this thesis, which will identify a set of 
factors associated with the risk of inpatient gout flare (prediction model) using a cohort 
of people with comorbid gout admitted to hospital for non-gout conditions. The chapter 
consists of rationale, objective, methods, results and discussion relevant to this 
particular study. Please refer to Chapter 2 for the overarching background literature of 
the study.  
This study was developed and the results were reported in compliance with the 
updated Transparent Reporting of a Multivariable Prediction Model for Individual 
Prognosis Or Diagnosis (TRIPOD) Statement. The TRIPOD Statement is a 22-item 
checklist deemed essential in transparent reporting of prediction model studies.(171) 
The complete TRIPOD statement checklist for this chapter can be found in the 
Appendix A.1. 
3.2.2 Publication 
 A paper based on this chapter was published as an original article in the March 
2020 issue of Annals of the Rheumatic Diseases (Impact Factor 16.102), an official 
journal of the European League Against Rheumatism (EULAR).(172) 
 Citation. Jatuworapruk K, Grainger R, Dalbeth N, Taylor WJ. Development of 
a prediction model for inpatient gout flares in people with comorbid gout. Annals of the 
Rheumatic Diseases. 2020; 79:418-423. DOI: 10.1136/annrheumdis-2019-216277. 
3.3 Rationale 
There is no large controlled study evaluating the variables associated with the 
risk of inpatient gout flare in people with comorbid gout. This study aims to identify 
such variables using statistical methods combined with existing clinical knowledge. 
The identification of these variables will be a foundation for the development of a risk 
stratification tool for inpatient gout flare and potentially guide future research seeking 
to reduce the rates of gout flare in the hospital setting. 
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3.4 Objective  
This study aims to identify a set of factors associated with the risk of inpatient 
gout flare among people with comorbid gout. This set of variables will serve as a basis 
for the following studies, with an overarching aim of developing a risk stratification 
tool for inpatient gout flare. 
3.5 Study design 
The study adopted a retrospective cohort design to explore the association 
between candidate variables and the occurrence of inpatient gout flare. The population 
of interest was people with comorbid gout who were admitted to the participating 
hospitals in the Wellington Region for reasons other than gout during the 2017 calendar 
year. The primary outcome was the occurrence of inpatient gout flare. Data were 
collected from physical medical records and electronic laboratory databases.  
3.6 Ethical approval 
The study protocol was reviewed and approved by the University of Otago 
Human Ethics Committee (UOHEC), reference number H18/012. For this type of 
retrospective, hospital note review study, informed consent was not required. The letter 
of ethics approval is enclosed in Appendix A.2. Permissions to access medical records 
were obtained from CCDHB (Wellington and Kenepuru hospitals) and HVDHB (Hutt 
hospital). 
3.7 Study population 
Hospitalized adults with comorbid gout in the participating hospitals during the 
2017 calendar year were included. The participating hospitals were Wellington 
(CCDHB), Kenepuru (CCDHB) and Hutt hospitals (HVDHB). Table 3-1 shows the 
inclusion and exclusion criteria.  
Comorbid gout was defined as having received the diagnosis of ‘gout’, ‘gouty 
arthritis’, ‘chronic gout’ or ‘tophaceous gout’ as comorbid disease by manual review of 
the hospital records or discharge letters. Hospital discharge date was considered as the 
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determinant of the calendar year in which hospitalization took place. For example, an 
individual who was admitted on December 30, 2016 and discharged on January 2, 2017 
would be included. However, another individual admitted between December 30, 2017 
and January 2, 2018 would be excluded. The study excluded people who received the 
diagnosis of gout for the first time during hospital admission and people whose primary 
cause of hospitalization was gout or gout-related complications such as ulcerated 
tophus. Since a number of people had more than one hospital admission in the 2017 
calendar year, this study included only the first admission of the calendar year for 
analysis to ensure that every case was independent from each other.  
The included participants were subsequently divided into two groups reflecting 
the outcome of interest: ‘flare group’ consisting of people with comorbid gout who 
developed flare during admission, and ‘non-flare group’ consisting of people with 
comorbid gout who did not experience flare during admission.  
Table 3-1 Inclusion and exclusion criteria for study 1 participants 
Inclusion criteria 
• Age 18 years or older 
• Having a discharge date in the 2017 calendar year 
• First admission of the 2017 calendar year  
• Having gout as a comorbid disease, defined as receiving a diagnosis of ‘gout’, 
‘gouty arthritis’, ‘chronic gout’ or ‘tophaceous gout’ in hospital records 
Exclusion criteria 
• Having gout or gout-related complications as the primary admission diagnosis 
• First-time gout diagnosis during admission 
 
3.8 Patient ascertainment 
Eligible people were identified using two methods of search: (1) discharge 
diagnosis coding and (2) discharge letter word search. A search using discharge 
diagnosis according to the International Statistical Classification of Diseases and 
Related Health Problems (ICD) coding was used in previously published studies of 
inpatient gout.(154, 158) Using the tenth Revision, Australian Modification of the ICD 
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coding (ICD-10-AM), all admissions that received the discharge comorbid diagnosis of 
M10 were identified (Table 3-2).  
Table 3-2 Hospital discharge ICD-10 codes for the identification of potential study 
1 participants 
M10 Gout  
M10.0 Idiopathic gout 
M10.1 Lead-induced gout 
M10.2 Drug-induced gout 
M10.3 Gout due to impairment of renal function 
M10.4 Other secondary gout 
M10.9 Gout, unspecified 
  
However, it was anticipated that a large number of people especially those with 
inactive gout might not receive ICD-10-AM gout diagnosis coding at discharge. As a 
result, the second search method was implemented using key words from electronic 
discharge letters. Discharge letters were written by the medical staff in the treating 
team, usually the junior member such as first or second year postgraduate doctors. 
These discharge letters typically listed all the comorbid conditions, active or otherwise 
as well as a list of all medications taken. This was to ensure the widest possible 
coverage of inpatient population with comorbid gout. We used the structured query 
language (SQL) ‘LIKE’ operators to search for specific pattern in the electronic 
database of discharge letters. Wildcard characters ‘%_%’ were used to capture the 
words of interest which could appear anywhere within the discharge letters. These 
characters included ‘gout’, ‘allopurinol’, ‘febuxostat’ and ‘colchicine’. The search 
yielded a list of admissions with discharge letters containing at least one of the wildcard 
characters. The SQL operators entered into the database were as the following. 
ObservationNote LIKE '%gout%' 
OR ObservationNote LIKE '%allopurinol%' 
OR ObservationNote LIKE '%febuxostat%' 
OR ObservationNote LIKE '%colchicine%' 
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Finally, the physical copies of the medical records and discharged letters 
identified by both methods were obtained and manually reviewed to ensure that the 
participants truly had gout and satisfied all the inclusion criteria. 
3.9 Data collection 
3.9.1 Medical record review 
The physical medical records were obtained from Wellington, Kenepuru and 
Hutt hospitals using event numbers corresponding to the admissions identified through 
discharge letter word search or discharge diagnosis coding method as previously 
described. Demographics, comorbidities, admission data and gout history were 
extracted from admission notes, discharge notes and prescription records. Further 
details regarding inpatient gout flare were drawn from physicians’ hand-written 
progression notes in the physical files. Laboratory results were extracted from CCDHB 
or HVDHB electronic records. Serum urate results were available in the laboratory 
reports labelled ‘uric acid’, ‘urate’, ‘general chemistry’ or ‘renal function test’, while C-
reactive protein (CRP) level were available in the section labelled ‘general chemistry’. 
Neutrophil and platelet counts were available in the section labeled ‘hematology’. Data 
extraction was performed manually and recorded in a pre-determined paper case record 
form (CRF) (Appendix A.3). Data collection was performed in alphabetical order of the 
participants’ unique National Health Index (NHI) number until the target sample size 
was met. 
3.9.2 Variables and their definitions 
Variables collected in this study consisted of six domains: demographics, 




Table 3-3 Summary of variables categorized by domains in study 1 
Domains  Variables 
Demographics Age, gender, ethnicity 
Comorbidities  Functional comorbidity index (the number of 18 comorbid 
conditions), acute kidney injury, hypercholesterolemia, 
urinary tract stone, alcohol drinking 
Admission data Principle diagnosis (13 categories), length of stay, 
inpatient department, mortality, treatments received 
(medication adjustments, procedure, and fluids) 
Gout history Tophus, pre-admission gout medications and their 
adjustment during admission  
Inpatient gout flare Duration from admission to onset of flare, total duration of 
flare, number and location of joints affected, 
ACR/EULAR gout classification criteria score, treatments 
received, rheumatology consultation 
Laboratory tests Serum urate level (pre-admission), C-reactive protein 




Age was defined as the number of years between the date of birth and the date 
of hospital admission. For the analysis, age variable was categorized as age ≥65 vs. age 
<65 years. The District Health Boards record up to three of the following self-identified 
ethnicities; New Zealand European, New Zealand Māori, Samoan, Cook Island Māori, 
Tongan, Niuean, Tokelauan, Chinese, Indian, other European, other Asian and others. 
All ethnicity items were recorded and later categorized into prioritized ethnic groups 
including New Zealand Māori, Pacific Peoples (Cook Island Māori, Samoan, Tongan, 
Niuean and other Pacific Island), European (New Zealand European and other 
European), Asian (Chinese, Indian and other Asian) and others. When more than one 
ethnicity was recorded, the participant would be classified as single ethnic group 
according to ethnic group priority: (1) New Zealand Māori, (2) Tokelauan, (3) Niuean, 
(4) Tongan, (5) Cook Island Māori, (6) Samoan, (7) other Pacific Island, (8) Indian, (9) 
Chinese, (10) other Asian, (11) other European, (12) New Zealand European and (13) 
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others.(173) For the final analysis, the ethnicity variable was modified to Māori or 
Pacific vs. non- Māori/non-Pacific. 
3.9.2.2 Comorbidities 
As gout flare mainly affects patients’ physical function, comorbidities were 
collected in accordance to the 18-item Functional Comorbidity Index (FCI) which was 
developed with physical function as the outcome (Table 3-4).(174) Other comorbidities 
which had been linked to gout flare were also collected. Hypercholesterolemia was 
defined as receiving diagnosis of ‘hypercholesterolemia’, or ‘hyperlipidemia’ or having 
total cholesterol level >5.2 mmol/L (>200 mg/dl). Acute kidney injury (AKI) was 
defined as receiving diagnosis of ‘acute kidney injury’, ‘acute renal failure’ or ‘acute on 
top chronic renal failure’. Only AKI occurring during admission and prior to flare was 
recorded. Urinary tract stone was defined as receiving the diagnosis of stone or 
urolithiasis or radiological evidence of stone in the kidney or urinary tract. Alcohol 
drinking was defined as receiving diagnosis of current alcoholism or record of active 
alcohol consumption in the admission or discharge notes. 
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Table 3-4 Functional Comorbidity Index(174) 
1. Arthritis (rheumatoid and osteoarthritis) 
2. Osteoporosis 
3. Asthma 
4. Chronic obstructive pulmonary disease (COPD), acquired respiratory distress 
syndrome (ARDS) or emphysema 
5. Angina 
6. Congestive heart failure (or heart disease) 
7. Heart attack (myocardial infarct) 
8. Neurological disease (such as multiple sclerosis or Parkinson’s) 
9. Stroke or transient ischemic attack (TIA) 
10. Peripheral vascular disease (PVD) 
11. Diabetes type I and II 
12. Upper gastrointestinal (GI) disease (ulcer, hernia, reflux) 
13. Depression  
14. Anxiety or panic disorders 
15. Visual impairment (such as cataracts, glaucoma, macular degeneration) 
16. Hearing impairment (very hard of hearing, even with hearing aids) 
17. Degenerative disc disease (back disease, spinal stenosis or severe chronic back 
pain) 
18. Obesity and/or body mass index >30 (weight in kg/height in meters2) 
 
3.9.2.3 Admission data 
Primary diagnoses were the primary conditions that led to the current hospital 
admission. The primary diagnoses were recorded as stated in the hospital discharge 
letter. Afterwards, the primary diagnoses were categorized into 13 groups in accordance 
with ICD-10 coding: infectious disease, neoplasm, diseases of the blood, endocrine 
disease, diseases of nervous system, diseases of the eye/ear, diseases of circulatory 
system, diseases of respiratory system, diseases of digestive systems, diseases of the 
skin, diseases of musculoskeletal system, diseases of genitourinary system and 
injury/external causes. 
Length of hospital stay was the number of days between the date of hospital 
admission and the date of hospital discharge. Inpatient department was the ward to 
40 
 
which the participant was first admitted. General medicine, all subspecialties of 
medicine and rehabilitation departments were recorded as ‘medicine department’. All 
subspecialties of surgery, orthopedics, ophthalmology and ear, nose and throat (ENT) 
were recorded as ‘surgical department’. Short stay unit and emergency department were 
recorded as ‘short stay unit’.  
Treatments received encompassed procedures, intravenous infusions, and 
medications deemed relevant to gout. All procedures performed in the operating theatre 
and dialysis were recorded. The volume of all types of intravenous fluids and blood 
products (e.g., packed red cells, fresh frozen plasma) given within the first 48 hours of 
admission were documented. If gout flare occurred earlier than 48 hours after 
admission, only the fluid volume received prior to flare was documented. For the 
analysis, the IV fluid variable was categorized into IV fluid ≥2L vs. IV fluid <2L. 
Adjustment of medications that could alter serum urate level was recorded, which 
included adjustment of diuretics (loop and thiazide), cyclosporine, warfarin, nicotinic 
acid, ethambutol and pyrazinamide.(175-177) Adjustment of medication was defined as 
any change made to the medicine dosage including increase, decrease, initiation and 
withdrawal of the medication. For people who developed inpatient gout flare, only 
adjustment of medications prior to the flare episode was recorded. 
3.9.2.4 Gout history 
Participants were considered to have tophus when there were records of 
‘tophaceous gout’ or there were ‘tophus’ noted in physical examination by attending 
doctors. Pre-admission gout medication included ULT (allopurinol, febuxostat, 
benzbromarone, probenecid or sulfinpyrazone) and anti-inflammatory agents used for 
prevention of gout flare (colchicine, NSAIDs, prednisone) which the participants had 
been taking until the day of admission. The presence of pre-admission ULT and gout 
prophylaxis medications was extracted from the list of current medicines in the 
admission note or the medicine reconciliation records. Any adjustment to the dosage of 
ULT after admission and prior to flare episode was recorded. For the adjustment of 
gout prophylaxis, three categories were recorded: gout prophylaxis started/increased, 
gout prophylaxis stopped/decreased and no adjustment. This particular classification for 
gout prophylaxis adjustment was due to a different clinical implication associated with 
how gout prophylaxis was modified. A withdrawal or decrease of gout prophylaxis 
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might be associated with higher risk of flare, but an increase or initiation may be 
protective against flare. 
3.9.2.5 Inpatient gout flare 
Inpatient gout flare was defined as the development of new episode of joint pain 
and swelling judged to be gout by the attending doctor or consultant rheumatologist 
according to the hospital notes. In the case of multiple gout flare episodes in a single 
admission, only data about the first episode were extracted. Duration of flare episode 
was defined by the number of days between flare onset and the withdrawal of anti-
inflammatory medication or hospital discharge. Documented medications for treatment 
of flare included colchicine, NSAIDs, corticosteroids (oral, intra-articular, intravenous 
or intramuscular) or others. Initiation of ULT prior to or subsequent to flare episode 
was also recorded. Items from the ACR/EULAR gout classification criteria were also 
collected for all gout flare episode where available. 
3.9.2.6 Laboratory tests 
Serum urate level tested anytime during the 12-month period prior to admission 
was recorded. In case of multiple available serum urate test results, only the highest 
result was selected for further analysis. There were three possible categories: high 
(>0.36 mmol/L), normal (≤0.36 mmol/L) and not tested. We did not consider ‘not 
tested’ as missing data because the lack of urate testing had clinical meaning (e.g., lack 
of monitoring). The threshold of 0.36 mmol/L was selected in accordance with the 
Study for Updated Gout Classification Criteria (SUGAR), which also reflected the 
therapeutic serum urate target for gout management.(76)  
Inflammatory markers including CRP, neutrophil count and platelet count 
during admission were also documented. If there was flare in the admission, only the 
inflammatory markers tested prior to flare episode were recorded. Similar to pre-
admission serum urate, there were three possible categories for the inflammatory 
markers. The cut points for the inflammatory markers were ≥100 mg/L for CRP, ≥15 
x109/L for neutrophil count and ≥450 x109/L for platelet count, respectively. 
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3.10 Data analysis 
3.10.1 Sample size 
The events per variables (EPV) ratio between 5 and 10 was considered 
acceptable, with EPV of 10 being the optimal ratio to minimize over-optimism of the 
regression model.(178) According to this rule, 50 to 100 inpatient flare episodes were 
needed to evaluate 10 candidate variables. Assuming that the prevalence of inpatient 
gout flare was 35% among hospitalized people with comorbid gout,(155) a total sample 
size of 150-300 would be sufficient. However, there was a possibility that the 
prevalence of inpatient gout flare would be lower than expected. The use of discharge 
letter word search in addition to the traditional ICD-10 coding search could possibly 
lead to identification of more people with comorbid gout who did not have inpatient 
flare, since ICD-10 coding may plausibly under-identify such patients. With this 
possibility in mind, a sample size target of 600 admissions was planned and shrinkage 
methods were applied to the prediction models to correct for potential model over-
optimism.  
3.10.2 Descriptive analysis 
Categorical variables were described as frequency and percentage. Continuous 
variables which were normally distributed were presented as mean and standard 
deviation (SD). If the variables did not show normal distribution, median and 
interquartile range (IQR) were used. Shapiro-Wilk Test was selected for the test of 
normality due to the potentially low number of subjects in the flare subgroup. A p-value 
less than 0.05 from the test of normality indicated that the dataset deviated significantly 
from normal distribution. In addition to the description of the overall cohort, a 
descriptive analysis was performed separately for flare and non-flare subgroups. 
Comparison of categorical variables between flare and non-flare groups was done using 
chi-square test or Fisher’s exact test when the expected cell count was less than five. 
Since not all of the continuous variables in this study showed normal distribution, 
comparison of these variables between flare and non-flare groups was performed using 




The characteristics of inpatient gout flare episodes were described separately. 
The description included the pattern and number of joints affected, all items from the 
ACR/EULAR classification criteria, the number of days between hospital admission 
and the onset of gout flare, flare duration (days) and treatments received.  
3.10.3 Development of prediction models 
3.10.3.1 Candidate variables and missing data 
Fifty-two candidate variables from five domains were explored (Table 3-5): 51 
categorical variables and one continuous variable (FCI score).  
Missing data occurred only in the ethnicity variable in which 20 of 625 patients 
(3%) did not have ethnicity recorded. For the analysis, however, the ethnicity variable 
was transformed to a binary variable of ‘Maori or Pacific’ vs. ‘non-Māori/non-Pacific’, 
thus effectively classifying people with unreported ethnicity as ‘non-Māori/non-
Pacific’. 
Table 3-5 Candidate variables for the final analysis of study 1 
Domains  Variables* 
Demographics (1) age ≥65 years, (2) male, (3) Māori or Pacific ethnicity 
Comorbidities (4) AKI,†‡ (5) urinary tract stone, (6) hypercholesterolemia, (7) 
alcohol drinking,† (8) arthritis, (9) osteoporosis, (10) asthma, (11) 
COPD, ARDS, emphysema, (12) angina, (13) CHF, (14) heart 
attack, (15) neurological disease, (16) stroke or TIA, (17) PVD, 
(18) DM, (19) upper GI disease, (20) depression, (21) anxiety or 
panic, (22) visual impairment, (23) hearing impairment, (24) DDD, 
(25) obesity, (26) FCI score 
Admission§ Principal diagnosis : (27) infectious disease, (28) neoplasm, (29) 
diseases of the blood, (30) diseases of nervous system, (31) diseases 
of circulatory system, (32) diseases of respiratory system, (33) 
diseases of digestive systems, (34) diseases of the skin, (35) 
diseases of musculoskeletal system, (36) diseases of genitourinary 
system and (37) injury/external causes  
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Domains  Variables* 
Treatments: (38) diuretics adjustment,†‡ (39) warfarin 
adjustment,‡ (40) dialysis,†‡ (41) surgery,†‡ (42) IV fluid ≥2L,†‡ 
(43) blood product‡ 
Gout history (44) tophus,† (45) no pre-admission ULT,† (46) no pre-admission 
gout prophylaxis ,† (47) ULT adjustment,†‡ (48) gout prophylaxis 
adjustment (started/increased vs. stopped/decreased vs. no 
adjustment)†‡ 
Laboratory (49) pre-admission urate >0.36 mmol/L,† (50) CRP ≥100 mg/L,‡ 
(51) neutrophil >15 x109/L,‡ (52) platelet ≥450 x109/L‡ 
*All variables were included in statistics-driven and decision tree model. 
†Variables selected for the clinical knowledge-driven model 
‡ Occurs during admission and prior to gout flare. 
§Disease of endocrine system and disease of the eye/ear and cyclosporine adjustment 
were not included in the model due to the very low number of observations. 
Abbreviations: ARDS, acquired respiratory distress syndrome; CHF, congestive heart 
failure; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; 
DDD, degenerative disc disease; DM, diabetes mellitus; FCI, functional comorbidity 
index; GI, gastrointestinal; IV, intravenous; PVD, peripheral vascular disease; TIA, 
transient ischemic attack; ULT, urate-lowering therapy 
 
3.10.3.2 Approach to model development 
To ensure the robustness and validity of the prediction model, three different 
approaches of model development were pursued: (model A) clinical knowledge-driven 
model, (model B) statistics-driven model and (model C) decision tree model (Table 
3-6). The following sections describe the reasoning and protocol of each model. 
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Table 3-6 Approaches to the development of prediction models  for inpatient gout 
flare (study 1) 








Clinical knowledge  LASSO CHAID 
Estimation of 
coefficients 














CHAID, chi-square automatic interaction detection; LASSO, least absolute shrinkage 
and selection operator; NA, not applicable 
 
3.10.3.3 Model A: clinical knowledge-driven model 
The clinical knowledge-driven model reduced a large group of potential 
variables down to a smaller set of candidate variables using published literature and 
clinical knowledge. The knowledge-based variable selection ensured that the variables 
of interest were theoretically plausible, clinically practical and were not selected by 
accident.(179) When selecting variables, the following criteria were considered: (1) the 
variables were associated with gout flare from published literature or with fluctuation 
of serum urate level, leading to the theoretical risk of gout flare and (2) the variables 
were readily available in routine clinical setting and required no additional intervention 
to assess them (i.e., no additional blood test required). 
After selection, all candidate variables were simultaneously entered into a 
standard logistic regression model, with inpatient gout flare (yes/no) as the dependent 
variable. The final set of variables included only those with p-value <0.05 from the 
multivariable logistic regression analysis. 
To correct for potential over-optimism, the regression coefficient were further 
shrunk by multiplication with a linear shrinkage factor(s). Shrinkage factor(s) was 
derived from Van Houwelingen and Le Cassie’s heuristic formula: s = [model χ2 - (df - 
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1)]/ model χ2, where model χ2 indicated chi-square value of the model calculated from 
log-likelihood scale and df indicated degree of freedom of covariables in the 
model.(180, 181) The shrinkage factor approached zero when the number of 
covariables increased or the sample size decreased (thus lowering model χ2). The lower 
the shrinkage factor(s) were, the more penalty would be applied to the regression 
coefficients. The shrunken coefficients (βs) were reported for each variable in the final 
model, as well as their OR and 95%CI.  
3.10.3.4 Model B: statistics-driven model 
The statistics-driven model attempted to use solely a statistical process in the 
selection of variables associated with inpatient gout flare and the estimation of 
regression coefficients. This study had a relatively small dataset and low EPV ratio. In 
this particular situation, the standard protocol, which typically included univariable 
screening and stepwise multivariable regression, would have significant drawbacks. 
The most serious possible drawbacks were model instability (small change in data 
leading to different predictors selected), over-optimism (model adhering closely to 
specific dataset but failing to perform adequately in a new dataset) and overestimation 
of regression coefficients (β).(182) The application of shrinkage technique (linear 
shrinkage factor or penalized regression) could improve model calibration in a small 
dataset, compared to standard regression without shrinkage.(181) Consequently, the 
least absolute shrinkage and selection operator (LASSO) was the most appropriate 
procedure for variable selection and regression coefficient estimation for this statistics-
driven model.  
LASSO is a type of ‘penalized regression’ procedure that combines the 
estimation of regression coefficients with shrinkage and variable selection. LASSO 
procedure corrects for over-optimism of the model by constraining the sum of absolute 
values of regression coefficients using a penalty factor (λ). Penalty factor (λ) is derived 
from 10-fold cross validation procedure, with the best λ defined as the highest λ that 
gives the lowest mean-squared error in the cross validation. Furthermore, LASSO 
shrinks the regression coefficients of some variables to zero, effectively excluding 
those variables from the model. These qualities of LASSO lead to its being referred to 
as the ‘shrinkage with selection’ method.(181) 
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For this study, all 52 candidate variables were entered into the LASSO model. 
Inpatient gout flare (yes/no) was set as the dependent variable. For pre-admission serum 
urate, CRP, neutrophil count and platelet count, the ‘normal level’ was set as the 
reference category for regression analysis. Variables whose coefficients equaled zero 
were excluded from the model. The remaining set of variables were reported as the 
potential predictors for inpatient gout flare, as well as their regression coefficients, OR 
and 95%CI.  
3.10.3.5 Model C: decision tree model 
Decision tree is a type of supervised machine learning algorithm, which extracts 
a model from the observation of the dataset. It was previously used in marketing 
research but later gained popularity in genetic and medical research, especially for the 
purpose of prediction or classification.(183) Decision tree algorithm starts with a single 
node representing the entire dataset and splits the node using an appropriate test. The 
algorithm then continues to split each successive node, creating a tree-like structure. 
The branching stops when the specified stopping criteria apply. For prediction 
modelling, a decision tree has some advantages over regression analysis. Firstly, the 
decision tree visualizes the model in a way that is easy to interpret. Secondly, in 
addition to variable selection, the decision tree provides a visualized ranking of the 
variables according to their relevance to the target outcome (the most powerful 
predictors are employed first and the weakest predictor are applied last). Lastly, 
decision tree is a non-parametric universal approximator, meaning that it does not make 
assumption about the dataset (e.g., linearity, independence).(184) The most commonly 
used decision trees are chi-square automatic interaction detection (CHAID) and 
classification and regression trees (CART). 
For this study, CHAID was selected over CART because CHAID could make 
multiple node splits, while CART only makes a binary split. All 52 candidate variables 
were entered into the decision tree algorithm, with inpatient gout flare (yes/no) set as 
dependent variable. CHAID algorithm used chi-square test and Bonferroni-adjusted p-
value to find the pair of predictor categories with statistical significance and split the 
dataset accordingly in a successive manner. The splitting stopped when the following 
rules applied:  
(1) No more than three levels of branches 
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(2) Parent node size of at least 20 people 
(3) Child node size of at least 10 people  
The minimal size of the node should not be less than 1% of the total cohort size 
to prevent model overfitting and underfitting.(185) In this study, the minimal number in 
a child node should contain at least six subjects. The result was presented as a decision 
tree, with each node representing corresponding variable category and the percentage of 
inpatient gout flare. 
3.10.4 Model performance and model selection 
3.10.4.1 Discrimination 
C-statistic indicates the model’s ability to discriminate between flare and non-
flare group. The C-statistic is the area under the receiver operating characteristic (ROC) 
curve created by plotting the sensitivity (true positive rate) against 1-specificity (false 
positive rate) of the model. For model A and model B, the ROC curve was generated 
using the predicted probability of flare for each participant, which in turn was 
calculated from the models’ regression coefficients. The probability of flare was 
calculated using the following formula:  
• Patient’s probability of flare = exp(risk score) / [1 + exp(risk score)] 
• Risk score = intercept + (β1 × V1) + (β2 × V2) + (β3 × V3) + (β4 × V4) + … 
• Where β is the regression coefficient and V is the corresponding variable 
The area under the curve (AUC) ranges from 0.5 to 1.0, with the AUC of 1.0 
indicating a perfect discrimination between flare and non-flare group. On the other 
hand, the AUC of 0.5 indicates that the model’s ability to discriminate flare from non-
flare group is no better than chance. For model C, the algorithm readily produced the 
probability estimate for each participant and the ROC curve was generated in similar 
fashion.  
3.10.4.2 Calibration 
Calibration slope detects model overfitting by examining the relationship 
between the predicted probability (x-axis) and the observed probability of flare (y-axis). 
The participants were grouped by the deciles of their predicted probability of flare. The 
average values of each group were plotted against the group’s observed probability 
(calibration plot). The calibration slope of 1.0 indicates perfect agreement between the 
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probability of flare predicted by the model and the probability actually observed. In this 
ideal model, the intercept (value of y when x =0) equals 0 and visual assessment reveals 
the plot starting at the graph origin and running on a 45 degrees line. Assessment of 
calibration of model 3 was not applicable because the decision tree algorithm did not 
produce regression coefficients. 
3.10.4.3 Model selection 
With an ultimate goal of developing a simple clinical tool to predict inpatient 
gout flare in mind, model selection was based on the best performance (discrimination 
and calibration) as well as practicality. The model should have the values of C-statistics 
and calibration slope closest to 1. The model should ideally be simple enough for non-
specialist doctors to use in clinical practice without requiring additional intervention to 
the patients (i.e., no additional blood test required). 
3.10.5 Model internal validation 
Bootstrap procedure was used to internally validate the selected model. The 
current dataset had a relatively small number of events. It was therefore judged that 
further splitting the dataset into ‘development cohort’ and ‘validation cohort’ would 
undermine the power of both. Data splitting could also lead to unstable subsets because 
of fortuitous splitting.(186) As a result, bootstrap validation was a preferable option for 
this study. Bootstrap procedure produces a large number of imitations of the original 
dataset by performing random resampling with replacements on the original dataset. A 
large number of bootstrap samples are typically preferred (usually at least 200).(187) 
One thousand bootstrap samples were generated for this study. For internal validation, a 
prediction model was derived from each bootstrap sample using the same process 
performed for model development. Each bootstrap model was applied to the original 
dataset. The bootstrap Somers’ D (Dyx) and calibration slope for each bootstrap model 
were subsequently calculated. The bootstrap procedure estimated the average optimism 
across the bootstrap samples and subtracted it from the model’s performance indices, 
producing the optimism-corrected calibration slope and Dyx. The C-statistics were 
derived from Dyx using the following formula: C-statistics = 0.5(Dyx + 1). An ideal 
model would have the optimism-corrected C-statistics and calibration slope similar to 
the original values, which indicates that the model performed similarly in 1,000 
different hypothetical datasets.  
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3.10.6 Statistical software 
IBM SPSS Statistics (version 25) was used for the descriptive analyses, the 
generation of ROC curves (C-statistics) for the three prediction models and the CHAID 
decision tree algorithm. RStudio (version 1.2.1335) equipped with ‘glmnet’ package 
(version 2.0-18) was used for the logistic regression analysis (model A) and LASSO 
procedure (model B). Calibration plot and calibration slope for model A and model B 
were created in Microsoft Excel. Finally, RStudio equipped with ‘rms’ package 
(version 5.1-3.1) was used for the bootstrap validation. 
3.11 Results 
3.11.1 Cohort overview 
Sixteen hundred admission records were manually reviewed (Figure 3-1). Six 
hundred and forty-three admissions were excluded due to having non-gout diagnosis 
(e.g., calcium pyrophosphate crystal arthritis, taking allopurinol without gout diagnosis) 
or having gout as primary admission diagnosis. According to inclusion criteria, only the 
first admission in the 2017 calendar year would be analyzed. This excluded a further 
332 admissions. Ultimately, 625 admissions (from 625 individuals) were included in 
the final analysis. Four hundred and fifty-four (73%) admissions were from CCDHB 
(438 from Wellington hospital and 16 from Kenepuru hospital) and 171 (27%) were 
from Hutt hospital (HVDHB).  
According to the method of patient identification, 531 were identified only by 
discharge letter word search, one patient was identified only by discharge ICD-10 
coding and 93 were identified by both methods. There were 87 (14%) admissions with 
gout flare episodes, 72 (83%) of which were identified by both the discharge letter 
word search method and the discharge ICD-10 coding. The remaining 15 admissions 




Figure 3-1 Flow diagram of participant recruitment for study 1 
 
3.11.2 Characteristics of the cohort 
3.11.2.1 Demographics 
Men made up the majority of the cohort (487/625, 78%). The mean age at the 
time of admission was 68.9 years. The majority of people were New Zealand European 
(60%), followed by Māori (19%), Pacific people (17%) and Asian people (4%). 
Comparison between flare and non-flare groups showed significantly higher proportion 
of men in the flare group. Table 3-7 shows the demographics of the study cohort. 
52 
 









Male, n (%) 487 (77.9) 75 (86.2) 412 (76.6) 0.045 
Age (year), mean±SD 68.9±13.6 69.3±13.2 68.8±13.7 0.89 
Ethnicity, n (%) (n=605)     
New Zealand European 361 (59.7) 44 (51.8) 317 (61.0) 0.11 
Māori 115 (19.0) 16 (18.8) 99 (19.0) 0.96 
Pacific 103 (17.0) 18 (21.2) 85 (16.3) 0.27 
Asian 26 (4.3) 7 (8.2) 19 (3.7) 0.08 
Māori/Pacific* 218 (35.0) 34 (39.1) 184 (34.2) 0.38 
*N =625 (people with unknown ethnicity categorized as non-Māori/non-Pacific) 
NS, not significant; SD, standard deviation 
 
3.11.2.2 Comorbidities 
The FCI score ranged from 0 to 7, with the median of two. The five most 
common comorbidities were diabetes mellitus (30%), heart attack (30%), congestive 
heart failure (29%), hypercholesterolemia (24%) and arthritis (23%). Compared to the 
non-flare group, the flare group had significantly higher prevalence of heart attack 
(40% vs. 28%, p =0.021), AKI (31% vs. 13%, p <0.001) and stroke or TIA (29% vs. 
18%, p =0.015). Table 3-8 shows the comorbidities categorized by study groups. 
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FCI score , median (IQR) 2 (2) 2 (2) 2 (2) 0.31 
FCI, n (%)     
Diabetes mellitus 188 (30.1) 26 (29.9) 162 (30.1) 0.97 
Heart attack 186 (29.8) 35 (40.2) 151 (28.1) 0.021 
Congestive heart failure 178 (28.5) 30 (34.5) 148 (27.5) 0.18 
Arthritis 142 (22.7) 15 (17.2) 127 (23.6) 0.19 
Stroke or TIA 120 (19.2) 25 (28.7) 95 (17.7) 0.015 
Obesity 97 (15.5) 10 (11.5) 87 (16.2) 0.26 
Asthma 85 (13.6) 11 (12.6) 74 (13.8) 0.78 
COPD, ARDS, emphysema 83 (13.3) 13 (14.9) 70 (13.0) 0.62 
Upper GI disease 75 (12.0) 12 (13.8) 63 (11.7) 0.58 
Degenerative disc disease 44 (7.0) 6 (6.9) 38 (7.1) 0.96 
Visual impairment 44 (7.0) 8 (9.2) 36 (6.7) 0.40 
Peripheral vascular disease 35 (5.6) 5 (5.7) 30 (5.6) 1.00 
Angina 32 (5.1) 5 (5.7) 27 (5.0) 0.79 
Hearing impairment 27 (4.3) 1 (1.1) 26 (4.8) 0.16 
Osteoporosis 25 (4.0) 2 (2.3) 23 (4.3) 0.56 
Depression 25 (4.0) 4 (4.6) 21 (3.9) 0.77 
Anxiety or panic 23 (3.7) 3 (3.4) 20 (3.7) 1.00 
Neurological disease 6 (1.0) 1 (1.1) 5 (0.9) 0.56 
Other comorbidities , n (%)     
Hypercholesterolemia 149 (23.8) 25 (28.7) 124 (23.0) 0.25 
Acute kidney injury 94 (15.0) 27 (31.0) 67 (12.5) <0.001 
Urinary tract stone 25 (4.0) 3 (3.4) 22 (4.1) 1.00 
Active alcohol drinking 23 (3.7) 2 (2.3) 21 (3.9) 0.76 
ARDS, adult respiratory distress syndrome; COPD, chronic obstructive pulmonary 
disease; FCI, functional comorbidity index; GI, gastrointestinal; IQR, interquartile 




3.11.2.3 Admission data 
Over two-thirds of people (69%) were discharged from the medical 
departments, while 30% were discharged from the surgical departments and 1% from 
the short stay unit. Overall, people stayed in hospital for a median of three days, with 
the flare group having significantly longer length of stay compared to the non-flare 
group (median (IQR) of 8 (13) vs. 2 (4) days, p<0.001). There were 10 deaths (2%), 
nine were in the non-flare group. There were 13 categories of primary diagnoses. The 
five most common categories of primary diagnosis were diseases of the circulatory 
system (27%), followed by diseases of the digestive system (13%), respiratory diseases 
(12%), musculoskeletal diseases (10%) and genitourinary diseases (8%). The flare 
group received significantly higher primary diagnosis of disease of the nervous system 
(14% vs. 7%, p =0.032). 
One hundred and five people (17%) had their diuretics adjusted during 
hospitalization, of which 29 (33%) were in the flare group and 76 (14%) were in the 
non-flare group (p <0.001). Warfarin adjustment was recorded in 47 (8%) people 
overall. People in the flare group had significantly higher prevalence of warfarin 
adjustment compared to the non-flare group (17% vs. 6%, p <0.001). Two people had 
their cyclosporine adjusted during admission, both in the non-flare group. No 
adjustment of nicotinic acid, ethambutol or pyrazinamide was documented. The flare 
group received significantly more surgery, blood product and intravenous fluid ≥2L, 
compared to the non-flare group. Admission data are summarized in Table 3-9. 
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Medical department, n (%) 434 (69.4) 62 (71.3) 372 (69.1) 0.69 
Surgical department, n (%) 188 (30.1) 25 (28.7) 163 (30.3) 0.77 
Short stay unit, n (%) 3 (0.5) 0 (0.0) 3 (0.6) 1.00 
Length of stay (day), median (IQR) 3 (6) 8 (13) 2 (4) <0.001 
Mortality, n (%) 10 (1.6) 1 (1.1) 9 (1.7) 1.00 
Categories of primary diagnosis , n (%) 
Circulation 168 (26.8) 21 (24.2) 147 (27.4) 0.53 
Digestive system 78 (12.5) 11 (12.6) 67 (12.5) 0.96 
Respiratory system 75 (12.0) 14 (16.2) 61 (11.3) 0.21 
Musculoskeletal system 65 (10.4) 6 (6.9) 59 (11.0) 0.25 
Genitourinary system 51 (8.2) 9 (10.3) 42 (7.8) 0.42 
Nervous system 50 (8.0) 12 (13.8) 38 (7.1) 0.032 
Skin 38 (6.1) 2 (2.3) 36 (6.7) 0.11 
External causes 33 (5.3) 3 (3.4) 30 (5.6) 0.61 
Infectious disease 29 (4.6) 4 (4.6) 25 (4.6) 1.00 
Neoplasm 16 (2.6) 4 (4.6) 12 (2.2) 0.26 
Endocrine system 11 (1.8) 0 (0.0) 11 (2.0) 0.38 
Blood 7 (1.1) 1 (1.1) 6 (1.1) 1.00 
Eye-ear 4 (0.6) 0 (0.0) 4 (0.7) 1.00 
Hospital treatments , n (%) 
Diuretics adjustment 105 (16.8) 29 (33.3) 76 (14.1) <0.001 
Surgery 112 (17.9) 23 (26.4) 89 (16.5) 0.026 
Intravenous fluid ≥2 L 103 (16.5) 26 (29.9) 77 (14.3) <0.001 
Warfarin adjustment 47 (7.5) 15 (17.2) 32 (5.9) <0.001 
Blood products 30 (4.8) 9 (10.3) 21 (3.9) 0.025 
Dialysis 19 (3.0) 3 (3.4) 16 (3.0) 0.74 
Cyclosporine adjustment 2 (0.3) 0 (0.0) 2 (0.4) 1.00 




3.11.2.4 Gout history 
Clinical tophus was documented in 23 (4%) people: nine (10%) in the flare 
group, compared to 14 (3%) in the non-flare group (p=0.002). Over two-third of people 
(409/625, 66%) received ULT prior to admission, the majority of which were taking 
allopurinol (394/409, 96%). Significantly higher proportion of people in the non-flare 
group received pre-admission ULT, compared to the flare group (69% vs. 44%, p 
<0.001). Adjustment of ULT during admission was found in 16% of the flare group, 
compared to 6% of non-flare group (p=0.001). Prior to admission, 108 (17%) people 
were receiving anti-inflammatory agent for the prevention of gout flare, the majority of 
which were in the non-flare group. Twenty people overall had their gout prophylaxis 
adjusted (3%): 10 initiated or increased dose and 10 stopped or decreased dose. Gout 
prophylaxis started or increased was more prevalent in the flare group compared to the 
non-flare group (6% vs. 1%, p=0.007). Table 3-10 shows the cohort’s gout history.  
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Tophus, n (%) 23 (3.7) 9 (10.3) 14 (2.6) 0.002 
ULT, pre-admission, n (%)  409 (65.4) 38 (43.7) 371 (69.0) <0.001 
Allopurinol 394 (63.0) 37 (42.5) 357 (66.4) <0.001 
Febuxostat 15 (2.4) 2 (2.3) 13 (2.4) 1.00 
Probenecid 4 (0.6) 1 (1.1) 3 (0.6) 0.45 
Benzbromarone 1 (0.2) 0 (0.0) 1 (0.2) 1.00 
Combination 4 (0.6) 1 (1.1) 3 (0.6) 0.45 
ULT adjustment, n (%) 48 (7.7) 14 (16.1) 34 (6.3) 0.001 
Prophylaxis, pre-admission, n (%) 108 (17.3) 6 (6.9) 102 (19.0) 0.006 
Corticosteroids 72 (11.5) 3 (3.4) 69 (12.8) 0.011 
Colchicine 24 (3.8) 3 (3.4) 21 (3.9) 1.00 
NSAIDs 17 (2.7) 1 (1.1) 16 (3.0) 0.49 
Combination 4 (0.6) 1 (1.1) 3 (0.6) 0.45 
Prophylaxis adjustment, n (%) 20 (3.2) 7 (8.0) 13 (2.4) 0.013 
Started/increase 10 (1.6) 5 (5.7) 5 (0.9) 0.007 
Stopped/decrease 10 (1.6) 2 (2.3) 8 (1.5) 0.64 
NS, not significant; NSAIDs, non-steroidal anti-inflammatory drugs; ULT, urate-
lowering therapy 
 
3.11.2.5 Laboratory tests 
Serum urate level was tested in 386 (62%) people within 12 months prior to 
hospital admission. Overall, the median level of the highest pre-admission serum urate 
was 0.41 mmol/L. Prevalence of pre-admission serum urate >0.36 mmol/L was 61% in 
the flare group, compared to 38% in the non-flare group (p <0.001). Similarly, the 
prevalence of CRP ≥100 mg/L and platelet count ≥450 x109/L were significantly higher 












Pre-admission serum urate >0.36 
mmol/L, n (%) 
255 (40.8) 53 (60.9) 202 (37.5) <0.001 
CRP ≥100 mg/L, n (%) 68 (10.9) 21 (24.1) 47 (8.7) <0.001 
Neutrophil ≥15 x109/L), n (%) 31 (5.0) 7 (8.0) 24 (4.5) 0.18 
Platelet ≥450 x109/L, n (%) 18 (2.9) 6 (6.9) 12 (2.2) 0.027 
*Number of people tested: 386 for serum urate, 331 for CRP, 564 for neutrophil 
count and 563 for platelet count. 
CRP, C-reactive protein; NS, not significant 
 
3.11.2.6 Characteristics of inpatient gout flare episodes 
Out of the 625 admissions, there were 87 gout flare episodes recorded (14%). 
The median number of days between hospital admission date and gout flare occurrence 
was six days (range 1 to 41 days). The median duration of flare episodes was three 
days. The majority of flare episodes affected a single joint (79%). Seventeen episodes 
(20%) involved two to four joints and only one episode (1%) affected more than four 
joints. First MTP joint was the most commonly affected location (39%), followed by 
the knee (26%) and ankle joint (18%). Synovial fluid examination for the presence of 
crystal was performed in 10 episodes, seven of which were MSU crystal positive. When 
applied with the ACR/EULAR classification criteria for gout, 48 (56%) episodes could 
be classified as gout. The median ACR/EULAR classification criteria score was eight 
points. 
All but one flare episodes were treated with one or more anti-inflammatory 
agents. Systemic corticosteroids were the most common agent prescribed (55%), 
followed by colchicine (39%), NSAIDs (10%) and intra-articular corticosteroids (2%). 
Four (5%) episodes were treated with a combination of agents, while three (3%) 
episodes received flare medications in a sequential manner. Rheumatology consultation 
was sought for only a single flare episode. Description of gout flare episodes are shown 
in Table 3-12. 
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Table 3-12 Characteristics of the 87 gout flare episodes in the study 1 cohort 
Variables  Frequency  
Days between admission and flare, median (IQR) 6 (6), range 1 to 41 
Duration of episode (day), median (IQR) 3 (2), range 1 to 13 
Number of joint affected, n (%) (n=86)*  
One 68 (79.0) 
Two to four 17 (19.8) 
More than four 1 (1.2) 
Joints affected, n (%) (n=86)*  
First MTP 33 (38.8) 
Knee 22 (25.9) 
Ankle 15 (17.6) 
Wrist 9 (10.6) 
MCP or PIP 8 (9.4) 
2nd-5th MTP 5 (5.9) 
Elbow 3 (3.5) 
Tarsal 1 (1.2) 
Crystal identified (out of 10 joint aspirations), n (%) 7 (70.0) 
ACR/EULAR classification criteria (n=86)*  
Total ACR/EULAR criteria score, median (IQR) 8 (3), range 0 to 14 
Classified as gout by ACR/EULAR criteria, n (%) 48 (55.8) 
Flare treatments , n (%)  
Any medical treatment 86 (98.9) 
Corticosteroids, systemic 48 (55.2) 
Colchicine 34 (39.1) 
NSAIDs 9 (10.3) 
Corticosteroids, intra-articular 2 (2.3) 
Combination of medications 4 (4.6) 
Sequential medications 3 (3.4) 
Rheumatology consultation, n (%) 1 (1.1) 
*One gout flare episode was not described in detail. 




3.11.3 Prediction models for inpatient gout flare 
The three approaches of prediction model development resulted in three 
different sets of variables associated with inpatient gout flare. Despite the difference in 
protocol, four variables were consistently selected across all three approaches: ‘no pre-
admission ULT’, ‘pre-admission serum urate >0.36 mmol/L’ ‘ULT adjustment’, 
‘diuretic adjustment’. Table 3-13 summarizes the results of the three models. 
3.11.3.1 Model A: clinical knowledge-driven model 
From the original 52 candidate variables, 12 were selected using clinical 
judgment. These 12 variables directly contributed to the fluctuation of serum urate 
level, were previously linked to inpatient gout flare and were deemed clinically 
feasible. Demographics, primary diagnosis categories and most of the comorbidities 
were removed as they were risk factors for incident gout in general or frequently 
coexisting conditions, rather than plausible direct contributors to gout flare risk. The 
inflammatory markers (CRP, neutrophil and platelet count) were removed as their link 
to gout flare was not well established and their inclusion would require additional blood 
tests from the patients.  
The 12 candidate variables included: (1) pre-admission serum urate >0.36 
mmol/L, (2) no pre-admission ULT, (3) ULT adjustment, (4) no pre-admission 
prophylaxis, (5) gout prophylaxis adjustment, (6) tophus, (7) diuretic adjustment, (8) 
AKI, (9) surgery, (10) dialysis, (11) IV fluid ≥2L, and (12) alcohol drinking. The final 
model indicated that nine variables were associated with inpatient gout flare. A linear 
shrinkage factor (s) of 0.89 was applied to the regression coefficients to minimize over-
optimism. The linear shrinkage factor was calculated using a heuristic formula (s = 
[model χ2 - (df - 1)]/ model χ2), where model χ2 was 115.5 and df was 13. 
3.11.3.2 Model B: statistics-driven model  
The LASSO procedure was used for all 52 candidate variables. To ensure the 
simplest final model, the procedure applied the penalty factor (λ) of 0.03, which was 
the highest λ with the lowest error. The penalty factor (λ) was derived using the 10-fold 
cross validation process. The final model consisted of 15 variables across five domains. 
The variables with the highest penalized coefficients were ‘gout prophylaxis started or 
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increased’, ‘no pre-admission ULT’, ‘tophus’, ‘diuretic adjustment’, ‘AKI’, and ‘pre-
admission serum urate >0.36 mmol/L’.  
3.11.3.3 Model C: decision tree model 
The decision tree produced a model, which described people at high risk of 
inpatient gout flare using five influential variables (Table 3-13 and Figure 3-2). Four 
patterns of people at high risk of inpatient gout flare emerged from the decision tree. 
More than half (54%) of people who were not taking ULT prior to admission and had 
their diuretics adjusted developed flare. Alternatively, 30% of those who were not 
taking ULT prior to admission and had serum urate level >0.36 mmol/L experienced 
flare. Thirty percent of people who had their existing ULT adjusted after admission 
developed inpatient flare. On the other hand, 17% of people who continued taking their 




Table 3-13 Variables selected by the three model-building approaches and their 
corresponding regression coefficients (study 1) 
Variables in the final model Model A* Model B† Model C‡ 
Intercept -5.39 -2.87 NA 
1. No pre-admission ULT     1.32 0.69 Level 1 
2. No pre-admission prophylaxis 1.90 0.30 x 
3. Tophus  1.30 0.50 x 
4. Pre-admission serum urate >0.36 
mmol/L§ 
1.08 0.40 Level 3 
5. ULT adjustment 0.99 0.28 Level 2 
6. Prophylaxis started or increased 2.54 0.70 x 
7. Diuretics adjustment 0.95 0.46 Level 2 
8. Acute kidney injury  0.75 0.44 x 
9. Surgery 0.54 x x 
10.  IV Fluid ≥2L within 48 hours  x 0.20 Level 3 
11.  Disease of the nervous system 
(primary diagnosis) 
NE 0.17 x 
12.  Stroke (comorbidity) NE 0.07 x 
13.  Warfarin adjustment    NE 0.36 x 
14.  Blood product within 48 hours NE 0.05 x 
15.  C-reactive protein ≥100 mg/L NE 0.40 x 
• CRP not tested NE -0.10 x 
16.  Platelet ≥450 x109/L NE 0.02 x 
17.  Dialysis  x x x 
18.  Alcohol drinking x x x 
* Shrunken regression coefficients for model A (linear shrinkage factor =0.89). 
† Penalized regression coefficients for model B (penalty factor λ =0.03). 
‡ For model C, variables were ranked according to their level of tree branch. 
§ Urate ≤0.36 mmol/L set as reference. 
‘x’ indicates the variables entered into the model but were subsequently removed. 
‘NE’ indicates the variables not entered into the model. 





Figure 3-2 Chi-square automatic interaction detection (CHAID) decision tree 
(study 1) 
 
3.11.4 Model performance and selection 
C-statistics were used to assess the discrimination of all three prediction models. 
Calibration slope was used for the assessment of calibration for model A and model B. 
Calibration slope was not applicable for model C because the decision tree algorithm 
did not produce regression coefficients. In addition to the discrimination and 
calibration, practicality is also considered when choosing the most appropriate final 
model. The model should be as simple as possible so that it can be easily applied to 
clinical practice.  
Models A and B showed comparable discrimination between flare and non-flare 
groups (0.82 and 0.81, respectively). Model C had relatively inferior discrimination at 
0.76. Model A displayed the best model fit with calibration slope of 0.93 and the 
predicted probability of flare between the lower and upper most decile of the calibration 
plot of 1% and 48%, respectively. Table 3-14 and Figure 3-3 summarize the 
performance of each model.  
Taking practicality into consideration, models A and C had fewer variables 
compared to model B. They also contained variables that were available through 
routine history taking and physical examination and did not require additional blood 
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test. Ultimately, the clinical knowledge-driven model (model A) was selected for its 
satisfactory performance and practicality. Table 3-15 shows the variables, as well as 
their coefficients, OR and 95%CI, in the final model. 
Table 3-14 Performance of the three prediction models in study 1 






Model A: clinical 
knowledge-driven 
9 0.82 (0.77 to 0.86) 0.93 (0.33 to 1.52) 
Model B: statistics-driven 15 0.81 (0.76 to 0.86) 2.11 (1.66 to 2.56) 






Figure 3-3 Calibration slopes for model A and B (study 1). X-axis and Y-axis 





Table 3-15 Variables in the final prediction model (study 1) 







Intercept - - -6.06 -5.39 
No pre-admission 
ULT     
4.40 (2.50 to 7.87) <0.001 1.48 1.32 
No pre-admission 
prophylaxis 
8.44 (2.26 to 31.57) 0.002 2.13 1.90 
Tophus  4.32 (1.39 to 13.40) 0.011 1.46 1.30 
Pre-admission serum 
urate >0.36 mmol/L 
3.36 (1.31 to 8.61) 0.012 1.21 1.08 
ULT adjustment† 3.04 (1.31 to 7.03) 0.009 1.11 0.99 
Prophylaxis started 
or increased† 
17.36 (2.76 to 
109.24) 
0.002 2.85 2.54 
Diuretic adjustment† 2.91 (1.58 to 5.39) 0.001 1.07 0.95 
Acute kidney injury† 2.33 (1.23 to 4.43) 0.01 0.85 0.75 
Surgery 1.84 (1.01 to 3.38) 0.049 0.61 0.54 
* Linear shrinkage factor =0.89 
† Occurs during admission and prior to flare 
CI, confidence interval; OR, odds ratio; ULT, urate-lowering therapy 
 
3.11.5 Model internal validation 
A 1,000-sample bootstrap validation was performed on the selected model A. 
The optimism-corrected C-statistic was 0.80 (95%CI 0.78 to 0.88), which was 
comparable to the original C-statistic (0.82). The optimism-corrected calibration slope 
was 0.78 (95%CI 0.52 to 1.02), compared to the original slope of 0.93. In other words, 
model A showed similar discrimination but slightly lower calibration when tested in 






This study identified a set of variables associated with the risk of inpatient gout 
flare, using a cohort of 625 people from three hospitals in the Wellington region. Three 
main observations emerged from the study. First, the prevalence of inpatient gout flare 
was lower than previously reported. Second, the cohort provided insights into the 
characteristics of inpatient gout population. For the third and most important 
observation, a set of variables associated with the risk of inpatient gout flare was 
identified. The following discussion will address these three observations followed by 
the study’s strengths and limitations, as well as potential clinical application. 
3.12.2 Word search method paints a different picture for the prevalence of 
inpatient gout flare 
In the current study, the prevalence of inpatient gout flare among people with 
comorbid gout was 14%, a number much lower than the existing literature had 
suggested (Table 2-5). The previous two studies that recorded people with inactive 
comorbid gout reported the prevalence of inpatient gout flare of 34% and 35%.(154, 
155) Notably, both these studies identified people with comorbid gout using hospital 
discharge ICD-10 coding provided by attending clinicians. This method could indicate 
selection bias, as people who developed inpatient gout flare were more likely to gain 
attention from attending doctors and thus were more likely to have their gout flare 
coded at discharge. On the other hand, people with comorbid gout who did not develop 
inpatient flare (the non-flare population) were more likely to be overlooked and did not 
receive discharge coding. A similar pattern was observed in the current study. When 
only people identified by discharge ICD-10 coding were considered, the prevalence of 
inpatient gout flare was as high as 77% (72/94 people). 
The current study managed to partially overcome this bias by also adopting the 
‘discharge letter word search’ as an additional method for identifying people with 
comorbid gout. The word search methods could identify specific terms (e.g., gout) that 
appeared anywhere in the electronic hospital discharge letter. For the discharge letter 
from hospitals in CCDHB and HVDHB, it was common for the medical staff 
completing the discharge summary to list gout as one of the known comorbid 
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conditions or inactive conditions. Over 84% of people in the current study were 
identified only by discharge letter word search methods. This led to a more accurate 
portrayal of hospitalized people with comorbid gout, because people with comorbid 
gout who did not have inpatient flare were more comprehensively captured compared 
to previous studies. 
The word search method may provide a valuable alternative to the discharge 
coding for patient identification in future research. This method would be especially 
effective in identifying inactive comorbidities not usually captured simply by ICD-10 
diagnosis codes. A possible disadvantage of the word search method is the need for 
manual review to ensure accurate identification. The appearance of the word ‘gout’ in 
the discharge letter could entail several possible meanings. For example, gout might be 
one of the initial differential diagnoses or it could appear as family history rather than 
comorbidity. As a result, word search may carry high chance of false positive 
identification. In the current study, all medical records identified by word search were 
manually reviewed to ensure gout diagnosis and thus overcome this potential 
disadvantage. 
3.12.3 Insights into the inpatient gout population 
3.12.3.1 Inpatient gout differs from outpatient gout 
The population of hospitalized people with comorbid gout has not been directly 
described in a large study before. The existing large gout cohorts were outpatient-
based(164, 188, 189) or they did not discern outpatient from inpatient population.(190, 
191) Several hospital-based studies have been published but they only focused on 
people who had gout flare rather than people with comorbid gout overall.(157-160) As 
a result, the current study provides a valuable insight into the particular population of 
hospitalized people with comorbid gout.  
Table 3-16 shows the demographics and comorbidities of the current study, 
compared with two recent large outpatient cohorts.(164, 188) Compared to the 
outpatient setting, the inpatient population was older and had a lower proportion of 
men. The larger percentage of women could be explained by the higher average age of 
the inpatient population, as gout typically manifests at a later age in women compared 
to men.(41) Inpatient population also had higher prevalence of comorbidities compared 
to outpatient population, most commonly cardiovascular disease, heart failure, 
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cerebrovascular disease and diabetes mellitus. These comorbidities might influence the 
treatment of gout flare by raising safety concerns over the use of anti-inflammatory 
drugs especially NSAIDs and corticosteroids. The findings further reinforced the 
significance of this particular population who was older and burdened with multiple 
comorbidities, potentially requiring different management strategy compared to the 
general gout population. 
Table 3-16 Demographics and comorbidities of people  with comorbid gout in the 
study 1 cohort compared with two large outpatient cohorts  




Setting Inpatient  Outpatient  Outpatient  
Number of patients 625 1003 778 
Male, %  78% 88% 98% 
Age, mean±SD (years) 68.9±13.6 62.6±11.4 NR 
Dyslipidemia, % 24% (cholesterol) 47% 67% 
Diabetes, % 30% 15% 11% 
Cerebrovascular disease, % 19% 3% 3% 





Heart failure, % 29% 3% NR 
BMI >30, % 16% 29% 35% (obesity) 
BMI, body mass index; CAD, coronary artery disease; CHD, coronary heart disease; 
MI, myocardial infarction; NR, not reported; SD, standard deviation 
 
3.12.3.2 The current study cohort agrees with other inpatient cohorts 
In this study, the majority of people were admitted to a medical department and 
the most common primary diagnosis included diseases of the circulatory, digestive, 
respiratory, musculoskeletal and genitourinary system. These findings mirrored 
previous hospital-based studies.(153, 155, 156) Among people with comorbid gout, 
having gout flare was statistically associated with longer length of hospital stay 
compared to the non-flare group in the current study (median 8 vs. 2 days, p <0.001). 
This observation was similar to previous hospital-based reports from Australia which 
identified 77 admissions with inpatient gout flares. The median length of stay in people 
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with gout flare was nine days, compared to two days among non-gout control 
population.(168) Similarly, an inpatient study of hospitalization with comorbid gout 
from the United States reported median length of stay for hospitalization with inpatient 
gout flare of six days, compared to three days in hospitalization without inpatient gout 
flare.(156) 
3.12.3.3 Gout management in the Wellington region is suboptimal 
Overall, 65% of the people received ULT prior to admission. This overall 
prevalence was higher than those reported in a recent meta-analysis of gout 
management in general practice.(192) In this meta-analysis, six out of eight included 
studies found less than 50% of people receiving ULT. The higher ULT use in the 
current study could be due to the cohort having greater number of people with 
advanced gout who were more likely to be prescribed with ULT. However, the 
prevalence of ULT use was low (44%) when only the flare group was considered. This 
observation was in agreement with previous studies of people with gout flare, which 
reported the prevalence of ULT use between 26% and 50%.(154, 157, 158) Adjustment 
of ULT was documented in 8% of the flare group in the current study, a prevalence 
lower than that observed in an Australian study (27%).(154) 
Sixty-two percent of the current cohort had serum urate level tested at least once 
within 12 months prior to admission, a prevalence comparable to the rates of urate 
monitoring in the general Australian gout population (55% within 5 years).(193) The 
observations reflected suboptimal quality of gout management in the current cohort, 
which appears to be a persistent global problem.(3, 192-195) 
Joint aspiration was performed in only 10 episodes (12%). Previous hospital-
based studies found that 31% to 41% of episodes underwent joint aspiration.(155, 158, 
160) This might be associated with the very low rates of rheumatology consultation in 
the current cohort (1%), compared to the previous similar studies (17% to 57%).(155, 
158, 160) In terms of gout flare treatment, the majority of people received systemic 
corticosteroids (55%), which was likely due to concomitant comorbid conditions 
preventing the use of NSAIDs and colchicine. Other hospital-based studies also 
reported high prevalence of systemic corticosteroid use for flare treatment (61% to 
72%).(157, 158) These findings emphasized the challenges in the diagnosis and 
treatment of gout flare in hospital setting, an area that still needed improvement. 
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3.12.4 A critique of the prediction models for inpatient gout flare 
A prediction model for inpatient gout flare has not been previously reported. 
Three different approaches were taken in the development of the prediction model: 
clinical knowledge-driven (model A), statistics-driven (model B) and decision tree 
models (model C). Ultimately, the nine-item clinical knowledge-driven model was 
selected as the final model due to its satisfactory performance and practicality. Four out 
of nine variables from the final model were also selected by the other two approaches. 
The remaining five were also selected by one other approach. The final model’s 
performance remained acceptable after 1,000-sample bootstrap validation procedure. 
3.12.4.1 The robustness of the model development approaches 
It must be emphasized that a prediction model derived from any development 
cohort, regardless of the quality, cannot capture all existing predictors for the target 
event. Furthermore, some of the significant predictors could potentially be surrogate 
variables or simply random variation (statistical noise). The decision to take three 
approaches in model development allowed different patterns of variables to emerge. 
For the nine-item final model, all variables were also picked by at least one other 
method (four were picked by all methods). This relative agreement between different 
methods provided some evidence indicating that the approaches were robust and that 
the selected predictors were sufficiently reliable.  
Over-optimism. Model over-optimism was one of the major concerns for this 
type of study. An over-optimistic model would underestimate the probability of flare in 
low risk people but overestimate the probability of flare in high risk people, resulting in 
poor calibration. The current cohort had a relatively small number of subjects and lower 
than expected number of events. Therefore, the cohort was prone to over-optimism and 
instability.(187) To minimize this over-optimism, shrinkage techniques (LASSO and 
linear shrinkage factor) were applied to correct for potentially over-optimistic 
regression coefficients. Shrinkage techniques, regardless of the type, could significantly 
improve model calibration compared to simple regression in a small dataset.(181)  
Validation. For the validation of the selected model (model A), bootstrap 
resampling method was adopted, which could be classified as an ‘internal validation’. 
The current study refrained from splitting the cohort into development and validation 
datasets. Data splitting required very large sample size to be sufficient and could suffer 
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from fortuitous splitting, where some variation occurred by chance.(186) Bootstrap 
procedure resampled the original cohort with replacements, creating multiple mimics of 
the original dataset. The original model development process was repeated in the 
bootstrap samples and the new models were tested against the original cohort, 
producing the optimism-corrected performance estimates. In a small dataset, bootstrap 
validation was not inferior to validation by data splitting and was in fact recommended 
by some prediction model researchers.(171, 196)  
3.12.4.2 Clinical knowledge-driven model (model A): prior knowledge is 
relevant 
The clinical knowledge-driven model included a reduced set of variables, pre-
selected based on published literature and clinical judgment.  These pre-selected 
variables were entered into a regression model to determine the degree of association to 
inpatient gout flare. Variable selection by clinical knowledge was a preferable 
alternative to purely p-value based selection (univariable and stepwise selection) which 
was prone to selecting noises by chance.(179) Knowledge-based variable selection also 
ensured that all variables in the final model were intuitive to clinicians. This was 
especially advantageous, because the model was intended to be used in clinical 
practice. However, this approach was not effective for exploring variables outside the 
existing boundary of knowledge. 
The final model contained nine variables, most of which were long assumed to 
be associated with the risk of inpatient gout flare through clinical experience and 
clinical reasoning. The nine-item model was simple enough for potential application in 
clinical practice and the items were readily available in typical inpatient settings. The 
model showed superior discrimination to model C (0.82 vs. 0.76) and comparable 
discrimination to model B (0.82 vs. 0.81). Furthermore, model A displayed an excellent 
calibration compared to model B (0.93 vs. 2.11).  
For validation, the optimism-corrected C-statistic was comparable to the 
original value (0.80 vs. 0.82), confirming the model’s ability to discriminate flare from 
non-flare group. The optimism-corrected calibration slope, however, deviated away 
from the original value (0.78 vs. 0.93), which indicated that the model was somewhat 
over-optimistic. A certain degree of over-optimism was to be expected from this type of 
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prediction model study. Ultimately, the optimism-corrected calibration was judged to 
be acceptable. 
3.12.4.3 Statistics-driven model (model B): let the numbers decide 
The idea for the statistics-driven model (model B) was to ‘let the numbers 
decide’ on which combination of variables was associated with inpatient gout flare 
without external intervention. This could be a chance to explore new variables not 
previously linked to inpatient gout flare. LASSO procedure was chosen due to its 
ability in both variable selection and shrinkage. LASSO was a reasonable alternative to 
the traditional regression protocol, which included univariable screening followed by 
stepwise multivariable regression analysis. For a small dataset with low event per 
variable ratio, the traditional regression protocol was not recommended because it had 
limited power to select important variables, thus compromising the predictive ability. 
Stepwise regression could also lead to unstable selection, meaning that a small change 
in the dataset could alter the variables selected.(179)  
The results of model B revealed a set of 15 variables deemed to be associated 
with inpatient gout flare. From a clinician’s perspective, a 15-item prediction model 
could be difficult to apply in clinical practice. The model had acceptable discrimination 
between flare vs. non-flare group (C-statistic 0.81). However, it had suboptimal 
calibration (calibration slope 2.11), meaning there was significant disagreement 
between the predicted probability and the observed probability of flare. The poor 
calibration could be the result of large number of candidate variables and the possibility 
that some of them correlated with one another. Model B was ultimately dropped due to 
its suboptimal calibration and complexity. However, some variables selected by this 
model might warrant further study as to how they could be linked to inpatient gout 
flare. These potential variables are further discussed in section 3.12.5. 
3.12.4.4 Decision tree model (model C): let the machine decide 
The use of tree-based machine learning algorithm has gained more popularity in 
medical research in the past three decades since it was introduced in 1986.(197) The 
algorithm, specifically CHAID, was previously used in a number of medical researches 
for prediction model development.(198-200) Decision tree can process large amounts 
of data and produce results that are easy to interpret. It is also a non-parametric 
procedure, making no assumption of the dataset.(184) The use of decision tree model 
74 
 
was considered an alternative to model A and model B, which were both regression 
models. The highly visualized decision tree would also add valuable insights into the 
relationship between the variables and inpatient gout flare.  
However, decision tree algorithm has a major drawback. The model tends to be 
unstable and minor change in the dataset can lead to a different tree.(184) This is why 
decision tree has worked well with large datasets but data splitting into development 
and validation cohort was often needed. The current study faced this particular issue, as 
the sample size was relatively small. The current cohort was too small for data splitting 
and could not handle a very large tree, leading to a limited level of tree branches, as 
well as limited number of child nodes.  
The final decision tree contained five variables, all of which also appeared in the 
other two models. This relative agreement between models derived by different 
methods was reassuring in terms of the model validity. The model portrayed an 
interesting picture of four groups of people who may be at high risk of developing 
inpatient gout flare:  
(1) People not taking ULT prior to admission who had their diuretics adjusted. 
(2) People not taking ULT who had pre-admission serum urate >0.36 mmol/L.  
(3) People who had their existing ULT adjusted during admission. 
(4) People who were taking ULT prior to admission and received intravenous fluid 
≥2L during admission. 
This portrayal of how each variable interacted with one another provided 
unique insight not available from regression models. However, the decision tree model 
was not chosen because it had the lowest discrimination. It was possible that a larger 
dataset would produce a more complex tree with better precision. 
3.12.5 The predictors of inpatient gout flare in the context of existing 
knowledge 
The final model (clinical knowledge-driven) consisted of nine variables. Their 
association to the risk of inpatient gout flare was largely backed by existing knowledge. 
In theory, an acute illness could prime the macrophage for an inflammatory response 
against the deposited MSU crystals.(124) Fluctuation of serum urate could further 
trigger acute inflammatory episode by crystal dissolution or formation. The nine 
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proposed predictors could be roughly divided into two groups: (1) predictors reflecting 
poorly controlled gout (pre-admission urate, tophus, absence of pre-admission gout 
medications and prophylaxis started or increased) and (2) predictors reflecting acute 
event that could trigger gout flare (ULT adjustment, diuretic adjustment, surgery and 
AKI). 
To date, there were only a few studies examining the predictors of inpatient 
gout flare. Some of these studies were done in specific groups of people, such as 
postsurgical patients(130, 170) and acute cerebrovascular disease patients.(162) A 
recent study by Zleik et al. from the United States evaluated the potential predictors of 
inpatient gout flare among 454 admissions (169 people and 23 inpatient flares episodes) 
with comorbid gout. They however did not find association between any candidate 
variables and inpatient gout flare. Their low number of flare episodes might have 
limited the study’s power.(156) In a study by Dubreuil et al., hospitalization was 
associated with increased risk of flare. The use of ULT, colchicine and NSAIDs might 
have lowered the risk of flare but did not reach statistical significance. The study also 
had a small number of flares (33 episodes).(11)  
Considering the lack of existing published evidence of predictors of inpatient 
gout flare, the current study provided a valuable addition to this understudied subject. 
The following section will provide some evidence-based explanation on how the newly 
identified set of predictors may be associated with the risk of inpatient gout flare in 
people with comorbid gout. 
3.12.5.1 Pre-admission serum urate 
Elevated serum urate is a major risk factor for incident gout as it plays a central 
role in crystal formation, crystal deposition and subsequently the occurrence of acute 
inflammatory response. In theory, an alteration of serum urate level contributes to the 
occurrence of gout flare. A decrease in serum urate level could lead to crystal 
dissolution and shedding into the joint, which then triggers flare. On the other hand, an 
increase of serum urate level might lead to crystal formation, which then triggers 
inflammatory response.(1) However, it must be noted that the latter assumption was 
disputed as crystal formation was generally a slow process.(135) 
An association between pre-admission serum urate level >0.36 mmol/L and 
inpatient gout flare in this study did not come as a surprise. In the general gout 
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population, many large studies had drawn similar connection between serum urate 
levels to the risk of gout flare, with most of the association showing a dose-response 
trend.(103, 128, 201-203) For the inpatient gout population, increasing pre-admission 
serum urate and in-admission, pre-surgical urate ≥0.54 mmol/L had been linked to 
inpatient gout flare in two small controlled studies among stroke and postsurgical 
patients, respectively.(130, 162) 
For the current study, pre-admission serum urate level was chosen as candidate 
predictor instead of in-admission serum urate to avoid the need for additional blood test 
for hospitalized people. The pre-admission serum urate represented how well gout was 
controlled prior to admission. A poorly controlled serum urate level would put the 
patients at risk of inpatient gout flare. However, the occurrence of inpatient gout flare 
would theoretically need a separate in-admission factor to trigger gout flare (e.g., acute 
illness, diuretic adjustment, ULT withdrawal). 
3.12.5.2 Pre-admission gout medications and their adjustment 
Maintaining serum urate at sub-saturation level with ULT is central in the treat-
to-target strategy of gout management. Sub-saturation level of serum urate induces 
urate crystal dissolution, reduces tophus size and diminishes the risk of gout flare.(14) 
The absence of ULT prior to admission in people with comorbid gout could indicate 
suboptimal control of serum urate, putting them at risk of inpatient gout flare. Stopping 
or reducing the dosage of existing ULT could cause sudden rise of serum urate and 
increases the chance of flare.(113) On the other hand, initiation of ULT could rapidly 
lower serum urate level and trigger flare. This particular phenomenon was well 
established by randomized controlled trials of allopurinol and febuxostat, which found 
a rise in gout flare rates during the first eight weeks of ULT initiation.(110, 112)  
ULT adjustment was widely presumed to increase the risk of inpatient gout flare 
but the evidence remained lacking so far. Two previous studies evaluated ULT 
withdrawal in relation to inpatient gout flare but found no significant association. 
However, both studies had smaller populations and numbers of flare episodes, 
compared to the current study.(156, 162)  
Pre-admission gout prophylaxis with anti-inflammatory agent was 
recommended during at least the first three to six months of ULT in order to prevent 
gout flare.(21, 113) The absence of prophylactic agent during admission would 
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predictably leave the patients vulnerable to triggers of flare frequently found in hospital 
setting. As expected, the lack of pre-admission gout prophylaxis was found to be 
associated with the risk of inpatient gout flare in the current study. 
Regarding gout prophylaxis adjustment, the current study found that starting or 
increasing gout prophylaxis medication was associated with the risk of inpatient gout 
flare. This could reflect poorly controlled gout and perceived higher risk of flare (i.e., 
recent or frequent flare, low treatment adherence) that prompted the attending doctors 
to take preventive action during hospital admission. However, this speculation could 
not be confirmed due to the retrospective nature of the study. 
3.12.5.3 Tophus  
A clinical hallmark of gout, the presence of palpable tophus typically represents 
high urate burden. Up to 90% of people with palpable tophus and serum urate ≥0.36 
mmol/L had evidence of urate deposition from DECT.(204) A recent DECT study 
found an association between volume of urate deposition in the feet and 2-fold increase 
of the risk of gout flare within six months.(205) A recent single-centre study also 
reported an association of clinical tophus to the risk of recurrent gout flare in a Korean 
population with gout.(206) In the current study, the presence of tophus indicated 
advanced and poorly controlled disease and subsequently high risk of gout flare. 
However, it was possible that the prevalence of palpable tophus might have been 
underestimated in the current cohort especially in the non-flare group where gout was 
not the main focus during the hospital course. This limitation could lead to possible bias 
of tophus prevalence towards the flare group. 
3.12.5.4 Diuretic adjustment 
Diuretics increase uric acid reabsorption in the renal proximal tubules, causing 
rise of serum urate within a few days.(175) In the general gout population, diuretics 
was associated with both the risk of incident gout(68) and the risk of developing gout 
flare.(136) However, previous studies in hospital setting could not establish the link 
between diuretic use and the risk of gout flare.(156, 162) This could be explained by 
the fact that long-term diuretic exposure only caused hyperuricemia, but a rapid change 
in serum urate level was instrumental for the development of gout flare. Therefore, the 
current study collected data on ‘diuretic adjustment’ instead of ‘diuretic use’ and found 
association between the two variables. 
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3.12.5.5 Acute kidney injury 
A decrease in glomerular filtration rate typically results in elevated level of 
serum urate. Chronic kidney disease was associated with the risk of incident gout(207) 
and the risk of gout flare in the general gout population.(208) However, it was not 
established whether AKI was associated with gout flare. For the current cohort, data on 
AKI, rather than chronic kidney disease, was collected based on the assumption that 
AKI would cause sudden change of serum urate level and could directly contribute to 
flare. Furthermore, the data on AKI was anticipated to be more reliable in the hospital 
records, as AKI was a serious condition that required medical intervention and 
monitoring. 
3.12.5.6 Surgery  
Postsurgical gout has been described in a number of studies, with prevalence of 
postsurgical flare among people with comorbid gout ranging from 17% to 33%.(131, 
209)  Cancer surgery(130) and abdominal surgery(170) were reported to be associated 
with postsurgical gout flare. There were many possible mechanistic explanations for 
postsurgical gout flare, including tissue breakdown,(131) starvation and 
overhydration.(1) Gout flare following intra-articular procedure such as arthroscopy or 
arthroplasty was occasionally reported.(210, 211) Such procedure might cause synovial 
injury and crystal shedding into the joint. Systemic inflammation following knee and 
hip surgery has been shown to lower serum urate, though the study was done in a non-
gout population.(134) Notably, postsurgical decrease in serum urate level was recently 
reported to be associated with postsurgical gout flare in a cohort of surgical patients in 
China.(170) Nothing-by-mouth (NPO) patients would have to stop taking their existing 
gout medications which could also contribute to the risk of gout flare. In conclusion, 
surgery could theoretically contribute to the risk of inpatient gout flare via multiple 
mechanisms. The current study could confirm the association between surgery and the 
risk of inpatient gout flare, but was not able to provide clear mechanistic explanation.  
3.12.5.7 Other potential predictors  
Multiple predictors excluded from the final model (model A) were nevertheless 
selected by either model B or model C. The majority of these factors had unclear 
connection to the risk of inpatient gout flare. It was possible that some of them were 
surrogate variables. Nevertheless, they might be worth exploring in future studies. 
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Male gender was a well-established risk factor for incident gout. The link 
between male gender and the risk of inpatient gout flare in this study could be 
explained by the fact that most people in the cohort were men. The onset of gout was 
also typically earlier in men, compared to women.(41) This could lead to greater 
likelihood for men to have advanced disease and higher risk of flare. However, Zleik et 
al. previously explored male gender and the risk of inpatient gout flare, but found no 
association.(156) 
Model B selected stroke (comorbidity) as a potential predictor for inpatient gout 
flare. Stroke frequently accompanied gout.(81) It was however difficult to draw direct 
connection between comorbid stroke and inpatient gout flare. People admitted due to 
disease of the nervous system might face multiple events that increase the risk of gout 
flare. For example, an acute stroke patient might not be able to take oral medication 
(nothing by mouth) and may have received a large amount of intravenous fluids. 
Intravenous fluid in the first 48 hours was selected by both model B and model 
C, while blood product was selected by only model B. IV fluids could alter serum urate 
level and this was believed to play a role in inpatient gout flare.(130) It was unclear 
how receiving blood product might be associated with gout flare. It was possible that 
the same explanation for IV fluid would also be applicable to blood product. 
The effect of warfarin on urate level was conflicting. A study suggested 
warfarin elevated serum urate level through increased urate production,(176) while 
another study found no effect.(212) So far, no study has drawn any connection between 
warfarin use and gout flare. Warfarin adjustment was selected by model B. It could be a 
surrogate for other variables such as coexisting heart disease. 
Inflammatory markers during admission including CRP and platelet count were 
selected by model B as predictors of inpatient gout flare. Systemic inflammation could 
decrease urate level in a study of postoperative normouricaemic non-gout patients.(134) 
No study has evaluated the association of these inflammatory markers to gout flare in 
hospital setting. In this study, the in-admission inflammatory markers likely indicated 
high degree of systemic inflammation related to the primary admission diagnosis, 
which was highly non-specific. As a result, it was difficult to draw any conclusion 
regarding the role of these markers from the current study. Inflammatory markers were 
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not selected for model A because they would require additional blood test, which was 
judged to be too invasive for the assessment of the risk of gout flare. 
3.12.6 Limitations 
3.12.6.1 Some people with comorbid gout might not be identified 
Two methods for participant identification (discharge ICD-10 coding and 
discharge letter word search) were used to ensure that most eligible people were 
identified. However, a small number of eligible people could still be overlooked. This 
was presumably more likely to happen in the non-flare group, where comorbid gout 
might not be documented in either the discharge letter or coded as comorbid diagnosis 
at hospital discharge.  
3.12.6.2 Some predictors were not available in hospital notes 
It is important to emphasize that no prediction model could capture all existing 
predictors. The nine proposed predictors in this study were derived from data that were 
available in the hospital notes. The model development was therefore limited to the 
variables directly related to those particular hospital events. The data regarding past 
history of gout (e.g., duration of disease, past history of flare, medication adherence, 
life style information) were mostly not available in hospital records. This limitation 
disproportionally affected the non-flare group whose inactive gout did not gain much 
attention from the attending doctors. Due to the same limitation, the prevalence of some 
variables such as alcohol drinking, palpable tophus and urinary tract stone could have 
been underestimated as well. 
People with high serum urate level earlier in the past year but had low serum 
urate just before hospital admission (i.e., after starting ULT) would have been labelled 
as having serum urate >0.36 mmol/L. This could have led to potential overestimation of 
the prevalence of pre-admission serum urate >0.36 mmol/L in the cohort. 
3.12.6.3 Potential inclusion of non-gout arthritis episodes 
 There was a possibility that people with acute arthritis episode from conditions 
other than gout could have been erroneously included in the cohort because crystal 
identification was not required for the classification of the flare episode. However, this 
likely accounted for a very small proportion of the cohort due to the following reasons:  
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• People in the cohort were already known to have gout.  They have therefore 
had evaluation of musculoskeletal symptoms at least once before in primary 
care, previous outpatient clinic or previous hospitalizations.  It would be 
reasonable to assume that any new diagnosis related to the musculoskeletal 
system (or arthritis) would have been listed in admission notes.  
• Flare episodes occurred in the hospital setting, which meant that any major 
misdiagnosis (e.g., septic arthritis, psoriatic arthritis, hemarthrosis) would 
likely to have been identified during the same hospital event.  
• Gout prevalence is very high in New Zealand. Therefore, the doctors are 
presumably familiar with gout diagnosis. Furthermore, inpatient setting 
usually involves more than one clinician, leading to even lower chance of 
major misdiagnosis.  
There is still a possibility that people with conditions which often mimic the 
natural course of gout flare (e.g., calcium pyrophosphate crystal arthritis or 
osteoarthritis with acute inflammation) could have been mistakenly included as having 
a gout flare episode. However, this could be considered a strength. If the cohort were 
indeed confounded by non-gout episodes, the association of the selected variables 
should have been weaker because the variables were highly specific to gout (e.g., serum 
urate, ULT adjustment). The strong association found in this study despite this 
limitation is compelling. 
3.12.6.4 Relatively small cohort size and number of flare episode 
The current cohort of hospitalized people with comorbid gout was one of the 
largest compared to previously published studies. However, the sample size remained 
relatively small for prediction model development. The number of gout flare episodes 
were also lower than originally expected, which further limited the power of the 
regression analysis. Multiple measures were applied to address this limitation: taking 
multiple approaches in model development, implementing shrinkage techniques to 
minimize model overfitting and using bootstrap procedure to ensure the model’s 
validity. Despite these efforts to make the model as robust as possible, there was still a 
possibility that the model would not perform as well as expected when applied to a 
different population. An external validation in an independent cohort is therefore 
conducted in Chapter 5. 
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3.12.7 Application and further research 
The final prediction model was practical and non-invasive, as the predictors 
were readily available in typical hospital care setting. The predictors were easily 
accessible by focused history taking, review of medication, past laboratory results and 
physical examination. These predictors could assist clinicians in assessing the risk of 
inpatient gout flare in people with comorbid gout.  
There were however some practical issues to consider. Since the target 
population of the prediction model was people with comorbid gout, it was essential for 
the attending doctors to identify people with comorbid gout at the time of admission 
before risk stratification could begin. This could be challenging, as the attending 
doctors’ attention would typically be divided between multiple active problems. 
Nevertheless, a quick review of comorbidities usually revealed a history of gout, which 
subsequently raised awareness of gout flare as a potential inpatient complication. It 
would also be ideal to evaluate the risk of gout flare throughout the course of hospital 
stay, because the predictors of flare could build up overtime. For example, some people 
might need urgent surgery several days after admission and have to stop taking existing 
ULT. 
It is important to emphasize that this set of proposed predictors is not definitive. 
The absence of the proposed predictors does not guarantee a flare-free hospital course 
and, on the other hand, some people may not develop flare despite having multiple 
predictors. Ultimately, the judgment regarding the risk of inpatient gout flare belongs to 
the attending doctors.  
Currently, there is no standardized way to stratify the risk of inpatient gout flare. 
Consequently, there is no scientific evidence for any intervention to prevent such 
complication. The proposed prediction model could at least help identify the people at 
high risk and encourage clinicians to be more attentive to this particular group of 
people. Heightened awareness of the risk of gout flare may lead to earlier detection and 
treatment for flare episodes. Simple actions could also be taken, as some predictors are 
easy to correct such as making sure the patient continues existing ULT and/or gout flare 
prophylaxis if appropriate during admission. 
The overarching aim of the thesis is to propose a simple clinical tool to identify 
people at high risk of inpatient gout flare. This may lead to future studies on preventive 
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intervention such as the use of prophylactic agent during hospital stay. This chapter 
serves as the basis for Chapter 5, in which such a clinical tool will be developed and 
tested in an independent cohort.  
3.12.8 Conclusion  
The study identified a nine-item prediction model for inpatient gout flare in 
people with comorbid gout. The model was derived from a cohort of 625 hospitalized 
people with comorbid gout in the Wellington Region. Three different approaches were 
taken for model development, including clinical knowledge-driven, statistics-driven, 
and decision tree models. The clinical knowledge-driven model was chosen for its 
superior performance and practicality. The performance of the final model was 
acceptable after bootstrap validation. The nine predictors were accessible in routine 
hospital care setting without requiring any addition intervention. Using the results of 
this study, a simple risk stratification tool for inpatient gout flare will be developed and 





Chapter 4 Association between the 
predictors of inpatient gout flare and the 
length of hospital stay (study 2) 
4.1 Summary 
 Inpatient gout flare is associated with longer length of hospital stay, irrespective 
of the original reason for hospital admission. In the previous chapter, nine predictors of 
inpatient gout flare in people with comorbid gout were identified. However, the 
relationship between these predictors and the length of hospital stay has not been 
evaluated. This study aimed to explore the association between the predictors of 
inpatient gout flare (identified from the previous study) and the length of hospital stay, 
using health administrative data from the New Zealand Ministry of Health national data 
collections. The population was people with comorbid gout who were hospitalized in 
publicly funded hospitals in New Zealand in the 2017 calendar year. The primary 
outcome was the length of hospital stay. Using a generalized linear model (GLM), the 
study identified twelve variables independently associated with the length of hospital 
stay: pre-admission regular urate-lowering therapy (ULT), pre-admission urate testing, 
pre-admission diuretics (loop, thiazide and potassium-sparing), pre-admission 
corticosteroids, operation, acute (unplanned) admission, Māori ethnicity, Pacific 
ethnicity, male gender and age. Regular ULT, urate testing, thiazide diuretics and male 
gender were associated with a shorter length of stay, while the other eight variables 
were associated with a longer length of stay. The final model had acceptable goodness 
of fit, according to the residual plot and observed vs. predicted plot. In conclusion, this 
study identified a set of twelve gout-related variables associated with the length of 
hospital stay in people with comorbid gout admitted to hospital for non-gout conditions. 
This study emphasized the impact of variables associated with inpatient gout flare on 
the key hospital outcome (length of stay). The association of regular ULT to the length 
of hospital stay also strengthens the argument for establishing long-term, regular ULT 
in people with gout, where ULT is indicated. 
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4.2 Chapter structure 
 This chapter covers the second study of the thesis. The chapter focuses on the 
same theme of inpatient gout flare in people with comorbid gout, but using a 
nationwide population-based cohort rather than a local hospital-based cohort. The 
chapter describes the study’s rationale, objective, methods, results and concludes with a 
discussion of the study.  
4.3 Rationale 
 Nine predictors of inpatient gout flare were identified in the previous chapter, 
consisting of pre-admission serum urate >0.36 mmol/L, tophus, no pre-admission ULT, 
no pre-admission gout prophylaxis, acute kidney injury, surgery, initiation or increase 
of gout prophylaxis, ULT adjustment and diuretic adjustment. However, the association 
between these predictors and the length of hospital stay has not been explored before. 
Hospital length of stay is an important outcome of a hospital event, being directly 
related to the costs of healthcare and risks for iatrogenic harm. Furthermore, it is known 
that inpatient gout flare is strongly associated with the length of hospital stay. This 
chapter will further explore the impact of some of the predictors of inpatient gout flare 
on the hospital outcome, specifically the length of stay, at a national scale using the 
New Zealand Ministry of Health national data collections. 
4.4 Objective 
This study aims to explore the association between the predictors of inpatient 
gout flare and the length of hospital stay in people with comorbid gout who were 
admitted for conditions other than gout. 
4.5 Study design 
 This is a retrospective cohort study. The population of interest is people with 
comorbid gout admitted to publicly funded hospitals in New Zealand for conditions 
other than gout in the 2017 calendar year. The primary outcome is the length of hospital 
stay (days). Data were extracted from the New Zealand Ministry of Health national data 
collections, where people with comorbid gout were identified using hospital discharge 
87 
 
diagnosis coding or history of ULT or colchicine dispensing. The association between 
the predictors of inpatient gout flare and the length of hospital stay was explored using 
a generalized linear model.  
4.6 Ethical approval 
 The study protocol was first submitted to the Health and Disability Ethics 
Committee (HDEC) for approval, but it was judged to be out of scope for HDEC 
review. The protocol was subsequently submitted to and approved by the University of 
Otago Human Ethics Committee (UOHEC), reference number H19/033. A consultation 
with the Ngāi Tahu Research Consultation Committee was sought. The committee 
considered the research to be of importance to Māori health. The documents concerning 
the ethical consideration process of the study protocol are included in the Appendix B. 
4.7 Study population 
 Adults with comorbid gout who were hospitalized in New Zealand publicly 
funded hospitals in the 2017 calendar year were included in the analysis. The inclusion 
and exclusion criteria for this study were modeled after a study by Winnard et al., 
which described the national prevalence of gout in New Zealand using similar 
administrative health databases.(47) Adult patients were defined as individuals aged 20 
years or older. People with comorbid gout were defined as people who met one of the 
following criteria: (1) people who received ICD-10-AM coding for gout (M10) as 
‘Other diagnosis’ at hospital discharge, OR (2) People who received at least one 
dispensing of gout medication (allopurinol, febuxostat, probenecid, benzbromarone or 
colchicine) in the 2016 or 2017 calendar year. For a condition to be coded as ‘Other 
diagnosis’, the condition typically affects the inpatient management in terms of 
increased clinical care and/or monitoring, alteration of therapeutic treatment or 
requiring diagnostic procedure. For people diagnosed with hematological malignancy 
within 24 months prior to the study period, dispensation of gout medication was not 
used as an indicator of gout case. This was based on the possibility that these people 
received allopurinol for control of hematological malignancy-related hyperuricemia 
rather than for the treatment of gout.  
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Admission in the 2017 calendar year was defined as having both the admission 
date and discharge date in the 2017 calendar year. For people with more than one 
admission in the study period, only data from the first admission were analyzed. The 
selection of only one admission per individual was similar to the first study (Chapter 3) 
to ensure that all cases were independent from each other. Table 4-1 summarizes the 
inclusion and exclusion criteria. 
Table 4-1 Inclusion and exclusion criteria for participants in the study 2 
Inclusion criteria 
• Age 20 years or older 
• Having both admission and discharge dates in the 2017 calendar year 
• First admission of the 2017 calendar year 
• Having gout as a comorbid disease, defined as meeting at least one of the 
following: 
• People who received ICD-10-AM coding for gout (M10) as ‘Other 
diagnosis’ at hospital discharge. OR 
• People with at least one gout medication dispensing (allopurinol, 
febuxostat, probenecid, benzbromarone or colchicine) in the 2016 or 2017 
calendar year. 
Exclusion criteria 
• Receiving ICD-10-AM coding for hematological malignancy (C80 to C96) 
within 24 months prior to the study period 
 
4.8 Variables and their definition  
 The analysis included 19 variables, with the length of hospital stay (days) as the 
primary outcome (Table 4-2). The predictors of inpatient gout flare which could be 
extracted from the national data collections included operation, pre-admission ULT, 
pre-admission gout prophylaxis medications, warfarin and diuretics. Aspirin and 
cyclosporine were also included for their association with hyperuricemia and gout.(175) 
Older age, male gender, Māori and Pacific ethnicity and lower socio-economic status 
were associated with higher prevalence of gout.(47) Māori and Pacific ethnicity were 
also associated with inferior quality of gout care according to several indices (e.g., 
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regular allopurinol dispensing, hospitalization rate).(119, 213) Type of admission 
(acute vs. planned) was included because it was likely to be influential to hospital 
outcome (particularly length of stay). The list of variables, the rationale for including 
them in the analysis, as well as their sources are summarized in Table 4-2. 
Table 4-2 List of variables and their sources in study 2 
Variables  Rationale  Database  Derivation from original 
database 
Length of stay (days) Outcome  NMDS Calculated by subtracting 
the ‘event start date’ from 
the ‘event end date’ 
(1) age at discharge 
(year) 





NMDS Transformed from ethnicity 
code 
(4) gender Demographics NMDS Readily available 
(5) NZDep (1 to 10) Demographics NMDS Derived by matching the 
NZDep decile to ‘domicile 
code’  
(6) admission type 
(acute vs. planned) 
Predictor of 
LOS 
NMDS Readily available 
(7) operation/procedure Predictor of 
flare 
NMDS Transformed from 
‘procedure date’ variable 
(8) urate testing at least 






Derived by matching the 
‘test date’ for serum urate 
testing with the ‘event end 
date’ in NMDS. 
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Variables  Rationale  Database  Derivation from original 
database 
ULT dispensing: 
(9) regular ULT use*  






(14) low-dose aspirin 
(15) warfarin 
(16) cyclosporine 
(17) loop diuretics 







In NMDS, the 12-month 
period before the ‘event end 
date’ was divided into four 
quarters. The variable for 
each medication was 
derived by matching the 
‘date of dispensing’ from 
PHARM with the quarter of 
interest in NMDS.  
* Dispensing in at least three of four quarters of the 12-month period before 
admission 
† First dispensing within three months before admission 
‡ Dispensed at least once within the three months before admission 
LABS, Laboratory Claims Collection; LOS, length of stay; NHI, National Health 
Index; NMDS, National Minimum Dataset; NZCR, New Zealand Cancer Registry; 
NZDep, New Zealand Deprivation Index; PHARMS, Pharmaceutical Collection 
 
4.8.1 Demographics 
 Demographics for each included person admitted were ‘age at hospital 
discharge’ (year), ‘gender’ (male or female), ‘ethnicity’ and New Zealand Index of 
Deprivation score (NZDep). Ethnicity was categorized into Māori people, Pacific 
people and other, which includes New Zealand European, Asian, all other ethnicities 
and ‘not stated’. For people with multiple ethnic codes, the ethnicities were prioritized 
in the following order: New Zealand Māori, Pacific people (Tokelauan, Niuean, 
Tongan, Cook Island Māori, Samoan, other Pacific Island), Asian and New Zealand 
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European. NZDep is an ordinal score, which indicates socioeconomic deprivation for a 
geographical area in New Zealand containing a median of 81 people.(214) The score 
was developed from a combination of the following nine variables collected from the 
2013 census applied to that geographical area.  
(1) Aged <65 years with no access to the Internet at home 
(2) People aged 18 to 64 years receiving a means tested benefit 
(3) People living in households with income below an income threshold 
(4) People aged 18 to 64 years unemployed 
(5) People aged 18 to 64 years without any qualifications 
(6) People not living in own home 
(7) People aged <65 years living in a single parent family  
(8) People living in households below a bedroom occupancy threshold 
(9) People without access to a car 
NZDep score ranges from 1 to 10, corresponding to the decile of the degree of 
the area’s deprivation. A score of 10 indicates that the individual lives in the most 
deprived 10% of areas in New Zealand. 
4.8.2 Admission data 
 Admission data included ‘length of stay’ (days), ‘type of admission’ (acute or 
planned) and ‘operation/procedure’ (yes/no). Length of stay was defined as the number 
of days between the date of admission and the date of discharge from publicly funded 
hospitals. An individual was considered admitted in a hospital if that person received 
assessment and/or treatment for three hours or more, or had a general anaesthetic.(215) 
This definition also applied to people receiving service at the emergency department, 
acute assessment unit or short stay unit. Type of admission consisted of acute 
admission and planned admission. Acute admission included all unplanned admissions 
on the day of presentation at the hospital through emergency or outpatient 
department.(215) Operation/procedure included all operating-room and non-operating-
room therapeutic or diagnostic interventions.(216) For the national data collections, 
reporting the data of operating-room procedures was mandatory, but reporting data of 
non-operating-room procedures was optional. This meant that the operation/procedure 




4.8.3 Urate-lowering therapy and urate monitoring 
 Variables regarding the use of ULT are ‘regular ULT use’ and ‘new ULT use’. 
Regular ULT use was defined as having at least one ULT dispensing in at least three of 
the four quarters in the 12-month period prior to hospital admission. People who did not 
receive ‘regular ULT’ therefore included people with no ULT prescription and people 
with ULT prescription in one or two quarters of the previous year. This definition is 
clinically meaningful because ULT is effective at preventing gout flare by long term 
lowering of serum urate level. The definition complied with the indicator for gout 
quality of care reporting in New Zealand as defined by the Health Safety and Quality 
Commission.(117, 119)  
New ULT use was defined as having at least one episode of ULT dispensing in 
the three-month period prior to hospital admission without any earlier dispensing. New 
ULT use may affect hospital length of stay because initiation of ULT typically 
increases the risk of gout flare.(111) 
Serum urate testing referred to having been tested for serum urate level at least 
once in the past 12 months before the date of admission. The national data collections 
do not record laboratory results; that is, the fact of having the test done is recorded but 
not the result of the test (serum urate level). Consequently, serum urate level cannot be 
directly assessed as a variable in this study. 
4.8.4 Gout flare prophylaxis and medications associated with gout flare 
 The medications of interest were the following: gout prophylaxis medications 
(colchicine, NSAIDs and corticosteroids), diuretics (loop, thiazide, potassium-sparing), 
low-dose aspirin (300 mg daily or lower), warfarin and cyclosporine. An individual was 
considered to be exposed to these medications when the individual received at least one 
dispensing in the three-month period before the date of hospital admission. This 
definition was meant to indicate that these medications were likely to (or at least 
intended to) be taken at the time of admission and/or during hospital stay and could 
contribute to the risk of inpatient gout flare. Only oral formulation of the medications 
were included in the analysis to best reflect continuous usage. The rationale for this 
decision was to prevent inclusion of injected medications, which are likely to be 
prescribed for single use. For example, a solution for injection of diclofenac is likely to 
be used for a gout flare episode as a single prescription and was therefore excluded. 
The decision also prevented inclusion of other irrelevant forms of the medication, such 
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as eye drops and topical preparations. It is important to note that the national data 
collections only include medications dispensed by prescription and therefore do not 
include records of medications purchased without prescription (so called over-the-
counter medications). Consequently, some NSAIDs and low-dose aspirin use might not 
have been fully captured by the available databases. 
 In the national data collections, the medications of interest were identified using 
the formulation ID number. Formulation ID is a six-digit code, with the first four digit 
indicating the medication and the last two digits indicating the preparation. For 
example, the formulation ID number 164501 identifies a 25 mg tablet of indomethacin, 
while the ID number 164502 identifies a 50 mg tablet of indomethacin. Table 4-3 
shows the list of medications included in the analysis. For the full list of medication 
preparation and formulation ID number, please refer to Appendix B.4. 
Table 4-3 List of medications included in the study 2 analysis 
Groups Drug names 
Urate-lowering 
agents 
Allopurinol, febuxostat, benzbromarone, probenecid and 
sulfinpyrazone 
Gout prophylaxis Colchicine  
 NSAIDs: indomethacin, ibuprofen, naproxen, tiaprofenic acid, 
tenoxicam, sulindac, mefenamic acid, ketoprofen, flurbiprofen, 
fenoprofen, fenbufen, diflunisal, diclofenac, piroxicam, 
phenylbutazone and celecoxib 
 Corticosteroids: Prednisone and prednisolone 
Low-dose aspirin Aspirin 
Warfarin Warfarin 
Cyclosporine Cyclosporine 
Diuretics Loop: bumetanide, furosemide 
 Thiazide : bendroflumethiazide, chlortalidone, chlorothiazide, 
clopamide, cyclopenthiazide, hydrochlorothiazide, 
indapamide, methyclothiazide and metolazone 




4.9 Data extraction and processing 
This study extracted data from the national administrative health databases (the 
national data collections). After the study protocol received ethical approval from the 
UOHEC, a data request was made to the New Zealand Ministry of Health. The request 
contained specifications of the target population and lists of variables required from 
each database. The final dataset was subsequently derived from the acquired data. The 
following sections provide detailed steps of data extraction and processing. 
4.9.1 Databases 
 Four databases were the sources of data for this study: National Minimum 
Dataset (NMDS), New Zealand Cancer Registry (NZCR), Laboratory Claims 
Collection (LABS) and the Pharmaceutical Collection (PHARMS). 
 NMDS was the primary database, containing data of hospital events from 
publicly funded hospitals.(216) Demographic data and variables related to hospital 
admission were primarily drawn from NMDS. NZCR collected all invasive and in-situ 
malignant tumors first diagnosed in New Zealand, excluding squamous cell and basal 
cell skin cancers.(217) This database was used to identify people diagnosed with 
hematological malignancy according to the exclusion criteria. LABS contained claims 
and payment information for all laboratory tests processed by the Sector Operations 
General Transaction Processing System (GTPS), Pegasus and Medlab South IPA 
providers.(218) This study extracted laboratory claims for test of serum urate level from 
the LABS database. PHARMS contained claims and payment information from 
pharmacists for subsidized dispensing that have been processed by the GTPS.(219) 
This study drew data of gout medications and other medications related to gout from 
PHARMS.  
4.9.2 Data extraction 
In the extracted datasets, the NHI number of each individual was replaced with 
a unique ‘repeatable custom encrypted master NHI’. The encrypted NHI for an 
individual was the same across different databases, allowing dataset merging. The 
encryption was to ensure that the dataset could not be matched with any other dataset 
outside this research and so that individual patients could not be identified. Data files 
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were delivered in comma delimited format (CSV file) which could be read by 
Microsoft Excel and IBM SPSS statistics package. 
Table 4-4 shows the specifications in the data extraction request made to the 
Ministry of Health. These specifications were in accordance with the cohort inclusion 
and exclusion criteria. However, data extraction specifications were more inclusive 
compared to the actual inclusion and exclusion criteria in order to make sure that no 
eligible person was erroneously left out during this step. The full details of data 
extraction specification are available in Appendix B.5. 
Table 4-4 Data extraction specifications for the study 2 
Part 1. Cohort identification 
People with an NMDS discharge in 2017 who had: 
• Any diagnosis of gout (M10) OR 
• A dispensing of a chemical ID of allopurinol, febuxostat, benzbromarone, 
probenecid or colchicine in the year 2016 and 2017. 
Part 2. Variables extracted for the cohort identified in Part 1 
Database  Time frame  Variables  
NMDS 2017 Encrypted master NHI, event ID, admission type, 
age at discharge, date of birth, sex, prioritized ethnic 
group, domicile code, event end type, event start 
date, event end date, diagnosis type, clinical code, 
procedure date 
NZCR 2017 and 
earlier 
Encrypted master NHI, ICD-10-AM code, date of 
diagnosis 
LABS 2016 to 2018 Encrypted master NHI, test date of serum urate/uric 
acid (coded as ‘BR3’) 
PHARMS 2016 to 2018 Encrypted master NHI, date of dispensing, chemical 
ID, formulation ID 
LABS, Laboratory Claims Collection; NHI, National Health Index; NMDS, National 





4.9.3 Derivation of the final dataset 
The final dataset was derived from the four national data collections. Dataset 
extracted from the NMDS database was the primary source for identification of people 
in the cohort. NZCR was used for the exclusion of people with hematological 
malignancy, and PHARMS and LABS databases were merged with the cohort in the 
final steps in order to provide data regarding medications and serum urate testing. 
Figure 4-1 shows the dataset processing flow. 
4.9.3.1 Processing the National Minimum Dataset 
 NMDS database is the primary source of cohort derivation. The raw NMDS 
dataset consisted of 245,747 admissions of people with comorbid gout (receiving M10 
gout discharge diagnosis coding or receiving ULT or colchicine dispensing), with 
discharge date ranging between the 2016 and 2018 calendar year. In the dataset, each 
row represented a discrete admission (with unique admission number). If multiple 
admissions belonged to the same person, they will share the same encrypted NHI 
number. The primary goal of data processing was to produce the final dataset, which 
complied with the inclusion and exclusion criteria. In the final dataset, each row must 
be independent from others, representing one admission per one person. 
First, the admission with the date of admission or date of discharge outside the 
2017 calendar year were removed, leaving 86,966 admissions in the dataset. An 
additional 50,060 admissions were further removed due to receiving gout as primary 
admission diagnosis (3,989 admissions) or repeat admission within study period 
(46,071 admissions). At this point, there was only one admission per person in the main 
dataset.  
4.9.3.2 Merging with the Cancer Registry 
 People who received an ICD-10-AM diagnosis code between C80 and C96 in 
the 2015 and 2016 calendar year were selected as ‘exclusion group’. C80 coding 
indicates malignancy without specific site and C81-C96 covers all malignant neoplasms 
of lymphoid, hematopoietic and related tissues. The exclusion cohort was merged with 
the main cohort (from NMDS dataset) in order to identify which person in the NMDS 
dataset received recent diagnosis of hematological malignancy. This step identified 730 
people, who were subsequently excluded from the main cohort. 
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According to the age limit from the inclusion criteria, 66 people younger than 
20 years old were further removed from the main dataset. After checking for missing 
data, domicile code was found to be missing in 63 people, who were again excluded. 
The final cohort comprised 36,047 admissions from 36,047 people with comorbid gout. 
After finalizing the cohort, some variables were modified to fit with the 
predetermined variable definitions. Ethnicity was categorized into Māori, Pacific and 
other. Domicile code represented the area corresponding to the residential address 
provided by the patients upon hospital admission. Domicile code was matched with the 
NZDep score (1 to 10 scale), using the data obtained from the Department of Public 
Health, University of Otago, Wellington, who published the NZDep full report.(214) 
4.9.3.3 Merging with the Laboratory Collection 
 LABS dataset contained every serum urate testing (test code ‘BR3’) done 
between the 2016 and 2018 calendar year. In the original extracted LABS dataset, each 
row represented one urate test and corresponding test date. The LABS dataset was 
merged with the main cohort dataset using encrypted NHI number as key variable. To 
identify the urate tests done within 12 months before the date of admission, the number 
of days between the date of admission and the date of urate testing was calculated for 
each patient in the main cohort. The time difference between 1 and 365 days indicated 
that serum urate was tested within the 12-month period before admission. Since some 
people had multiple serum urate testing, the tests belonging to the same individual were 
aggregated into a single variable representing the total number of tests done in the 12-
month period. 
4.9.3.4 Merging with the Pharmaceutical Collection 
The extracted PHARMS dataset contained all medication dispensing for the 
people identified in the main cohort. The medications of interest were selected using 
the formulation ID number (Table 4-3). The dataset was subsequently merged with the 
main dataset, using the universal encrypted NHI number. 
After dataset merging, the number of days between the date of admission and 
the date of each medication dispensing was calculated and all the dispensing outside the 
12-month period before admission were removed. The remaining dispensing were 
assigned into one of four quarters (90 days per quarter). The ‘regular ULT use’ variable 
was derived by selecting the people who had ULT dispensed in at least three out of four 
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quarters. The ‘new ULT use’ variable was derived by selecting the people who had 
ULT dispensing in the quarter nearest to the admission date and no dispensing in other 
earlier quarters. All other medication variables (gout prophylaxis, diuretics, low-dose 
aspirin, warfarin and cyclosporine) were derived by selecting the people with at least 
one dispensing in the quarter nearest to the admission date. 
 




4.10 Data analysis 
4.10.1 Sample size 
 This is a nationwide, population-based study of people with comorbid gout 
admitted to publicly funded hospitals. The cohort is sufficiently representative of the 
hospitalized population with comorbid gout in New Zealand. For a linear regression 
model, at least two subjects per variable are recommended for regression coefficient 
estimation with bias less than 10%.(220) In this study, which explored 19 candidate 
variables, the number of subject was sufficient to build a reliable linear regression 
model. 
4.10.2 Candidate variables and missing data 
  Candidate variables were mainly selected based on their association with 
inpatient gout flare as determined by the first study from this thesis. These variables 
included ULT use (‘regular ULT use’ and ‘new ULT use’), gout prophylaxis, diuretics, 
warfarin and operation/procedure. Frequency of urate monitoring was chosen as an 
alternative indicator of the quality of gout care, because the results of urate tests were 
not available in the national data collections.  Low-dose aspirin and cyclosporine were 
also included as they were known to be associated with gout flare and 
hyperuricemia.(175) Age, gender, ethnicity, type of admission and socioeconomic 
deprivation are influential to gout prevalence, treatment quality and hospital outcomes 
in New Zealand and therefore needed to be adjusted for.(47, 119, 213)  
 Missing data. Socioeconomic data (derived from domicile code) were missing 
in 63 people, which accounted for less than 1% of the cohort. These people were 
excluded from the final analysis.  
4.10.3 Statistical model 
4.10.3.1 Statistical model selection 
For a model with continuous dependent variable, a linear regression model is 
most commonly used. However, the distribution of the length of hospital stay is usually 
positively skewed, with a small number of people having the length of stay much 
longer than median. The skewed distribution violates the assumption of normality of 
the linear regression model, potentially leading to unreliable results. As expected, the 




Figure 4-2 Distribution of length of stay in study 2 cohort 
 
For the predictive modeling of length of hospital stay, generalized linear model 
(GLM) is preferable to classical linear regression model.(221) GLM is an extension of 
the classical linear regression model, consisting of three main components: (1) 
distribution from an exponential family, (2) linear predictors and (3) link function. 
Instead of treating length of stay as continuous data, GLM considers length of 
stay as count data where the mean is transformed by link function. The major advantage 
of GLM is its ability to fit dataset with skewed distribution.(222) There are many 
variations of the GLM. For this study, two GLM models were considered: Poisson 
regression model and negative binomial model. These two models have been 
successfully used for building a prediction model of the length of stay after coronary 
artery bypass grafting surgery,(221) total knee arthroplasty(223) and orthopedic trauma 
surgery.(224)  
Poisson regression model assumes that the dependent variable distribution is 
Poisson, meaning that the variance and its mean are equal (i.e., the variance increases 
with the mean). Poisson regression model therefore becomes less fit when there is over-
dispersion, which means the observed variance exceeds the predicted variance. 
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Negative binomial model is a generalized version of Poisson regression, which allows 
over-dispersion by adding a dispersion parameter to adjust for the variance irrespective 
of the mean.(221)  
In the current study, all 19 candidate variables were entered into the Poisson 
regression and negative binomial model, with the length of stay set as dependent 
variable. The final model was selected using Akaike Information Criterion (AIC).(222) 
AIC provide relative quality of the models in terms of the goodness of fit. A smaller 
AIC indicates that the model has comparatively better goodness of fit. For GLM with 
non-linear link function, the coefficients of determination (R-squared) was not reported 
because it was not a reliable indicator for goodness of fit.(225)  
In the final model, variables with p-value lower than 0.05 were considered to be 
statistically associated with the length of stay. The variables and their regression 
coefficients were reported, as well as the corresponding 95%CI of the coefficients and 
the p-values. 
4.10.3.2 Model interpretation 
 Regression coefficients represent the relationship between the predictor and the 
outcome variable, or how much the mean of outcome will change in response to the 
change in the predictor. In GLM, the change of the mean outcome is expressed using 
log link function. For easier interpretation, the regression coefficients, as well as their 
95%CI, were further transformed to ratio of mean length of stay by exponentiation. For 
example, loop diuretic use had regression coefficient of 0.19, which could be 
transformed to a 1.21 ratio of mean length of stay. This meant that an individual who 
received loop diuretics would stay in the hospital 21% longer than an individual who 
did not use loop diuretics when all other variables were the same. 
 Predicted mean length of stay was estimated using the following equation, 
where V was the predictor and β was the regression coefficient: 
Mean length of stay = exp(intercept + V1β1 + V2β2 + …) 
4.10.3.3 Model assessment 
Likelihood ratio chi-square test was a test of overall significance used to 
compare the GLM model with the intercept-only model (naïve model). A significant 
likelihood ratio chi-square test (p-value <0.05) meant that the model fit the dataset 
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significantly better than the intercept-only model. In other words, the presence of the 
predictors in the model had significant influence on the dependent variable. 
Model fit was further examined using ‘residual plot’, ‘observed vs. predicted 
plot’ and ‘component plus residual plots’.  
Residual plot. Predicted values of the linear predictors (x-axis) were plotted 
against the standardized deviance residuals (y-axis).(221) The linear predictors were the 
summation of Vβ, where V was the predictor and β was the coefficient. Deviance 
residuals in GLM were generalization of residuals from the linear model, which 
represented the difference between the predicted outcome and the observed outcome. 
Since there were too many data points in the plot to discern any specific pattern, a 
linear trend line was added to the plot for ease of visual assessment of the residual 
trend. In a good residual plot, the residuals trend line should be close to the horizontal 
zero line without showing any distinctive trend. This would mean that, on average, the 
summation of linear predictors in the model (and by extension, the predicted length of 
stay) consistently matched well with the observed length of stay.  
Observed vs. predicted plot. Predicted length of stay (x-axis) was plotted 
against the observed length of stay (y-axis). For ease of visual assessment, a reference 
line and a linear trend line were created. The reference line had a slope of one and the 
intercept of zero. The reference line represented the ideal points where the predicted 
length of stay matched perfectly with the observed length of stay. The linear trend line 
represented the overall trend of the regression model.(221) A model with good fit 
should have the trend line close to the reference line as much as possible. 
Component plus residual plots . Component plus residual plot (or ‘partial 
residual plot’) was used to help examine the relationship between individual predictor 
and the length of stay when all other predictors were also present in the model.(223) 
Each predictor (Vi) was plotted against the summation of the full model residual and 
Viβi, where βi was the coefficient of Vi. A model had good fit when the average 
component plus residual was close to the horizontal zero line as much as possible for 
each individual predictors 





4.11.1 Cohort characteristics 
4.11.1.1 Demographics 
 There were 36,047 admissions for 36,047 people in the final cohort. The mean 
age was 68.7±14.5 years and men made up the majority (73%) of the cohort. The three 
largest ethnic groups were New Zealand European (62%), Māori (20%) and Pacific 
people (12%), respectively. Almost a third (32%) of the people in the cohort were 
assigned the NZDep score of nine or ten, indicating they resided amongst the most 
deprived communities in New Zealand. Demographics of the cohort are shown in Table 
4-5. 
Table 4-5 Demographics of the study 2 cohort 
Characteristics Prevalence (N =36,047) 
Age at discharge, years, mean (standard deviation) 68.7 (14.5) 
Men, n (%)  26,163 (72.6) 
Ethnic group, n (%)  
New Zealand European and other 24,478 (67.9) 
Māori 7,248 (20.1) 
Pacific 4,321 (12.0) 
New Zealand Deprivation Index, n (%)    
1 to 2 4,332 (12.0) 
3 to 4 5,218 (14.5) 
5 to 6 6,601 (18.3) 
7 to 8 8,478 (23.5) 
9 to 10 11,418 (31.7) 
 
4.11.1.2 Admission data 
 The mean length of hospital stay was just over three days (3.1±5.2). Just under 
two-thirds (63%) of the admissions were unplanned, that is acute admissions. Operation 
or procedure was documented in nearly half of the admissions (48%). The most 
common categories of primary diagnosis were diseases of the circulatory system, 
injury/external cause, gastrointestinal system, respiratory system and neoplasms. Less 
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than 2% of the people died during the admission. Table 4-6 shows the cohort’s 
admission data. 
Table 4-6 Admission data of the study 2 cohort 
Characteristics Prevalence (N =36,047) 
Length of stay (days), mean (standard deviation) 3.1 (5.2) 
Acute admission, n (%) 22,536 (62.5) 
Operation/procedure, n (%) 17,299 (48.0) 
Mortality, n (%) 677 (1.9) 
Primary admission diagnosis , n (%)  
Circulatory system 5,384 (14.9) 
Injury/external causes 3,380 (9.4) 
Gastrointestinal system 3,251 (9.0) 
Respiratory system 3,075 (8.5) 
Neoplasm 2,975 (8.3) 
Musculoskeletal system 2,841 (7.9) 
Eye/ear  2,410 (6.7) 
Genitourinary system 1,994 (5.5) 
Skin 1,361 (3.8) 
Nervous system 1,071 (3.0) 
Infectious diseases 996 (2.8) 
Endocrine/metabolic 770 (2.1) 
Blood 619 (1.7) 
Mental/behavioral 367 (1.0) 
 
4.11.1.3 Gout treatment and other medications 
Serum urate level was tested at least once in the 12-month period before 
admission in about half (53%) of the cohort. When considering only the people with 
regular ULT dispensing, the prevalence of urate testing in the 12-month period before 
admission was 55%. Less than a quarter (23%) of people with regular ULT dispensing 
had two or more urate tests in the past year. Two-thirds of the cohort were regular ULT 
users (having ULT dispensing in at least three of four quarters in the past year), while 
new ULT users (having ULT dispensing for the first time within three months before 
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admission) accounted for only 2% of the cohort. One-third of the cohort were dispensed 
gout flare prophylaxis within three months prior to admission, with oral corticosteroids 
as the most frequent medication (16% of the cohort and 50% of people receiving 
prophylaxis prescription). Forty percent of the people received diuretics, the majority of 
which were loop diuretics (29% of the cohort and 72% of people receiving diuretics). 
Low-dose aspirin, warfarin and cyclosporine dispensing were found in 36%, 10% and 
less than 1% of the cohort, respectively. Table 4-7 shows the data for the serum urate 
testing and dispensing of ULT and other medications. 
Table 4-7 Urate-lowering therapy and other medications  in the study 2 cohort 
Characteristics Prevalence (N =36,047) 
Urate testing at least once in the past year before 
admission, n (%) 
19,043 (52.8) 
Urate-lowering agents , n (%)  
Regular ULT use* 24,734 (68.6) 
New ULT use† 752 (2.1) 
Gout flare prophylaxis , n (%)‡  11,253 (31.2) 
Corticosteroids 5,669 (15.7) 
NSAIDs 5,073 (14.1) 
Colchicine 2,750 (7.6) 
Diuretics , n (%)‡ 14,292 (39.6) 
Loop diuretics 10,297 (28.6) 
Thiazide 4,334 (12.0) 
Potassium-sparing 2,258 (6.3) 
Other medications , n (%)‡  
Low-dose aspirin 12,808 (35.5) 
Warfarin 3,524 (9.8) 
Cyclosporine 222 (0.6) 
* ULT dispensing in at least three of four quarters in the 12-month period before 
admission 
† First ULT dispensing within 3 months before admission 




4.11.2 Generalized linear model 
4.11.2.1 Model selection and results 
The Poisson regression and negative binomial models produced nine and twelve 
variables independently associated with the length of hospital stay, respectively. Age at 
discharge, male gender, Māori ethnicity, Pacific ethnicity, operation, acute admission, 
loop and potassium-sparing diuretics and regular ULT use were selected by both 
models. The 12-item negative binomial model was chosen as the final model based on 
the smaller AIC, indicating superior goodness of fit (Table 4-8). 
Table 4-9 shows the full results of the 12-item negative binomial model. The 
original regression coefficients and 95%CI are presented, as well as the corresponding 
transformed coefficients (ratio of length of stay) and their transformed 95%CI. 
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Table 4-8 Summary of the Poisson regression and the negative binomial models  
(study 2) 
















































AIC, Akaike Information Criterion; NSAIDs, non-steroidal anti-inflammatory drugs; 




Table 4-9 Variables selected by the negative binomial model in study 2 
Variables β 95%CI p-value Ratio of 
LOS* 
95%CI of ratio 
of LOS 
Intercept -0.01 -0.08 to 0.06 - - - 
Acute admission 0.53 0.51 to 0.56 <0.001 1.70 1.66 to 1.74 
Operation 0.19 0.17 to 0.22 <0.001 1.21 1.19 to 1.24 
Loop diuretics 0.19 0.16 to 0.22 <0.001 1.21 1.18 to 1.24 
K-sparing diuretics 0.09 0.05 to 0.13 <0.001 1.09 1.05 to 1.14 
Pacific people 0.08 0.05 to 0.11 <0.001 1.08 1.05 to 1.12 
Māori people 0.05 0.02 to 0.08 0.001 1.05 1.02 to 1.08 
Corticosteroids 0.03 0.01 to 0.06 0.035 1.03 1.01 to 1.06 
Age  0.01 0.009 to 0.011 <0.001 1.01 1.009 to 1.011 
Urate testing -0.02 -0.05 to -0.01 0.019 0.98 0.96 to 0.99 
Thiazide diuretics -0.03 -0.06 to -0.01 0.044 0.97 0.94 to 0.99 
Male  -0.04 -0.06 to 0.02 0.001 0.96 0.94 to 0.98 
Regular ULT use -0.12 -0.14 to -0.09 <0.001 0.89 0.87 to 0.91 
*Ratio of length of stay was calculated by exponentiation of the regression coefficients. 
β, regression coefficients; CI, confidence interval; K, potassium; LOS, length of stay; ULT, 
urate-lowering therapy 
 
4.11.2.2 Model interpretation 
In a generalized linear model, regression coefficients could be transformed to 
the ‘ratio of mean length of stay’ by exponentiation (Table 4-9). The example for 
interpretation of ratio of mean length of stay is as the following:  
• Loop diuretics had ratio of mean length of stay of 1.21, meaning the individual 
who received loop diuretics would on average stay in the hospital for 21% 
longer than another individual who did not use loop diuretics.  
• Regular ULT use had ratio of mean length of stay of 0.89, meaning the 
individual who received regular ULT would on average stay in the hospital for 
11% shorter compared to another individual who did not receive regular ULT.  
Among the variables associated with a longer length of stay, acute admission 
had the highest ratio of mean length of stay (1.70), followed by operation and loop 
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diuretics (both 1.21). Among the four variables associated with a shorter length of stay, 
regular ULT use had the strongest ratio of mean length of stay (0.89). Urate testing (at 
least once in the past year) had a statistically significant but small ratio of mean length 
of stay (0.98).  
Figure 4-3 compares the estimated length of stay of a hypothetical 69-year-old 
(mean age), female, New Zealand European patient. When all the variables associated 
with longer length of stay are present, the estimated length of stay are four days longer 
than a patient without any comparable predictors. The formula used for the estimation 




Figure 4-3 Predicted length of hospital stay for the study 2 cohort. The intercept-
only bar (solid bar) represents the length of stay of a 69-year-old, female, New 
Zealand European patient without any other predictor. The values on top of the 
bars are change in length of stay (days) for the presence of each additional 
variable. Multiple variables bar represents the length of stay for a female, Pacific 
patient with corticosteroids, potassium-sparing and loop diuretics, operation and 
acute admission. 
  
4.11.2.3 Model assessment 
For the model’s overall significance, the likelihood ratio chi-square test was 
3,725 (degree of freedom =19) with statistically significant p-value of <0.001. The 
significant likelihood ratio chi-square test indicated that the model with the combined 
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presence of the independent variables differed significantly from the model without 
independent variable (intercept-only model).  
Residual plot. The residual plot examined the relationship between the 
deviance residuals and the predicted values of the linear predictors (Figure 4-4). 
Despite some noticeable spread of the residuals, the trend line appeared very close to 
the horizontal zero reference, indicating a good model fit. 
 
Figure 4-4 The residual plot between the predicted values of linear predictors (x-
axis) and deviance residuals (y-axis) for the study 2. Dashed line is the horizontal 
zero reference. The solid red line is the linear trend line . 
 
Observed vs. predicted plot. The observed vs. predicted length of stay plot 
also indicated a good model fit (Figure 4-5). The trend line appeared very close to the 






Figure 4-5 Observed vs. predicted length of stay plot for the study 2. Dashed line is 
the reference where the observed and predicted length of stay are equal. The solid 
red line is the linear trend line . Both lines almost overlapped, indicating a good 
model fit. 
 
 Residual plus component plots . The residual plus component plots showed 
that the average residuals consistently gathered around zero for every individual 
variable in the model (Figure 4-6 and Figure 4-7). This also indicated a good model fit, 








Figure 4-6 Residual plus component plots for operation, male gender, acute 
admission, urate testing, Māori and Pacific ethnicity in the study 2. The number 0 








Figure 4-7 Residual plus component plots for corticosteroids, regular ULT use, 
loop diuretics, thiazide diuretics, potassium-sparing diuretics and age in the study 








This study explored the association between the predictors of inpatient gout 
flare (identified in Chapter 3) and the length of hospital stay. The final model consisted 
of twelve variables: four associated with a shorter length of hospital stay and eight 
associated with a longer length of hospital stay. The following discussion has four 
parts: (1) a critique of the study methodology which is essential for appropriate 
interpretation of the study results, (2) the cohort compared to the general population of 
people with comorbid gout in New Zealand, (3) the variables associated with the length 
of hospital stay in the context of existing knowledge and (4) potential clinical 
application. 
4.12.2 A critique of the study methodology 
The national data collections allowed extraction of data of large number of 
people, providing a large population-based cohort. Given the scale and the number of 
people included, the population in this study should have sufficiently represented 
hospitalized people with comorbid gout in New Zealand. This quality helped strengthen 
the validity and reliability of the statistical models. Nevertheless, the national data 
collections mainly documented administrative data with the primary goal of healthcare 
policymaking rather than epidemiological research. Consequently, there were some 
issues concerning data availability, patient identification and the definitions of variables 
that must be considered when interpreting the results of this study. 
4.12.2.1 Inpatient gout flare was not directly documented  
This study intended to explore the impact of predictors of inpatient gout flare on 
the length of hospital stay using a population-based cohort. The design was based on 
the assumption that the predictors of flare would be associated with inpatient gout flare, 
which in turn would affect the length of hospital stay. This assumption was justified by 
the results from previous studies (including the first study of this thesis) indicating that 
inpatient gout flare was linked to a longer length of hospital stay.(156, 162, 168) 
However, the national data collections did not include documentation of inpatient gout 
flare episodes, meaning that it was not possible to ensure that every individual in the 
cohort studied did or did not have gout flare episodes. Consequently, the presence of a 
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non-flare population, which was likely to be present, would have weakened the 
association of interest in this study, as the length of hospital stay was presumably 
influenced by many other factors and the association that was observed could be 
mediated by other factors (such as health literacy or general quality of health care). In 
other words, inpatient gout flare could at best only partially explain the significant 
association between the 12-item final model and the length of hospital stay in this 
study.  
4.12.2.2 Case definition  
 This study defined people with comorbid gout using ICD-10-AM discharge 
diagnosis code for comorbid condition or the dispensing of ULT or colchicine. The use 
of ICD-10-AM coding was reliable because gout must be clinically significant enough 
during hospital stay that the attending doctors documented it explicitly. For people with 
comorbid gout identified by the history of ULT or colchicine dispensing, it is possible 
that a proportion of them might not actually have gout. To help address this issue, the 
study excluded all people who were recently diagnosed with hematological neoplasm 
because these people likely received ULT (mainly allopurinol) for prevention of tumor 
lysis syndrome. However, a small number of people who took ULT or colchicine for 
other reasons could still have been included, such as people who received ULT for 
asymptomatic hyperuricemia and people who were prescribed colchicine for the 
treatment of pericarditis. On the other hand, this limitation could be considered a 
strength. If there were indeed a substantial number of people who did not have gout in 
the cohort, the association between the predictors of inpatient gout flare and the length 
of stay should have been weaker or neutralized. The significant findings from the study 
supported the assumption that if there were non-gout cases in the cohort, they likely 
accounted for only a small minority of the cohort.  
It was also possible that some people with gout who were admitted to hospital 
were never dispensed colchicine or allopurinol, so that such people would fail to be 
included in this cohort of people. It is likely that such individuals have less severe gout 
and are therefore less likely to experience inpatient flare. So the exclusion of these 
cases will likely have minimal effect on the findings from the present study. 
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4.12.2.3 Variable definitions 
Due to the study design and the nature of the national data collections, some 
variables in this study might have carried some bias. The prevalence of regular ULT 
use (69%) in the study cohort would likely be overestimated, because the ULT 
dispensing was part of the criteria used for patient identification. The prevalence of 
serum urate testing (53%) might also carry similar bias as ‘regular ULT use’, because 
people who took ULT could be more likely to have their serum urate level tested during 
follow up. For the dispensing of gout prophylaxis medications, it was difficult to 
distinguish between people who received continuous prophylaxis (e.g., daily colchicine 
as gout prophylaxis) from the people who only took a short course regimen (e.g., three-
day colchicine to treat a single gout flare episode). This was due to the incomplete 
record of the number of days that the patients were supplied with the medications. The 
‘days supplied’ variable was not provided in most cases, leading to the variable being 
omitted from analysis. To minimize this potential bias, the study excluded all injectable 
forms of NSAIDs and corticosteroids, which are typically used as treatment for acute 
flare. However, it was not possible to do the same with oral medications. Finally, the 
national data collections did not record over the counter NSAIDs purchase. This meant 
that NSAIDs dispensing data in the cohort did not capture all NSAIDs use. However, it 
would seem likely that over the counter NSAIDs purchases were for short term use, 
which was not of clinical relevance for this study. 
4.12.2.4 Variable availability 
Some predictors of inpatient gout flare proposed in the first study were not 
available in the national data collections. These variables included pre-admission serum 
urate level, tophus on examination and in-admission adjustment of medications (ULT, 
gout prophylaxis and diuretics). Pre-admission urate and tophus generally can indicate 
how well controlled gout was before admission. To overcome this limitation, this study 
extracted the data on regular ULT dispensing (as a surrogate for regular ULT use) and 
history of serum urate testing as alternative indicators of pre-admission gout control. 
Regular ULT use is required for long-term control of serum urate and is already 
an accepted indicator for the quality of gout management in New Zealand.(119) It was 
therefore judged to be an appropriate surrogate for gout control for this study. 
Furthermore, ‘regular ULT use’ differed from the ULT variable from the first study. In 
the first study, only the use of ULT (or absence of ULT) at the time of admission could 
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be extracted. As an indicator for past quality of gout management, the ‘regular ULT 
use’ variable in this study could be considered more meaningful than ‘ULT at 
admission’ in the first study. 
The implication of serum urate testing, however, is less clear. History of urate 
testing may imply that the individuals received regular follow up and that gout is under 
controlled (i.e., patients with well controlled gout receiving routine annual urate 
testing). However, serum urate testing could also mean that the individuals did not 
achieve target serum urate level and subsequently had their ULT adjusted and serum 
urate repeatedly tested.  
In-admission adjustments of diuretics and gout prophylaxis were not reported in 
the national data collections. Extracting the history of dispensing within three months 
before admission only suggests that the individuals were taking the medications at the 
time of admission. In other words, the variables for diuretics and gout prophylaxis 
medications in this study only indicate immediate exposure to the medication, but 
cannot specify whether the medications were adjusted during admissions.  
On the other hand, the national data collections also provide opportunity to 
explore some gout-related variables not possible in the first study. New ULT use, in 
particular, is a compelling candidate variable because initiation of ULT is a well-
established risk factor for gout flare in the general gout population.(112) Newly 
initiated ULT is also an indicator of uncontrolled gout. Another variable not included in 
the first study was the NZDep, indicating the socio-economic deprivation associated 
with the patients’ place of residence. 
4.12.2.5 Statistical protocol 
 Length of hospital stay is one of the major outcomes of inpatients care. 
However, there is no established protocol for prediction modelling of the length of 
hospital stay. Despite the fact that length of stay typically has a skewed distribution, a 
recent systematic review of length of stay modelling studies found that the majority 
(78%) employed statistical models that assumed normal distribution (i.e., linear 
regression model).(226) Unfortunately, the violation of the assumption of normality 
could lead to unreliable estimation of coefficients.(221)  Some studies instead chose to 
transform the length of stay into a binary variable.(227-229) However, dichotomizing 
118 
 
continuous variables usually leads to clinically irrelevant cut points, as well as loss of 
information and statistical power.(230)   
 To overcome the issue of skewed data distribution, the current study used the 
generalized linear model (GLM), which accommodated skewed distribution of the 
length of stay.(221) Two types of GLM were applied: Poisson regression and negative 
binomial model. Ultimately, the negative binomial model was chosen over the other 
due to its superior fit with a smaller AIC. The superior fit of the negative binomial 
model was not surprising, because the model allowed over-dispersion of the data while 
Poisson regression model did not. The stronger performance of the negative binomial 
model over Poisson regression model was also observed in a previous study examining 
the length of hospital stay after knee surgery.(223) The final model showed acceptable 
goodness of fit when assessed by the residual plots and the observed vs. predicted plots.  
It must be emphasized that there is currently no standard modelling protocol for 
the prediction of length of hospital stay. However, judging by the existing literature, 
GLM could be considered one of the most robust options for the analysis of length of 
hospital stay, especially when the distribution is highly skewed. 
4.12.3 The cohort in comparison to the general gout population in New 
Zealand 
 A national cohort of hospitalized people with comorbid gout who were admitted 
for non-gout conditions in New Zealand has not been previously reported. However, 
two population-based reports of people with gout were published in 2012 and 2014, 
extracting data from the year 2009 and 2010/2011 (July 2010 to June 2011), 
respectively.(47, 119) These two studies used similar criteria for the identification of 
people with comorbid gout in the national data collections; age 20 years or older, 
receiving ICD-10 discharge diagnosis coding of gout or having history of allopurinol or 
colchicine dispensing, and exclusion of hematological malignancy cases. Furthermore, 
the New Zealand Health Quality & Safety Commission recently released a 
comprehensive population-based online dataset of people with gout in New Zealand 
with the emphasis on the quality of care (Atlas of Healthcare Variation: Gout).(117, 
231) This online dataset covers the time between the 2012 and 2016 calendar years. 
These published sources provide some interesting insights into how the current cohort 
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of the 2017 calendar year compares to the general population with comorbid gout in 
New Zealand. 
 Table 4-10 compares the demographics of the study cohort to the general gout 
population in New Zealand from the 2009 calendar year. The inpatient cohort and the 
general gout population have similar proportion of Māori people, Pacific people and 
socio-economic distribution according to the NZDep score. The study inpatient cohort, 
however, has a higher proportion of women, as well as people in the ‘70 to 79’ and ‘80 
or older’ age groups. This is likely explained by women’s longer life expectancy 
compared to men and women’s tendency to develop gout at older age.(42) It is also 
worth noting that the people at the lowest socio-economic status (NZDep score 9 and 
10) make up approximately one-third of the people with comorbid gout in both cohorts. 
 Regular ULT use (at least three of four quarters in the past year) is one of the 
major indicators of the quality of gout care.(119) Data from the general gout population 
in 2010/2011 showed that 39% of people with comorbid gout received regular 
allopurinol dispensing,(119) which was much lower than the 69% in the current cohort 
of hospitalized people with comorbid gout. More than one factor could have 
contributed to this difference. The current study inpatient cohort may be biased towards 
people who received ULT dispensing due to the inclusion criteria. The current cohort 
also includes people using ULT other than allopurinol (e.g., febuxostat) for participant 
identification, also leading to a higher proportion of ULT use. Furthermore, 
hospitalized people with comorbid gout are older and have potentially had gout for 
longer, leading to higher prevalence of ULT dispensing. The difference in the year of 
data extraction (2010/2011 vs. 2017) is unlikely to play a major explanatory role 
because the prevalence of regular ULT dispensing in the general gout population has 
been largely static between the 2012 and 2016 calendar years.(231)  
 Serum urate testing, especially for people taking ULT, is essential for a 
successful treat to target strategy for gout management. The percentage of people with 
regular ULT dispensing who were tested for serum urate level at least once in the past 
year was 55% in this cohort, which was higher than the 34% prevalence reported by 
another cohort from New Zealand.(119) However, this prevalence of serum urate 
testing in the general gout population was for a period of six months, rather than one 
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year. The higher prevalence of ULT use in the current study may also contribute to the 
higher rate of serum urate testing.  
 In New Zealand, ideal gout management is considered to be that every person 
with gout and appropriate indications takes ULT regularly and has serum urate tested at 
least once within six months after ULT treatment.(119) From the current cohort and the 
previous reports from the general gout population, it is clear that the quality of gout 
care still falls short of this expectation. 
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Table 4-10 Demographics of the study 2 inpatient cohort compared to the general 
gout population in New Zealand 
Variables  Study 2 cohort: 
inpatient gout (2017), 
N=36,047 
General gout population 
(2009), N=114,318 
Men, n (%) 26,163 (72.6) 86,063 (75.3) 
Ethnicities , n (%)   
New Zealand 
European/other 
24,478 (67.9) 77,870 (68.2) 
Māori 7,248 (20.1) 22,689 (19.8) 
Pacific 4,321 (12.0) 13,759 (12.0) 
NZDep score , n (%)*   
9 to 10 11,418 (31.7) 33,074 (29.0) 
7 to 8 8,478 (23.5) 26,519 (23.3) 
5 to 6 6,601 (18.3) 21,935 (19.3) 
3 to 4 5,218 (14.5) 16,829 (14.8) 
1 to 2 4,332 (12.0) 15,431 (13.6) 
Age group (year), n (%)   
20 to 29 480 (1.3) 2,159 (1.9) 
30 to 39 1,100 (3.1) 6,102 (5.3) 
40 to 49 2,220 (6.2) 13,579 (11.9) 
50 to 59 4,787 (13.3) 22,421 (19.6) 
60 to 69 8,222 (22.8) 27,788 (24.3) 
70 to 79 10,379 (28.7) 25,231 (22.1) 
80 and over 8,859 (24.6) 17,038 (14.9) 
NZDep, New Zealand Deprivation Index 






4.12.4 The current study in the context of existing knowledge 
4.12.4.1 The complex relationship between the predictors of inpatient 
gout flares and the length of hospital stay 
This study attempted to explore connection between the predictors of inpatient 
gout flare and the length of hospital stay in hospitalized people with comorbid gout 
who were admitted for non-gout conditions. Twelve variables were found to be 
associated with the length of hospital stay: regular ULT use, serum urate testing, 
operation/procedure, acute admission, Māori ethnicity, Pacific ethnicity, male gender, 
age at discharge and dispensing of loop diuretics, thiazide diuretics, potassium-sparing 
diuretics and corticosteroids. The primary hypothesis was that these variables were 
linked to the risk of inpatient gout flare and subsequently influence the length of 
hospital stay. Figure 4-8 shows the schematic diagram of the study’s hypothesis. 
Although the current study could not specifically identify gout flare episodes, two 
supporting arguments may help substantiate this hypothesis: (1) the first study linked 
ULT use, gout prophylaxis medications, pre-admission serum urate, diuretic adjustment 
and surgery to inpatient gout flare and (2) inpatient gout flare is associated with longer 
length of hospital stay according to existing literature.(156, 162, 168) To an extent, the 
association between the twelve variables and the length of hospital stay could plausibly 
be explained by inpatient flare episodes, although other explanations are possible. 
The primary hypothesis is, however, only part of the puzzle. The people in the 
current cohort were admitted for non-gout conditions, meaning that there were other 
active problems and interventions in the same hospital admission (Figure 4-8). 
Logically, these non-gout conditions and their associated management would also 
contribute to the length of hospital stay. For example, the length of stay for a patient 
admitted for acute myocardial infarction who developed inpatient gout flare would be 
largely influenced by the severity, complications of and interventions for the cardiac 
condition. In this scenario, gout flare episode would presumably play a smaller role in 





Figure 4-8 Schematic diagram of the interaction between predictors of inpatient 
gout flare and the length of hospital stay in study 2 
 
The complexity of the inpatient events contributing to the hospital outcome is 
reflected by the apparent spread of the model residuals in the residual plot (Figure 4-4). 
The complex relationship between the predictors and the length of stay is also reflected 
in the relatively small ratio of mean length of stay for the majority of variables in the 
final model (Table 4-9). For example, the ratio of mean length of stay for ‘regular ULT 
use’ was 0.89, which translated to 11% shorter length of stay compared to people who 
were not taking regular ULT. The 11% difference in predicted length of stay associated 
with regular ULT use was relatively small, but not unexpected. In a typical hospital 
admission event, it was expected that regular ULT use would be one of many variables 
influential to the length of hospital stay. 
The influence of coexisting conditions on the length of hospital stay in people 
with gout flare were reported in another administrative claims study from the United 
States.(232) This study explored the variables associated with the length of hospital 
stay in people hospitalized with gout as primary admission diagnosis. The study 
extracted data of people who were admitted for gout through an emergency department 
from the United States National Emergency Department Sample (NEDS) in the years 
2009, 2010 and 2012. Coexisting renal failure, heart failure, age, insurance status, 
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residence (urban vs. rural), and hospital location were statistically associated with the 
length of hospital stay. Although the study did not explore any gout-specific variables, 
it confirmed that coexisting conditions and other variables still contribute to the length 
of stay even when gout was the primary admission diagnosis. Given the fact that people 
with comorbid gout tend to have high burden of comorbidities,(81, 82) it is logical to 
assume that these comorbid conditions and their complications also substantially 
contributed to the overall length of hospital stay in the current study. 
In conclusion, the twelve variables in the final model are independently 
associated with the length of hospital stay in people with comorbid gout and, depending 
on each variable, contributed to the length of stay to a varying degree. However, they 
are only part of the complex hospital event that was not and could not be fully 
explained by a single statistical model.  
4.12.4.2 Variables associated with the length of hospital stay 
This section will discuss the possible connections between the selected variables 
and the length of hospital stay in the context of existing knowledge. 
Regular urate-lowering therapy. ‘Regular ULT use’ had the strongest 
association with a shorter length of stay in the final model. Regular ULT is the best and 
only way to achieve the recommended target serum urate level in the management of 
gout.(233) Elevated serum urate level is associated with increased risk of recurrent gout 
flare in people with comorbid gout.(234) According to the first study, serum urate level 
>0.36 mmol/L, above recommended therapeutic target, is a predictor of inpatient gout 
flare in people with comorbid gout. In people with comorbid gout, regular ULT could 
be an indicator of better access to regular healthcare, higher health literacy, greater 
medication adherence, and/or lower risk of gout flare. All of these factors could have 
contributed to a less eventful hospital course, including lower chance of developing 
inpatient gout flare during hospital admission. 
There is also a possibility that regular ULT also has positive effect on the 
patients’ comorbid conditions, which further translate to better hospital outcome. There 
were studies showing that higher serum urate level at admission was associated with 
higher mortality and higher risk of inpatient complication such as acute kidney injury in 
the general population.(235, 236) However, the evidence directly linking ULT or serum 
urate level to the length of hospital stay in people with comorbid gout is still lacking. 
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Serum urate testing. History of serum urate testing was intended to be another 
indicator of the patients’ gout control. In the final model, having been tested for serum 
urate at least once in the past year was associated with a shorter length of stay, albeit to 
a small degree (ratio of mean length of stay of 0.98). The small impact of serum urate 
testing could be explained by its wide range of possible contexts behind urate testing. 
Urate testing could indicate a well-controlled gout (i.e., people under ULT having 
routine serum urate testing). However, serum urate testing could also include people 
with uncontrolled gout who were recently started on ULT or people undergoing ULT 
escalation to achieve therapeutic serum urate target. There is currently no published 
study linking serum urate testing to hospital outcome in people with comorbid gout. 
Diuretics . Exposure to diuretics could be associated with the length of hospital 
stay in people with comorbid gout through more than one mechanism. Loop and 
thiazide, but not potassium-sparing, diuretics are associated with the risk of incident 
gout,(68) as well as the risk of recurrent gout flare in people with comorbid gout 
especially within 48 hours after exposure.(136) The elevated risk of gout flare is likely 
explained by the rapid rise of serum urate level from increased uric acid reabsorption 
and secretion at the renal proximal tubules and volume contraction.(175) In the first 
study, diuretic adjustment (regardless of diuretic types) was one of the predictors of 
inpatient gout flare. The relatively strong association between loop diuretics and longer 
length of hospital stay (21% longer) therefore could be explained by an elevated risk of 
inpatient gout flare, in addition to the presence of other comorbid conditions especially 
complex cardiovascular or kidney disease. 
Potassium-sparing diuretics were associated with a longer length of stay (9% 
longer) in the current study, while thiazide diuretics showed weak association with a 
shorter length of stay (3% shorter). These associations were likely explained by 
comorbidities other than gout. According to a recent New Zealand study, people with 
gout who were taking diuretics had higher prevalence of comorbidities compared to 
people with gout who did not use any diuretics.(237) In conclusion, diuretic use could 
possibly be acting as surrogates for comorbid conditions other than gout, such as heart 
or kidney disease, which contributed to the length of hospital stay. 
Corticosteroids. Corticosteroid dispensing within three months before 
admission was associated with a longer length of hospital stay. Corticosteroids 
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dispensing could indicate a more advanced gout and/or other complicated comorbid 
conditions (e.g., severe asthma, inflammatory bowel disease, and transplant). In people 
with comorbid gout, oral corticosteroids (e.g., prednisone) is not the recommended first 
line medication for gout flare prophylaxis.(21) Therefore, the presence of 
corticosteroids before admission could indicate a more complicated gout population 
who had contraindications for colchicine and NSAIDs for prophylaxis or people who 
were unable to control gout with colchicine or NSAIDs alone. In conclusion, 
corticosteroid exposure could be associated with a longer length of stay as a surrogate 
for more severe comorbid conditions, including uncontrolled gout. 
 Operation/procedure . The association between operation/procedure and the 
longer length of hospital stay likely has a number of possible explanations. Surgery is a 
predictor of inpatient gout flare according to the first study. Previous studies conducted 
among surgical patients also suggested that abdominal surgery(170) and cancer 
surgery(130) were associated with the risk of postsurgical gout flare. Therefore, the 
association between operation and longer length of hospital stay could be partially 
explained by the elevated risk of inpatient gout flare. Operations or procedures 
themselves also reflect the primary diagnosis both in cases admitted for elective 
operation/procedure and acute conditions requiring surgical intervention. Furthermore, 
operation/procedure could happen in response to major in-hospital complications. All 
of these possibilities typically lead to longer length of stay. 
Age, gender and ethnicity. Older age, female gender and Māori and Pacific 
ethnicities were found to be associated with a longer length of stay. This particular set 
of demographics have been associated with a longer length of stay in people admitted 
for acute coronary syndrome(238) and people with osteoarthritis admitted for elective 
knee or hip replacement surgery in New Zealand.(239) Older people, women and Māori 
and Pacific people in New Zealand also had higher prevalence of multi-morbidity, 
defined as having two or more long-term health conditions, according to a recent 
nationwide survey.(240) These observations could have explained the association 
between these demographic characteristics and a longer length of stay in hospitalized 
people in New Zealand.  
Māori and Pacific ethnicities, in particular, have also been associated with 
suboptimal gout care. According to the 2016 survey in New Zealand, Pacific people 
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have the highest prevalence of gout (14%), highest rate of hospitalization with gout as 
primary admission diagnosis (230 per 100,000 population) and the lowest prevalence of 
regularly receiving ULT (35%). Māori people had the second highest prevalence of 
gout (8%), second highest rate of hospitalization (112 per 100,000 population) and 
second lowest prevalence of receiving regular ULT (40%) compared to non-Māori/non-
Pacific people.(117, 231) The high prevalence and suboptimal gout management in 
both ethnic groups could lead to higher chance of gout flare which further contributed 
to a longer length of hospital stay. 
Acute admission. Compared to planned admission, acute admission may have 
represented a more severe primary admission diagnosis, or an unstable or evolving 
health condition, which likely led to longer length of hospital stay. This variable was 
not related to inpatient gout, but it was an important variable that needed to be adjusted 
for during the analysis of the length of stay. 
The lack of association for ‘new ULT use’. Only 2% of the cohort met the 
definition of ‘new ULT use’ (having ULT dispensing for the first time within three 
months before admission). This is not unexpected because the cohort included people 
with comorbid gout rather than people with new gout diagnosis. As a result, the 
prevalence of new ULT users was very low and did not have enough power to detect 
any association in the analysis, if one existed. 
4.12.5 Clinical implication 
The study provides further, though very indirect, evidence in support of regular 
ULT use and urate testing in people with comorbid gout. In particular, this study found 
that regular ULT use and history of urate testing were associated with shorter length of 
hospital stay. Shorter length of hospital stay means less healthcare resource utilization 
and lower chance of in-hospital complications. Despite the availability of effective 
urate-lowering agents and well-established treatment strategy for people with gout, the 
proportion of people with comorbid gout receiving ULT and urate monitoring has been 
consistently low in the majority of recent population-based studies,(3, 5, 193, 195) 
including those from New Zealand.(119, 231) People with gout and their primary 
healthcare providers may consider gout a self-limiting condition, without major health 
implications.(241) In addition to the eradication of gout flares, evidence indicating that 
regular ULT use and urate testing is associated with shorter hospital stay after 
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admission for any reason may help convince patients and healthcare providers to 
prioritize regular ULT and urate testing for gout management.  This finding may have 
significant value at a health system level and therefore be a worthwhile quality 
improvement goal across the health system, as well as for individuals.  
It is worth noting that the association between regular ULT use and the length 
of stay was statistically significant regardless of whether the patients’ urate level met 
the therapeutic target of below 0.36 mmol/L. Serum urate results were not accessible in 
the national data collections but it seems highly unlikely that all people receiving 
regular ULT achieved target serum urate level. Therefore, this study shows that regular 
ULT use may be beneficial even when the target serum urate is not achieved. In other 
words, any urate control is better than no urate control. 
This study proposed a set of twelve variables associated with the length of 
hospital stay, four with shorter and eight with longer length of stay. Identification of 
people with comorbid gout who carry these variables at admission may alert clinicians 
for potential complications (including gout flare), which could lead to longer length of 
hospital stay. People who carry all variables associated with a longer length of stay may 
stand to benefit the most from better monitoring and appropriate management, because 
they are at risk of adding at least four extra days to their hospital course (Figure 4-3). 
Finally, this study further emphasizes the impact of the prediction model for inpatient 
gout flare proposed in the first study by drawing connection between some of the 
predictors of inpatient gout flare and the length of hospital stay, which is a major 
hospital outcome. 
4.12.6 Conclusion 
 This study explores the association between some of the previously identified 
predictors of inpatient gout flare and the length of hospital stay. Using a population-
based cohort of hospitalized people with comorbid gout, this study identified a set of 
twelve variables associated with the length of hospital stay. Regular ULT use, serum 
urate testing, male gender and thiazide diuretics are associated with a shorter length of 
stay, while the other eight variables (loop and potassium-sparing diuretics, 
corticosteroids, operation/procedure, acute admission, Māori ethnicity, Pacific ethnicity 
and age) are associated with a longer length of hospital stay. The results provide some 
evidence for the impact of the predictors of inpatient gout flare on the hospital outcome. 
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Furthermore, the significant association of regular ULT use and the length of hospital 
stay may help strengthen the argument for long-term ULT as well as serum urate 





Chapter 5 Prediction rule for inpatient gout 
flare: derivation and external validation 
(study 3) 
5.1 Summary 
 A set of nine predictors of inpatient gout flare were identified from a 
retrospective cohort study of people with comorbid gout in the Wellington region, New 
Zealand (Chapter 3). This chapter aims to develop a simple clinical tool to identify 
people with comorbid gout who are at high risk of inpatient gout flare. Using the 
predictors from the New Zealand (derivation) cohort, three candidate prediction rules 
for inpatient gout flare were developed: the regression coefficient (β)-based rule, the 
simple rule and the first-day rule. The nine-item β-based rule assigned points to each 
item by rounding the regression coefficients to their closest integer. The simple rule 
assigned all items with one point. The first-day rule included only the four items 
available for assessment on the first day of hospital admission and assigned all items 
with a single point. The selection of the final prediction rule was decided by prioritizing 
sensitivity and practicality for non-specialist doctors. The first-day prediction rule was 
chosen for its high sensitivity (0.84) and practicality (fewer items and simpler scoring 
system). It was renamed the ‘GOUT-36’ prediction rule as an acronym for the four 
items in the rule: no pre-admission GOut prophylaxis, no pre-admission Urate-lowering 
therapy, Tophus and pre-admission serum urate >0.36 mmol/L in the previous year. 
The chosen threshold for maximizing Youden Index was two or more items. 
For the external validation, a new cohort of 184 hospitalized people with 
comorbid gout was prospectively recruited from a hospital in Thailand, the validation 
cohort. There were 50 (27%) inpatient gout flare episodes. The GOUT-36 prediction 
rule performed adequately in the validation cohort: sensitivity 0.74, specificity 0.69 and 
discrimination (area under the ROC curve) 0.71. Four risk groups were proposed: low 
(0 point), moderate (1 point), high (2 points) and very high (3 or 4 points). In the 
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validation cohort, 8% of people in the low risk group had a gout flare, while 75% of 
people in the very high risk group had a gout flare. The GOUT-36 prediction rule is a 
reasonably sensitive and practical risk stratification tool for inpatient gout flare. The 
rule may help clinicians identify people with comorbid gout who are at high risk of 
gout flare during a hospitalization on the first day of hospital admission, and 
subsequently allow preventive measures to be implemented where appropriate. 
5.2 Chapter structure 
 This is the third and final study of the thesis. Similar to the previous two 
studies, inpatient gout flare in people with comorbid gout is the main theme. The 
chapter describes the rationale, objective, methods, results and discussions. The 
methods section, in particular, has two main subsections: the development of the 
prediction rule for inpatient gout flare, followed by its external validation in an 
independent cohort. 
5.3 Rationale 
 Nine predictors of inpatient gout flare in people with comorbid gout have been 
identified, including pre-admission serum urate >0.36 mmol/L, no pre-admission ULT, 
no pre-admission gout prophylaxis, ULT adjustment, gout prophylaxis 
started/increased, tophus, diuretic adjustment, acute kidney injury and surgery (Chapter 
3). Some of these predictors (diuretics, surgery, and corticosteroids) were found to be 
associated with a longer length of hospital stay from the analysis of the New Zealand 
Ministry of Health’s national data collections (Chapter 4). A clinical tool is needed to 
assist clinicians in the identification of people with comorbid gout who are at higher 
risk of developing inpatient gout flare. The clinical tool should be as simple as possible 
to allow easy application in routine clinical practice. Most importantly, the clinical tool 
should be able to predict inpatient gout flare with reasonable accuracy. Using the 
previously identified predictors of inpatient gout flare, this chapter will develop a 
prediction rule for inpatient gout flare in people with comorbid gout. The proposed 
prediction rule will be validated in an independent cohort of hospitalized people with 




 This chapter aims to develop an evidence-based and simple risk stratification 
tool for inpatient gout flare in people with comorbid gout, and subsequently validate the 
tool in an independent cohort. 
5.5 Study design 
 The study is divided into two parts: the derivation of the prediction rule for 
inpatient gout flare and the external validation. The derivation cohort was collected 
from hospital notes in a retrospective cohort study to identify factors associated with 
inpatient gout flare (Chapter 3). The candidate prediction rules were developed from 
the regression coefficients of this nine-item set of predictors. The final prediction rule 
was selected based on sensitivity in predicting inpatient gout flare and practicality for 
non-specialist clinicians. 
 The external validation of the prediction rule was performed in a separate cohort 
recruited prospectively from a hospital in Thailand. This section used a prospective 
cohort study design. Participants with comorbid gout were recruited after hospital 
admission and were followed until their hospital discharge, with the occurrence of 
inpatient gout flare set as the primary outcome. Sensitivity, specificity, as well as the 
area under the ROC curve of the prediction rule were calculated for the validation 
cohort. 
5.6 Ethical approval 
 The derivation cohort was collected from hospitals in the Wellington region as 
part of the study to identify predictors of inpatient gout flare (Chapter 3). The study 
protocol was approved by the University of Otago Human Ethics Committee 
(UOHEC), reference number H18/012. Permissions to access medical records were 
obtained from CCDHB and HVDHB. Patient informed consent was not required 
because it was a retrospective chart-review cohort study. 
 The validation cohort was prospectively recruited from Thammasat University 
Hospital, Thailand. The study protocol was reviewed and approved by the Human 
Research Ethics Committee of Thammasat University No.1 (Faculty of Medicine), 
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certificate of approval reference number 266/2019 and project reference number MTU-
EC-IM-1-185/62. All participants gave their written informed consent before data 
collection. The Ethics Committee approval document is included in the Appendix C.1. 
5.7 Derivation of the prediction rule 
5.7.1 The derivation cohort 
 The derivation cohort was previously described in Chapter 3. Briefly, the cohort 
consisted of 625 hospitalized people with comorbid gout who were discharged from 
hospitals in the Wellington region (Wellington, Kenepuru or Hutt hospital) in the 2017 
calendar year. Inclusion criteria were age 18 years or older, discharge date in 2017, first 
admission of the 2017 calendar year, and having comorbid gout, defined as receiving a 
diagnosis of ‘gout’, ‘gouty arthritis’, ‘chronic gout’ or ‘tophaceous gout’ in the hospital 
records. People who received gout diagnosis for the first time during hospital stay and 
those who had gout or gout-related complication as primary admission diagnosis were 
excluded. Data were manually collected from physical hospital records, except for the 
serum urate levels which were collected from the local electronic laboratory database. 
There were 87 flare episodes, accounting for 14% of the cohort. The cohort had a mean 
age of 69 years old and the majority were men (78%). The major ethnicities in the 
derivation cohort were New Zealand European (60%), Māori (19%) and Pacific people 
(17%).  
5.7.2 The predictors of inpatient gout flare 
A logistic regression analysis (with shrinkage to minimize over-optimism) of 
the derivation cohort identified nine variables associated with the risk of inpatient gout 
flare. The nine predictors can be divided into pre-admission and in-admission domains, 
according to the time they became available for evaluation. The pre-admission domain 
has four predictors that are readily available for evaluation at the time of hospital 
admission, including (1) pre-admission serum urate >0.36 mmol/L in the previous year, 
(2) tophus, (3) no pre-admission ULT and (4) no pre-admission gout prophylaxis. The 
in-admission domain has five predictors which may occur at any time during hospital 
stay. The five predictors are (1) in-admission ULT adjustment, (2) in-admission gout 
prophylaxis started/increased, (3) in-admission diuretic adjustment, (4) acute kidney 
injury and (5) surgery. The nine predictors and their corresponding shrunken regression 
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coefficients will serve as the basis from which the prediction rule for inpatient gout 
flare would be derived. 
5.7.3 Development of the candidate prediction rules 
Using the nine predictors of inpatient gout flare, three candidate prediction rules 
were developed: (1) the regression coefficient (β)-based prediction rule, (2) the simple 
rule and (3) the first-day rule. The protocol and rationale for the development of each 
candidate prediction rule are described in the following section. 
5.7.3.1 The regression coefficient (β)-based rule 
The regression coefficient (β)-based rule assigned weight to each predictor by 
rounding the value of its respective shrunken regression coefficient to the closest 
integer (Table 5-1). The weighted scoring system allows the predictors with higher 
priorities to exert greater influence on the final classification. The system closely 
resembles how clinical judgments are typically made. 
Both regression coefficients and odds ratios have been used to assign weights to 
the predictors in scoring systems. However, the use of regression coefficients is a 
mathematically sound option, because regression coefficients represent the influence of 
the predictors on the outcome in an additive scale. Odds ratios are the exponential form 
of regression coefficients and therefore should be multiplied, rather than added or 
rounded up.(242) Previous studies have also found that regression coefficient-based 
scoring systems have superior model fit, compared to odds ratio-based scoring 
systems.(243)  
5.7.3.2 The simple rule 
The simple rule assigned a single point to all items in the prediction rule 
regardless of their regression coefficients (Table 5-1). A clinical tool that is too 
complicated (i.e., numerous items with different weights) could be considered too 
cumbersome.(244) The rationale for the simple rule was to prioritize the ease of 
application for clinicians. Compared to the β-based rule, two items had their scores 
simplified to a single point: ‘no pre-admission gout prophylaxis’ (original score of 2) 
and ‘gout prophylaxis started/increased’ (original score of 3). The reduction of the 
score for ‘gout prophylaxis started/increased’ was substantial but unlikely to have 
major effect on the overall model performance because this item had very low 
prevalence in the derivation cohort (2%). 
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5.7.3.3 The first-day rule 
The first-day rule included only the four predictors available on the first day of 
hospital admission (pre-admission domain) (Table 5-1). The first-day rule was intended 
to maximize potential clinical utility by providing a very early warning of the risk of 
gout flare on the first day of admission. In a typical inpatient setting, the initial 
evaluation on the first day is when the general plan for the hospital course will be made 
by the attending doctor or medical team. This first-day assessment will likely identify 
all comorbidities, whether they are of clinical concern and how to best manage them 
during hospital stay. Early identification of people with comorbid gout who are at risk 
of developing flare is essential to inform the inpatient management plan, which may 
include early detection (e.g., close monitoring) and prevention of potential gout flare 
(e.g., ensure continuation of existing ULT).  
Table 5-1 Development of the scoring system for the candidate prediction rules for 
inpatient gout flare (study 3) 
Predictors  β β-based Simple  First-day 
Pre-admission domain     
(1) Pre-admission serum urate 
>0.36 mmol/L  
1.08 1 1 1 
(2) No pre-admission ULT     1.32 1 1 1 
(3) No pre-admission gout 
prophylaxis 
1.90 2 1 1 
(4) Tophus 1.30 1 1 1 
In-admission domain     
(5) ULT adjustment 0.99 1 1 NA 
(6) Gout prophylaxis 
started/increased 
2.54 3 1 NA 
(7) Diuretic adjustment 0.95 1 1 NA 
(8) Acute kidney injury 0.75 1 1 NA 
(9) Surgery 0.54 1 1 NA 
Maximum possible score - 12 9 4 




5.7.4 Determination of the optimal cut-offs  
 Optimal cut-off point of a clinical scoring system or a biomarker is typically 
derived from criteria based on the ROC curve. The two methods most commonly used 
for the determination of the optimal cut-off are the Youden index and the point closest 
to (0, 1) corner on the ROC curve.(245) The maximum Youden index is the point of 
maximum sum of sensitivity and specificity. In other words, the maximum Youden 
index is the point on the ROC curve with the greatest vertical distance from the positive 
diagonal line which represents a classification purely by chance.(246) The point closest 
to (0, 1) corner on the ROC curve is effectively the point closest to perfect 
classification (sensitivity and specificity of 1.0).(247) However, the optimal cut-offs 
determined by the two methods do not always agree. The Youden index has been 
advocated as a more mathematically meaningful option because it reflects an aim to 
maximize correct classification and subsequently minimize misclassification, while the 
selection of the point closest to (0, 1) involves a quadratic function in its equation that 
has an unclear clinical meaning.(245) Therefore, the maximum Youden index was 
chosen as an indicator of the optimal cut-off point for each candidate prediction rule in 
the current study. The Youden index and its 95%CI was calculated using the formulae 
shown in Table 5-2.(246)  
 The Youden indices of the different cutoffs for each candidate prediction rule 
are shown in Table 5-3. For each candidate prediction rule, the cutoff with the highest 
Youden index was chosen: four or more points for the β-based rule, three or more 
points for the simple rule and two or more points for the first-day rule. 
Table 5-2 Calculation of the Youden index and its 95% confidence interval 
Youden index (J) 







 – 1 Test Yes No  
Positive A C  
Negative B D  







Total A+B C+D  




Table 5-3 Cutoffs and their Youden indices for each candidate prediction rule for 
inpatient gout flare (study 3) 
Candidate prediction rules and cutoffs Youden index 95%CI 
Regression coefficient (β)-based rule   
Three or more 0.31 0.28 to 0.34 
Four or more* 0.52 0.47 to 0.57 
Five or more 0.35 0.29 to 0.40 
The simple rule   
Two or more 0.28 0.25 to 0.31 
Three or more* 0.52 0.48 to 0.57 
Four or more 0.31 0.26 to 0.36 
The first-day rule   
One or more 0.06 0.03 to 0.09 
Two or more* 0.34 0.25 to 0.43 
Three or more 0.28 0.18 to 0.38 
* Cutoff with the highest Youden index for that particular candidate prediction rule. 
 
5.7.5 Determination of the sensitivity and specificity of the candidate 
prediction rules 
 A sensitivity and specificity were calculated for each candidate prediction rule, 
at the previously selected cut-offs (Table 5-3). These performance characteristics would 
be used later for the selection of the final prediction rule. The sensitivity or true positive 
rate reflects the probability of correctly identifying people who will develop gout flare. 
The specificity or true negative rate reflects the probability of correctly identifying 
people who will not develop gout flare. Table 5-4 summarizes the main characteristics 
of the three candidate prediction rules, as well as their performance. 
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Table 5-4 Characteristics and performance indicators of the candidate prediction 
rules for inpatient gout flare  in the derivation cohort (study 3) 
Performance  β-based rule Simple rule First-day rule 
Number of items 9 9 4 
Score per item 
(point) 
1 to 3 1 1 
Cutoffs (maximum 
score) 
≥4 (out of 12) ≥3 (out of 9) ≥2 (out of 4) 
Sensitivity (95%CI) 0.81 (0.71 to 0.88) 0.83 (0.73 to 0.90) 0.84 (0.75 to 0.91) 
Specificity (95%CI) 0.71 (0.67 to 0.75) 0.70 (0.65 to 0.73) 0.50 (0.46 to 0.54) 
AUC (95%CI) 0.76 (0.71 to 0.81) 0.76 (0.71 to 0.81) 0.67 (0.61 to 0.73) 
β, regression coefficients  
AUC, area under the receiver operating characteristic curve 
 
5.7.6 Selection of the final prediction rule 
 The selection of the final prediction rule prioritized sensitivity and practicality. 
The prediction rule was intended to be used by clinicians, particularly non-specialists, 
who took care of people admitted to hospitals for any reason. The final prediction rule 
was selected when both of the following criteria were satisfied: (1) sensitivity of 0.80 or 
higher and (2) easily applicable in routine clinical practice by non-specialist clinicians. 
5.7.6.1 High sensitivity 
The final prediction rule must have a sensitivity of 0.80 or higher. High 
sensitivity (true positive rate) was judged to be essential to ensure that the rule 
identified as many people at high risk of gout flare as possible. In terms of sensitivity, 
the first-day rule has the highest at 0.84 (Table 5-4).  
A potential disadvantage for prioritizing high sensitivity was the possibility of a 
low specificity (i.e., inclusion of people who would not have gout flare). The possibility 
of a low specificity was an acceptable tradeoff, because there was no foreseeable 
significant harm or cost in misclassifying low-risk people as high-risk people. There is 
currently no standard protocol for the prevention of inpatient gout flare. However, the 
options for inpatient gout flare prevention would most likely include close monitoring 
for signs of gout flare, avoiding risk factors of flare when possible (e.g., ensure 
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continuation of existing ULT) and prescribing gout prophylaxis medication (i.e., low-
dose colchicine). The prescription of low-dose colchicine is likely the most aggressive 
action for the prevention of inpatient gout flare. Low-dose colchicine for the prevention 
of gout flare is generally considered safe and cost-effective.(129, 248) In contrast, a 
prediction rule with high specificity but low sensitivity would leave out too many 
people who are at high risk of gout flare. Such prediction rule would have limited 
clinical value.  
5.7.6.2 Practicality 
The selected prediction rule should be as simple and practical as possible, while 
remaining reasonably accurate in classifying people with high risk. A rule that could be 
quickly recalled and applied by non-specialists during regular inpatient assessment is 
more desirable than a rule that requires a physical checklist or a calculator. An ideal 
prediction rule should also allow accurate risk stratification at the earliest time possible. 
Early identification of people at high risk of gout flare would accommodate early 
preventive intervention where appropriate.  
The first-day rule was judged to be the most practical. Having fewer number of 
items (four) and simpler scoring system (one point per item) made the first-day rule the 
most user-friendly, compared to the other candidate rules. The four items in the first-
day rule could easily be obtained during routine history taking and physical 
examination without the need for specialists’ input. Furthermore, the first-day rule 
could be assessed on the first day of hospital admission (pre-admission domain), 
allowing incorporation of the risk of gout flare into the management plan for that 
particular hospital event. In contrast, the β-based rule and the simple rule would require 
repeated risk assessment throughout the hospital course, because the items in the in-
admission domain could occur at any time (e.g., diuretic adjustment, AKI). Such 
requirement could be considered too tedious and discouraging for clinicians who were 
already preoccupied with daily inpatient service.  
5.7.6.3 The final prediction rule 
The first-day rule best satisfied the selection criteria and was subsequently 
chosen as the final prediction rule. It had the highest sensitivity among the candidate 
prediction rules. It was also considered the most practical, having fewest items and 
allowing earliest risk stratification without requiring repeated assessment. The first-day 
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rule will next be validated in an independent cohort prospectively recruited from a 
hospital in Thailand (the validation cohort). 
5.8 External validation of the prediction rule 
5.8.1 The validation cohort 
 The selected prediction rule was validated in an independent cohort of 
hospitalized people with comorbid gout. Adults (age 18 or older) with comorbid gout 
who were admitted to Thammasat University Hospital, Thailand, between December 
2019 and July 2020 were prospectively recruited. Similar to the New Zealand cohort, 
comorbid gout was defined as having received a diagnosis of ‘gout’, ‘gouty arthritis’, 
‘chronic gout’ or ‘tophaceous gout’ in the outpatient clinical notes, hospital discharge 
notes or referral notes by the attending doctors at least once before the current hospital 
admission. People who received a gout or gout-related complication (e.g., infected 
tophus) as the primary admission diagnosis were not recruited. For people who were 
hospitalized more than once during the study period, only the first admission event was 
recorded. For people who developed more than one episode of inpatient gout flare in 
the same hospital event, only the first flare episode and the data prior to that episode 
were documented. The inclusion and exclusion criteria are shown in Table 5-5.  
Table 5-5 Inclusion and exclusion criteria for the participants in the validation 
cohort (Study 3) 
Inclusion criteria 
• Age 18 years or older. 
• Having an admission date between 1 December 2019 and 31 July 2020. 
• First admission in the study period. 
• Having gout as a comorbid disease, defined as receiving a diagnosis of ‘gout’, 
‘gouty arthritis’, ‘chronic gout’ or ‘tophaceous gout’ in an outpatient note, 
hospital discharge note or referral note before the current admission. 
Exclusion criteria 
• Having gout or gout-related complication as the primary admission diagnosis. 




5.8.2 Variables and their definitions 
The variables and their definitions resembled those used in the first study 
(Chapter 3). However, there were minor differences in the definitions of some variables 
due to the difference in the hospital systems and the prospective nature of the current 
study. The list of variables collected in this study is shown in Table 5-6. 
5.8.2.1 Demographics and admission data 
 Demographics included age at admission date, gender (male or female) and 
ethnicity (Thai or other). All non-Thai ethnicities were grouped together because it was 
anticipated that the overwhelming majority of the participants would be ethnic Thai. 
Inpatient department had three possible categories: medicine (internal medicine, 
coronary care unit, stroke unit and rehabilitation medicine), surgery (general surgery, 
orthopedics, ophthalmology and ENT wards) and short-stay unit. The primary 
admission diagnoses were recorded as written on the hospital admission note and were 
later categorized into 13 groups based on their ICD-10 coding: infectious disease, 
neoplasm, diseases of the blood, endocrine disease, diseases of nervous system, 
diseases of the eye/ear, diseases of circulatory system, diseases of respiratory system, 
diseases of digestive systems, diseases of the skin, diseases of musculoskeletal system, 
diseases of genitourinary system and injury/external causes. Hospital outcomes were 
recorded as the length of stay, defined as the number of days between the admission 
date and hospital discharge date, and mortality (yes/no). 
5.8.2.2 Inpatient gout flare data 
 Inpatient gout flare was defined as a new episode of joint swelling and 
tenderness judged by the attending doctor or consultant rheumatologist to be gout. The 
onset of the inflammatory episode must be after hospital admission. The following 
variables were collected for an episode of gout flare: number and location of the 
affected joints, number of days between the admission date and the onset of the flare 
episode, medical treatment for gout flare and duration of the episode (days). Flare 
episodes ended when complete resolution of joint swelling and tenderness was 
observed or when the participants were discharge from the hospital. The inflammatory 
episodes were also examined according to the 2015 ACR/EULAR classification criteria 
for gout.(94) All items from the ACR/EULAR criteria were collected at the onset of 
flare episode or at the earliest time after the episode was discovered. 
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5.8.2.3 Predictors of inpatient gout flare data 
  ‘Pre-admission serum urate <0.36 mmol/L’ was defined as being present if the 
highest serum urate level tested within one year before the admission date was lower 
than 0.36 mmol/L. Hospitals in Thailand typically report serum urate in mg/dL. 
Therefore, a serum urate level below 6.0 mg/dL would satisfy this definition. Serum 
urate results from another hospital (i.e., referring hospital) was accepted as evidence of 
this criterion when the official laboratory report was available or when the serum urate 
result and corresponding testing date were documented in the medical record by the 
attending doctor. Tophus was defined as at least one subcutaneous nodule palpable on 
physical examination by the investigator at the time of participant recruitment.  
 ‘No pre-admission ULT’ was defined as the absence of ULT prescription 
before the current admission. ULT included allopurinol, febuxostat, probenecid, 
benzbromarone and sulfinpyrazone. All possible sources of data available for each 
patient were scrutinized for documentation of ULT prescription including outpatient 
clinical note, hospital discharge note or referral note (in case of referred patients) prior 
to the current admission. Similarly, ‘No pre-admission gout prophylaxis’ was defined 
as the absence of gout prophylaxis medicine prescription before the current admission. 
Gout prophylaxis medications included colchicine, NSAIDs or oral corticosteroids 
(typically prednisolone in Thailand). A history of short-course prescription of these 
medications for the treatment of acute arthritis was not recorded. 
 In-admission adjustment of ULT was defined as a withdrawal, decrease, 
increase or initiation of any ULT at any time during hospital stay and before the 
occurrence of any gout flare episode.  For gout prophylaxis medications (colchicine, 
NSAIDs or oral corticosteroids), an increase or initiation of the medication during 
hospital stay was documented. The increase or initiation of gout prophylaxis must not 
be a treatment for gout flare and occur before any inpatient gout flare episode. 
Adjustment of diuretics included initiation, withdrawal or any changes to the dosage of 
existing diuretics at any time during hospital stay and before any inpatient gout flare 
episode. Diuretic included all loop and thiazide diuretics. 
Acute kidney injury was defined as receiving a diagnosis of ‘acute kidney 
injury’, ‘acute renal failure’ or ‘acute on top chronic renal failure’ by the attending 
doctor at any time during hospital stay and before the onset of any gout flare episode. 
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Surgery included all elective and emergency procedures performed in an operating 
theatre at any time during hospitalization and before the onset of any gout flare episode.   
Table 5-6 Variables collected for the validation cohort (Study 3) 
Categories of data Variables 
Demographics Age, gender (male/female), ethnicity (Thai/other) 
Admission data Primary admission diagnosis, length of stay (days), inpatient 
department (medicine, surgery or short-stay unit), mortality 
(yes/no) 
Inpatient gout flare Inpatient gout flare (yes/no), number of days from admission 
to onset of flare, duration of flare episode (days), number 
and location of joints affected, ACR/EULAR gout 
classification criteria score, treatments of gout flare 
Predictors of 
inpatient gout flare 
Pre-admission domain 
(1) Pre-admission serum urate >0.36 mmol/L, (2) tophus, (3) 
no pre-admission ULT and (4) no pre-admission gout 
prophylaxis. 
In-admission domain 
(5) In-admission ULT adjustment, (6) in-admission gout 
prophylaxis started or increased, (7) diuretic adjustment, (8) 
acute kidney injury and (9) surgery. 
ACR/EULAR, American College of Rheumatology/European League Against 
Rheumatism; ULT, urate-lowering therapy 
 
5.8.3 Hospital database and rheumatology service 
 This study identified participants from the hospital electronic database, as well 
as from rheumatology service. For context, the hospital database and the logistics of 
relevant services in Thammasat University Hospital are described below.  
5.8.3.1 Source of outpatient data 
Thammasat University Hospital utilizes an electronic clinical record system. 
The complete outpatient records are available from 2015 onwards. An outpatient note 
contains the doctor’s typed-in report of the visit, followed by list of diagnoses section, 
appointment schedule and the list of prescriptions for that particular visit. The doctor’s 
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typed-in report typically starts with a list of comorbidities (which are often copied and 
pasted from the previous visits’ notes) and followed by the details of the active 
problems being addressed in the current visit. The list of comorbidities are almost 
always written in English (e.g., ‘gout, DM, CAD’ for ‘gout, diabetes mellitus and 
coronary artery disease’). Furthermore, English is mandatory for the list of diagnoses in 
order to match with the corresponding ICD-10 codes. If an individual had an inpatient 
event, the hospital discharge note is also included among the list of outpatient visits in 
the same screen. Outpatient notes are ordered by the dates of visit or dates of hospital 
discharge in cases of discharge notes. 
5.8.3.2 Source of inpatient data 
The electronic hospital discharge notes have been available in the hospital 
database alongside the outpatient visit records since 2015. The inpatient notes (e.g., 
doctor’s orders, nurses’ notes, vital signs records) are still paper-based. Beginning in 
2019, however, scanned copies of the inpatient notes are available in the system, 
typically within two to three working days after discharge. For participants who are 
currently hospitalized, the physical clinical records are available at the departments 
where the participants are being treated. The list of active hospitalized patients, as well 
as their admission dates, can be accessed through the hospital electronic database. The 
list can be further crossed linked with the outpatient clinical notes. For people referred 
from other healthcare facilities, the referral letters are attached to the admission notes 
during hospital stay and their scanned copies available along with other inpatient 
documents after hospital discharge. Thammasat University Hospital accepts referrals 
from secondary and tertiary care hospitals in the northern Bangkok Metropolitan 
Region. 
5.8.3.3 Laboratory database 
Serum urate testing is performed in the hospital’s own laboratory department as 
part of the blood chemistry panel. All previous laboratory results are available for 
review in the same electronic system as the outpatient notes. 
5.8.3.4 Rheumatology consultation 
Paper rheumatology consultation requests are lodged to the department of 
medicine during business hours (Monday to Friday, 8.00 AM to 4.00 PM). Each month, 
an internal medicine resident is responsible for coordinating rheumatology consultation 
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with the on-duty consultant rheumatologist. The number of consultation requests ranges 
between 20 and 30 each month, with on average at least five consultation requests for 
acute crystal-associated arthritis.  
5.8.4 Identification of eligible participants 
 Participants were identified through two possible pathways: screening from the 
hospital electronic database and through rheumatology consultation (Figure 5-1).  
5.8.4.1 Screening from the electronic database  
Initial screening for potential eligible participants was done manually using the 
electronic database. Two research assistants obtained the list of newly hospitalized 
people stratified by departments (medicine, surgery or short-stay unit). A manual 
screening of the previous outpatient clinical notes and hospital discharge notes was 
done for each newly admitted person. The screening captured people who had the word 
‘gout’, ‘gouty arthritis’ or ‘tophaceous gout’ mentioned at least once in their previous 
outpatient or hospital discharge notes. The research assistants were advised to focus 
their search on the ‘list of comorbidities’ and ‘list of diagnoses’ sections of the clinical 
notes.  
The list of potential participants was then forwarded to the investigator to 
confirm eligibility. Past outpatient notes and hospital discharge notes were reviewed 
again by the investigator to determine whether the participants met all of the inclusion 
criteria and none of the exclusion criteria. A confirmatory review by the investigator 
was necessary because gout could have been mentioned in the clinical notes in a variety 
of contexts. For example, gout could have been mentioned as one of the differential 
diagnoses but was later ruled out. After the confirmation of the participants’ eligibility, 
the investigator approached the participants at the departments where they were being 
treated. 
5.8.4.2 Screening through the rheumatology consultation 
For each calendar month, an internal medicine resident is responsible for 
managing inpatient rheumatology consultation. The resident and the consultant 
rheumatologist were asked to notify the investigator via phone call or texts of any 
consultation requests for gout or acute arthritis suspected to be crystal-associated. The 
investigator reviewed the electronic clinical notes to confirm the eligibility of potential 
participants and, if confirmed, approached the participants at the departments where 
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they were admitted. The identification of participants through rheumatology 
consultation could capture participants who were referred from other healthcare 
facilities for the first time. This group of participants usually had no outpatient records 
in the local system and therefore could not be screened from the hospital electronic 
database. 
 
Figure 5-1 Participant screening and data collection flow diagram for study 3 
 
5.8.5 Data collection procedure 
5.8.5.1 Recruitment and initial data collection 
 The investigator visited the participants at the departments where they were 
being treated and invited the participants to join the study. The participants were 
approached by the investigator as soon as their eligibility was confirmed. The screening 
and the first visit typically took place on the same day (Table 5-7). If the participants 
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could not be reached on the day they were identified (i.e., undergoing surgery), they 
were approached on the next day or as soon as possible. 
All participants were given a copy of the participants’ information sheet and 
were asked to provide written informed consent before first data collection. Initial data 
collection commenced immediately after participant consent was obtained. Data were 
recorded in a pre-determined paper case record form. To protect the participants’ 
privacy, each participant was assigned a study identification number (e.g., TU-001) 
which could not be traced back to their original hospital number. The participants’ 
information sheet and case record form are included in Appendix C. 
 Data were gathered from interview (demographics), previous electronic 
outpatient notes (history of ULT and gout prophylaxis prescription), laboratory 
database (pre-admission serum urate results) and current physical inpatient records 
(admission data, AKI, surgery and adjustment of ULT, gout prophylaxis and diuretics). 
The presence of tophus was confirmed on physical examination performed by the 
investigator. If the participant was experiencing a gout flare at the time of recruitment, 
data for the gout flare episode were also collected by interview and physical 
examination (number and location of joints involved and the ACR/EULAR criteria). 
For participants with no gout flare at the time of recruitment, they were asked to call the 
investigator on the phone whenever they believed they might be experiencing a gout 
flare. 
5.8.5.2 In-hospital follow-up 
Bedside follow-up visits were scheduled two times per week (Table 5-7) for all 
participants actively being treated in the hospital. During follow-up visits, the 
investigator asked the participants whether they experienced joint pain or swelling since 
the last visit. The physical inpatient notes were also reviewed, with a focus on any 
newly occurred predictors of gout flare: AKI, surgery and adjustment of ULT, gout 
prophylaxis or diuretics. If there was a gout flare during the scheduled follow-up visit, 
all variables on the gout flare episode were collected. If the participants directly 
notified the investigator of a suspected episode of gout flare, a special follow-up visit 
would be set up as soon as possible to collect data regarding the flare episode. In an 
exceptional case of the investigator discovering a gout flare episode before the 
attending doctors did, the investigator would inform the attending doctors of the 
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episode but would not take part in the management of the flare episode. Predictors of 
gout flare that occurred after a flare episode (e.g., a surgery that took place after gout 
flare episode) were not documented. If there were more than one gout flare episodes in 
the same admission, only the data related to the first episode were collected. 
Participants who had inpatient gout flare were categorized into the ‘flare group’ for the 
data analysis. 
Follow-up visits and data collection continued until hospital discharge. After the 
participants were discharged from hospital, the investigator performed the final data 
collection by reviewing the scanned copies of the inpatient notes and the electronic 
discharge notes for any additional variables (e.g., length of stay, mortality). Participants 
who did not develop inpatient gout flare were categorized into the ‘non-flare group’ for 
data analysis.  
Table 5-7 Activity time table for participant recruitment and data collection for 
the study 3 
Activities Mon Tue Wed Thu Fri 
Database screening for potential participants AM - AM - AM 
Electronic notes review to confirm eligibility PM - PM - PM 
Participant recruitment and initial data 
collection 
PM - PM - PM 
Bedside follow-up - PM - PM - 
Discharge notes review and final data 
collection 
- PM - PM - 
AM, 9 am to 12 pm; PM, 1 pm to 4 pm 
 
5.8.6 Data analysis  
5.8.6.1 Sample size 
 There is no widely accepted recommendation for the determination of sample 
size for an external validation of a prediction model. In principle, larger number of 
events are required to detect smaller change in the performance of the model in the 
validation dataset. For the regression model, it has been estimated that at least 81 events 
were required to detect a change of 0.1 in the value of C-statistics (AUC) with 80% 
power.(249) The current validation study therefore planned to recruit at least 160 
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people with comorbid gout (80 flares and 80 non-flares), in an eight-month period. It 
was anticipated that approximately ten people with gout flare and ten people without 
flare would be identified each month through rheumatology consultation, combined 
with electronic hospital database screening. 
5.8.6.2 Descriptive analysis 
 To describe the characteristics of the validation cohort, categorical data were 
expressed as frequency and percentage. Continuous data were described as mean and 
SD, or median and IQR for data which were not distributed normally. The 
characteristics of the flare group were compared to the non-flare group in the derivation 
cohort using chi-square test for categorical data and the Mann-Whitney U Test for 
continuous data. A p-value below 0.05 was considered statistically significant. 
5.8.6.3 Performance of the prediction rule in the validation cohort 
 Sensitivity, specificity, positive predictive value (PPV), negative predictive 
value (NPV), positive likelihood ratios (LR+) and negative likelihood ratios (LR-) were 
calculated for the selected prediction rule. The sensitivity and specificity reflect the 
characteristics of the prediction rule, independent of the prevalence of gout flare. The 
sensitivity is the probability of correctly identifying people who will develop gout flare 
(true positive rate). The specificity is the probability of correctly identifying people 
who will not develop gout flare (true negative rate).(250) An ideal prediction rule 
should have the sensitivity and specificity as close to 1.0 as possible, indicating a 
perfect discriminatory accuracy of the prediction rule.  
PPV and NPV indicate post-test probability. High PPV and NPV (close to 1.0) 
are preferable but they must be interpreted in the context of the population being 
studied, because they are heavily dependent on the prevalence of gout flare in that 
particular cohort. PPV is the probability of developing gout flare in people classified as 
having high risk by the prediction rule. NPV is the probability of not developing flare 
in people classified as having low risk by the prediction rule.(250)  
Likelihood ratio is defined as the proportion of the probability of a particular 
prediction in people with gout flare to the probability of the same prediction in people 
without gout flare.(251) In particular, LR+ is the proportion of the probability of being 
classified as high risk in people with flare (true positive rate) to the probability of being 
classified as high risk in people without flare (false positive rate). The LR- is the 
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proportion of the probability of being labelled as low risk in people with flare (false 
negative rate) to probability of being labelled as low risk in people without flare (true 
negative rate). LR can be interpreted as the degree to which the prediction rule affects 
the pre-test probability. The LR of 1.0 indicates that the prediction rule provides no 
additional value to the pre-test probability (pre-test and post-test probability are equal). 
An ideal prediction rule should have a LR+ substantially greater than 1.0 and a LR- 
substantially closer to zero.(251) 
The area under the ROC curve (AUC) was also determined. The AUC 
represents the ability of the prediction rule to discriminate people with inpatient gout 
flare from people without gout flare. The AUC ranges from 0.5 to 1.0, with the AUC of 
1.0 indicating a perfect discrimination between people who develop flare and those who 
do not. On the other hand, an AUC of 0.5 indicates that the prediction rule performs no 
better than chance. 
Descriptive statistics and AUC of the ROC curve were generated using IBM 
SPSS Statistics (version 16). Sensitivity, specificity, PPV, NPV and LR were calculated 
using the formulae shown in Table 5-8. The 95%CI of all the performance indicators 
were estimated using MedCalc Software (version 19.4). 
Table 5-8 Calculations of the prediction rules performance indicators (study 3) 
 Flare Sensitivity = A / A+B 
Specificity = C / C+D 
Positive predictive value = A / A+C 
Negative predictive value = D / B+D 
Positive likelihood ratios = sensitivity / (1-specificity) 
Negative likelihood ratios = (1-sensitivity) / specificity 
Test Yes No 
Positive A C 
Negative B D 
   







5.9.1 Characteristics of the validation cohort 
 There were 184 people with comorbid gout in the validation cohort, 50 (27%) of 
whom developed inpatient gout flare. The demographics, admission data, predictors of 
gout flare and characteristics of gout flare episodes are described in the following 
sections. 
5.9.1.1 Demographics and admission data 
 The mean age and SD of the cohort was 70±14 years. All but one participant in 
the cohort were ethnic Thai, with the majority of the participants being men (79%). The 
participants were admitted equally to the medical and surgical departments. No 
participants were recruited from the short-stay unit. The five most common categories 
of the primary admission diagnosis were disorders of the circulatory systems (21%), 
genitourinary system (16%), musculoskeletal system (15%), digestive system (13%) 
and neoplasms (12%). People who developed inpatient gout flare stayed in the hospital 
for a median of 10 days, compared to only five days for people without gout flare (p-
value <0.001). Seven (4%) deaths were recorded, without statistical difference between 
flare and non-flare group. The demographics and admission data of the validation 
cohort are shown in Table 5-9. 
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Table 5-9 Demographics and admission data of the validation cohort (study 3) 








Age (year), mean±SD  69.8±13.6 68.5±16.2 70.2±12.5 0.80 
Male, n (%) 145 (78.8) 38 (76.0) 107 (79.9) 0.57 
Department 
Medicine 92 (50.0) 31 (62.0) 61 (45.5) 0.047 
Surgery 92 (50.0) 19 (38.0) 73 (54.5) 0.047 
Length of stay (days), median 
(IQR) 
6.0 (6.0) 9.5 (10.0) 5.0 (5.0) <0.001 
Mortality, n (%) 7 (3.8) 2 (4.0) 5 (3.7) 1.00 
Most common categories of primary diagnosis , n (%) 
Circulatory system 38 (20.7) 13 (26.0) 25 (18.7) 0.27 
Genitourinary system 29 (15.8) 8 (16.0) 21 (15.7) 0.96 
Musculoskeletal system 27 (14.7) 3 (6.0) 24 (17.9) 0.042 
Digestive system 24 (13.0) 6 (12.0) 18 (13.4) 0.80 
Neoplasm 21 (11.4) 4 (8.0) 17 (12.7) 0.37 
*Comparison between flare and non-flare group 
IQR, interquartile range; NS, not significant; SD, standard deviation 
 
5.9.1.2 Predictors of inpatient gout flare 
 ‘No pre-admission ULT’ and ‘no pre-admission gout prophylaxis’ were found 
in 45% and 55% of the overall cohort, respectively. ‘No pre-admission ULT’ was 
significantly more prevalent in people who developed inpatient gout flare (78% vs. 
33%, p-value <0.001). The prevalence of ‘no pre-admission gout prophylaxis’ was also 
higher in the flare group compared to the non-flare group, but did not achieve statistical 
significance (66% vs. 52%, p-value 0.078). Pre-admission serum urate results were 
available in 77 people (42%). The mean and SD of the highest pre-admission serum 
urate level in the flare and non-flare group were 0.55±0.11 mmol/L and 0.42±0.14 
mmol/L, respectively (p<0.001). The prevalence of the ‘pre-admission serum urate 
>0.36 mmol/L in the previous year’ was 28% in both the flare and non-flare group. 
Fifteen percent of the cohort had tophus. People who developed inpatient gout flare had 
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significantly higher prevalence of tophus, compared to the people without flare (36% 
vs. 7%, p-value <0.001). 
 Surgery was the most prevalent predictor from the in-admission domain (39%), 
followed by AKI (20%), diuretic adjustment (14%), ULT adjustment (9%) and gout 
prophylaxis started or increased (2%). Among the predictors in the in-admission 
domain, AKI and gout prophylaxis started or increased were significantly more 
prevalent in people who developed gout flare, compared with people without flare. The 
prevalence of the nine predictors of inpatient gout flare stratified by the study groups 
are shown in Table 5-10.  










Pre-admission domain, n (%)     




33 (66.0) 69 (51.5) 0.08 
No pre-admission ULT 83 (45.1) 39 (78.0) 44 (32.8) <0.001 
Pre-admission serum urate 
>0.36 mmol/L 
51 (27.7) 14 (28.0) 37 (27.6) 0.96 
Tophus 27 (14.7) 18 (36.0) 9 (6.7) <0.001 
In-admission domain, n (%)     
Surgery 71 (38.6) 16 (32.0) 55 (41.0) 0.26 
Acute kidney injury 37 (20.1) 21 (42.0) 16 (11.9) <0.001 
Diuretic adjustment 26 (14.1) 11 (22.0) 15 (11.2) 0.06 
ULT adjustment 16 (8.7) 7 (14.0) 9 (6.7) 0.14 
Gout prophylaxis 
started/increased 
4 (2.2) 3 (6.0) 1 (0.7) 0.03 
*Comparison between flare and non-flare group. 




5.9.1.3 Characteristics of gout flare episodes 
 Fifty inpatient gout flare episodes were recorded, the majority of which 
involved a single joint (52%). The median episode duration was three days, with the 
median number of days between hospital admission and the onset of gout flare of five 
days. Knee and ankle joints were the two most common location of arthritis (56% 
each), followed by the first metatarsophalangeal joint (24%) and tarsal joint (16%). 
MSU crystal was identified in a joint aspirate in 24% of the cohort. Over two-third of 
the episodes fulfilled the ACR/EULAR classification criteria for gout. All but two 
episodes (96%) received at least one medication for the treatment of flare, with 
colchicine as the most common medication (62%). Seven people received a 
combination of medications for flare treatment: colchicine and corticosteroids in five 
and colchicine and NSAIDs in two. Characteristics of inpatient gout flare episode in the 
validation cohort are shown in Table 5-11. 
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Table 5-11 Characteristics of gout flare episodes in the validation cohort (study 3) 
Variables  Frequency (N=50) 
Days between admission and flare, median (IQR) 5 (3), range 1 to 22 
Duration of episode (day), median (IQR) 3 (1), range 2 to 7 
Number of joint affected, n (%)  
One 26 (52.0) 
Two to four 18 (36.0) 
More than four 6 (12.0) 
Joints affected, n (%)  
Knee 28 (56.0) 
Ankle 28 (56.0) 
First MTP 12 (24.0) 
Tarsal 8 (16.0) 
Wrist 4 (8.0) 
Elbow 3 (6.0) 
MCP or PIP 2 (4.0) 
2nd-5th MTP 2 (4.0) 
Crystal identified, n (%) 12 (24.0) 
ACR/EULAR classification criteria  
Total ACR/EULAR criteria score, median (IQR) 9 (6), range 3 to 18 
Classified as gout by ACR/EULAR criteria, n (%) 35 (70.0) 
Flare treatments*  
Any medical treatment 48 (96.0) 
Colchicine 31 (62.0) 
Corticosteroids, systemic 21 (42.0) 
Non-steroidal anti-inflammatory drugs 3 (6.0) 
*Seven people (14%) received two medications for the treatment of flare.  
IQR, interquartile range 
 
5.9.2 Performance of the first-day rule in the validation cohort 
The first-day rule had a sensitivity of 0.74 in the validation cohort, compared to 
the sensitivity of 0.84 in the derivation cohort (Table 5-12). However, the specificity of 
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0.69 in the validation cohort was higher than that from the derivation cohort (0.50). The 
first-day rule had acceptable performance characteristics: PPV of 0.47, NPV of 0.88, 
LR+ of 2.38 and LR- of 0.38. The first-day rule also showed superior discrimination in 
the validation cohort (AUC 0.71), compared to that in the derivation cohort (AUC 
0.67). 
Table 5-12 Performance characteristics and 95% confidence intervals  of the 'first-
day rule' in the validation cohort compared to the derivation cohort (study 3) 
Performance Validation (Thai) cohort Derivation (NZ) cohort 
Sensitivity 0.74 (0.60 to 0.85) 0.84 (0.75 to 0.91) 
Specificity 0.69 (0.60 to 0.76) 0.50 (0.46 to 0.54) 
Positive predictive value 0.47 (0.40 to 0.54) 0.21 (0.19 to 0.24) 
Negative predictive value 0.88 (0.81 to 0.92) 0.95 (0.92 to 0.97) 
Positive likelihood ratio 2.36 (1.75 to 3.19) 1.68 (1.48 to 1.90) 
Negative likelihood ratio 0.38 (0.23 to 0.61) 0.32 (0.20 to 0.52) 
AUC 0.71 (0.63 to 0.80) 0.67 (0.61 to 0.73) 
AUC, area under the receiver operating characteristic curve; NZ, New Zealand 
 
5.9.3 Determination of the risk groups 
 Four risk groups were developed according to the score received: low risk 
(score 0), moderate risk (score 1), high risk (score 2) and very high risk (score 3 or 4). 
The percentages of people who developed inpatient gout flare in each risk group in the 
derivation cohort and the validation cohort are shown in Table 5-13 and Figure 5-2.  
In the derivation cohort, 3% of people in the low-risk group developed gout 
flare and 5% in the moderate-risk group developed gout flare. Sixteen percent of people 
in the high-risk group developed inpatient gout flare, while over 40% of people in the 
very high-risk group developed gout flare. Similar trend was observed in the validation 
cohort, with relatively more pronounced absolute percentage. The low-risk group had 
the lowest percentage of people with gout flare (8%). In the validation cohort, over one-
third of the high-risk group and three-quarters of the very high-risk group developed 
inpatient gout flare. 
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Table 5-13 Percentage of people with gout flare according to the risk groups  in the 
derivation and validation cohorts (study 3) 
Risk groups (score) Derivation (NZ) cohort Validation (Thai) cohort 
Number of participants 625 (87 flares) 184 (50 flares) 
Low (score 0) 3% (1/37) 8% (2/26) 
Moderate (score 1) 5% (13/246) 14% (11/79) 
High (score 2) 16% (41/263) 35% (19/55) 




Figure 5-2 Percentage of people with gout flare in each risk group in the 




 In this study, three candidate prediction rules for inpatient gout flare in people 
with comorbid gout were derived from a set of predictors identified in Chapter 3. The 
four-item ‘first-day rule’ was eventually selected for its high sensitivity and 
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practicality. The four items were ‘no pre-admission gout prophylaxis’, ‘no pre-
admission ULT’, ‘tophus’ and ‘pre-admission serum urate >0.36 mmol/L in the 
previous year’, leading to the acronym “GOUT-36 rule” (no GOut prophylaxis, no 
Urate-lowering therapy, Tophus and serum urate >0.36 mmol/L) (Table 5-14). The 
four-item prediction rule was intended for use on the first day of hospital admission to 
allow early risk stratification. The GOUT-36 prediction rule performed relatively well 
in an independent cohort recruited from Thailand: sensitivity 0.74 and specificity 0.69. 
The following discussion is divided into three parts: (1) the rationale and intentions for 
developing the GOUT-36 prediction rule, (2) A critique of the study and (3) the gap in 
the knowledge and research priorities. 
Table 5-14 The GOUT-36 prediction rule  
GOUT-36 rules Definitions*  
Entry criteria A person must have a comorbid gout, defined as having 
received a diagnosis of gout by a doctor before the current 
hospital admission. 
Classification* A person with two or more of the following four items is 
classified as having high risk for inpatient gout flare. 
Criteria   
(1) No GOut 
prophylaxis 
No pre-admission gout prophylaxis medication according to 
medical records. Gout prophylaxis includes colchicine, 
NSAIDs and oral corticosteroids. 
(2) No Urate-
lowering therapy 
No pre-admission urate-lowering therapy (ULT) according to 
medical records. ULT includes allopurinol, febuxostat, 
probenecid, benzbromarone and sulfinpyrazone. 
(3) Tophus Subcutaneous nodule from a physical examination by a doctor. 
(4) Serum urate 
>0.36 mmol/L 
Highest serum urate level tested within 12 months before 
admission greater than 0.36 mmol/L (6 mg/dL). 





5.10.2 The GOUT-36 prediction rule 
5.10.2.1 Why do we need another clinical score? 
Clinical scores are popular tools designed to aid clinicians in their decision-
making on a wide range of clinical problems. The purpose of a clinical score is 
typically to determine the likelihood of having a condition (e.g., the Wells score for 
likelihood of deep vein thrombosis(252)), to assess the severity of a condition (e.g., the 
CURB-65 score for the severity of community-acquired pneumonia(253)) or to 
determine the risk of future adverse event (e.g., the Framingham risk score for 10-year 
risk of cardiovascular events(254)).  
Numerous scoring systems have been developed for the classification of gout or 
to measure gout impact. Most of the scoring systems for gout, however, were intended 
for use in clinical research. Examples of the scoring systems intended for gout research 
include the 1977 American Rheumatism Association classification criteria,(255) the 
2015 ACR/EULAR classification criteria,(94) the patient-report definition of gout 
flare,(256) the gout assessment questionnaire (GAQ and GAQ2.0),(257, 258) the Gout 
Activity Score (GAS),(259) the Tophus Impact Questionnaire (TIQ-20)(260) and the 
Gout Attack Intensity Score (GAIS).(261) Despite the high prevalence of gout in the 
general population, few clinical scores have been developed to aid clinicians in their 
assessment and care for people with gout in clinical practice. One such score was the 
diagnostic rule for acute gouty arthritis in primary care, which had family physicians as 
its target audience.(262) A clinical score to help stratify the risk of inpatient gout flare 
has not been developed before. 
Gout flare is a common medical problem encountered and managed by most 
clinicians regardless of their specialties. In the hospital setting, the chance of 
developing gout flare in people with comorbid gout increases four to tenfold.(11, 156) 
Inpatient gout flare is associated with a longer length of hospital stay (172) and greater 
healthcare cost.(150) A clinical tool for identifying people who are likely to develop 
inpatient gout flare could be very useful. The tool has to be intuitive and simple enough 
for effective implementation in routine hospital care by clinicians, specifically non-
rheumatologists. The GOUT-36 prediction rule was developed with the intention to 
streamline the initial assessment of people with comorbid gout on the first day of their 
hospital admission. With only four items, no requirement for additional blood test or 
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specialist input and acceptable performance, the GOUT-36 prediction rule may be a 
valuable tool for clinicians taking care of people with comorbid gout in an inpatient 
setting. 
5.10.2.2 How to best use the GOUT-36 rule? 
The target population. People with comorbid gout who are admitted to the 
hospital for reasons other than gout are the target population for the GOUT-36 
prediction rule. These people typically have more than one comorbid condition, in 
addition to their primary admission diagnosis. The development of gout flare in this 
scenario could substantially worsen the patients’ experience in the hospital and 
potentially lead to more exposure to investigations (e.g., joint aspiration, blood tests), 
medications (e.g., analgesics, NSAIDs) and a longer length of hospital stay. An 
effective prediction rule for inpatient gout flare may help clinicians take the most 
appropriate action to prevent gout flare in this particular group of people.  
The target audience . The main audience of the GOUT-36 prediction rule are 
non-specialist doctors who are taking care of people in an inpatient setting. In a typical 
inpatient scenario, the attending doctors’ attentions are divided between multiple active 
problems. A user-friendly and reasonably accurate risk stratification tool would help 
warn clinicians of the possibility of gout flare without requiring too much additional 
attention from them.  
Timing. The GOUT-36 prediction rule is intended for use on the first day of 
hospital admission, ideally during the first evaluation of the patient. This is to ensure 
the inclusion of risk assessment for gout flare in the routine inpatient practice. Early 
risk stratification may also allow gout care to be included in the general management 
plan for that hospital admission. The GOUT-36 prediction rule could be easily 
integrated into the initial history taking and physical examination of newly admitted 
patients without requiring substantial amount of additional time or resources. 
5.10.2.3 Cautions for the use of GOUT-36 prediction rule 
The GOUT-36 prediction rule is not meant to be a definitive indicator of the 
risk of inpatient gout flare. Some people classified as having high risk will not develop 
gout flare, while some people in the low-risk group will develop gout flare. This is due 
to the continuous nature of inpatient gout flare risk.(172) The prediction rule does not 
encompass all possible potential predictors of inpatient gout flare, because it was 
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derived from a retrospective cohort study using only data available in the medical 
notes. Consequently, the GOUT-36 prediction rule can provide a quick guide to 
identifying people at high-risk of gout flare, but the ultimate decision regarding whether 
a person is at risk of gout flare remains with the attending doctor. 
Attention is required to ensure that the definitions of the items in the prediction 
rule are closely followed. Pre-admission serum urate >0.36 mmol/L considers the 
highest serum urate results within the 12 months period before admission, rather than 
the latest pre-admission results. In-admission serum urate results are not counted in the 
GOUT-36 prediction rule because in-admission serum urate level could be influenced 
by multiple hospital-related factors (e.g., AKI, surgery) and subsequently is not a 
reliable indicator of gout control. The in-admission serum urate was excluded from the 
original clinical model (Chapter 3) because its inclusion would require an additional 
blood test which was considered too invasive.  
The presence of tophus is based on a physical examination by the attending 
doctor, rather than radiographic evidence of tophus, joint damage or urate crystal 
deposition. This was to ensure that tophus could be assessed by non-specialists without 
requiring advanced imaging studies. The presence of ULT and/or gout prophylaxis 
medications was based on medical records to ensure reliable data. Clinicians are 
discouraged from relying solely on patient history for the presence of these 
medications. For example, a patient’s claim of taking a ‘tablet for gout' without any 
data on specific ULT or gout prophylaxis in the medical records should not be counted 
when performing risk stratification. 
The GOUT-36 prediction rule is not designed for the general inpatient 
population or people who have a history of undiagnosed arthritis episodes. The 
prediction rule should be used only for the determination of the risk of gout flare in that 
particular hospital admission. If the same individual has a second hospital admission, 
the individual should be assessed for the risk of gout flare again on the first day of the 
new hospital event. It is also not known whether people receiving high score from the 
GOUT-36 prediction rule during hospitalization are also at higher risk of gout flare in 
an outpatient setting.  
Finally, the GOUT-36 prediction rule cannot be used for the diagnosis of an 
arthritis episode. An acute arthritis that occurs during a hospital admission in people 
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classified as ‘high-risk’ by the GOUT-36 prediction rule may not be due to gout. Other 
common causes of inpatient acute arthritis should always be considered, including other 
types of crystal-associated arthritis, osteoarthritis and infectious arthritis. The diagnosis 
of an inpatient arthritis episode is ultimately the responsibility of the attending doctors. 
5.10.3 Critique of the study 
5.10.3.1 Prediction rule derivation: the strengths 
The foundation from which the final prediction rule was derived was the 
retrospective cohort study in people with comorbid gout from Wellington, New 
Zealand. Nine predictors of inpatient gout flare were identified by exhaustive statistical 
processes: variables selection using existing clinical knowledge, determination of 
regression coefficients using a multivariable logistic regression with shrinkage and 
internal validation by bootstrap procedure. The resulting predictors of inpatient gout 
flare, which later became the criteria in the GOUT-36 prediction rule, were therefore 
supported by existing clinical knowledge and robust statistical methods.  
Based on the derivation cohort, three candidate prediction rules were 
subsequently developed (the ‘β-based rule’, the ‘simple rule’ and the ‘first-day rule’). 
By rounding the shrunken regression coefficients to the closest integer, the β-based rule 
was the candidate that shared the most resemblance to the original prediction model. 
The β-based rule displayed high sensitivity (0.80), specificity (0.71) and discrimination 
(AUC 0.76). However, the β-based rule was also the most complex among the three 
candidate rules, with nine items and weights ranging between one and three points. 
Furthermore, five out of nine items in the β-based rule had to be collected during 
admission (in-admission domain). The presence of items from the in-admission domain 
(e.g., diuretic adjustment and surgery) necessitates repeated assessments throughout the 
course of hospital admission. This could be considered too burdensome for clinicians 
working in busy inpatient services.  
The simple rule was similar to the β-based rule, except for the more simplified 
weight assignment (a single point to all nine items). The performance characteristics of 
the simple rule were similar to those of the β-based rule: sensitivity of 0.83, specificity 
of 0.70 and AUC of 0.76. However, the simple rule carried similar practical 




To circumvent the need for repeated assessment, the first-day rule was 
developed by shortening the simple rule down to only four items from the pre-
admission domain. The first-day rule could be completed in a single assessment using 
data that were available at the time of hospital admission (pre-admission serum urate, 
tophus and the absence of ULT or gout prophylaxis). This made the first-day rule the 
most practical candidate. Having fewer number of items also led to an increase in the 
sensitivity (0.84). In the context of predicting inpatient gout flare, high sensitivity (i.e., 
the ability to identify as many high-risk people as possible) was essential for a 
prediction rule to be considered clinically useful. The first-day rule (the GOUT-36 rule) 
was chosen for its practicality and high sensitivity. 
5.10.3.2 Prediction rule derivation: the tradeoffs 
The tradeoff of the high sensitivity in the first-day rule was its relatively low 
specificity: 0.50 in the derivation cohort and 0.69 in the validation cohort. This meant 
that substantial number of low-risk people could be misclassified as having high risk 
for gout flare. The low specificity was judged to be an acceptable tradeoff because the 
foreseeable consequences of misclassifying the risk of gout flare was not harmful or 
costly. Currently, it is not known what actions are effective in the prevention of 
inpatient gout flare. Clinical reasoning would suggest that removing the potential 
predictors of flare where possible (e.g., ensure continuation of existing ULT) during 
admission may help prevent inpatient gout flare. In this context, misclassifying some 
low-risk people as high-risk people would at most lead to a short-term unnecessary 
intake of colchicine in a supervised inpatient setting. 
In conclusion, the four-item first-day (GOUT-36) prediction rule was 
considered the candidate rule of choice when practicality and sensitivity were 
prioritized. Based on the current study, the GOUT-36 prediction rule has a relatively 
high sensitivity: 0.84 in the derivation cohort and 0.74 in the validation cohort. This 
meant that the rule was able to identify the majority of people who would eventually 
develop inpatient gout flare. Other major advantages of the rule are its practicality and 
its ability to allow very early risk stratification.   
5.10.3.3 External validation: the strengths 
The external validation showed satisfactory performance of the GOUT-36 
prediction rule in an independent cohort. The validation cohort was recruited from a 
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tertiary hospital in Thailand, a robust option for the external validation. To ensure a 
consistent performance of the prediction rule across different populations (i.e., 
universality), the prediction rule should ideally be tested with newly collected data from 
a population from a different center using the same inclusion criteria.(263) Compared 
to the derivation cohort, the validation cohort was vastly different in terms of ethnicity 
(majority European vs. majority Asian), country of origin (New Zealand vs. Thailand) 
and time of recruitment (2017 vs. 2020). Despite these differences, the GOUT-36 
prediction rule performed well in the validation cohort (sensitivity 0.74, specificity 0.69 
and AUC 0.71). The consistent performance across two independent cohorts was 
reassuring for the prediction rule’s universality. Furthermore, the participants in the 
validation cohort were prospectively recruited. The prospective design allowed 
complete and accurate data collection, a major advantage over a retrospective cohort 
design used in the derivation study. 
5.10.3.4 External validation: limitations 
There were a number of limitations pertaining to the validation study. The 
number of events was lower than anticipated. At least 81 gout flare episodes were 
judged to be the ideal number of events, but only 50 gout flare episodes were ultimately 
recorded. Consequently, there was a possibility that the performance characteristics of 
the GOUT-36 prediction rule could change for the better or worse in a larger cohort 
with greater number of flare episode.  
The participant screening protocol in the validation study was designed to be 
compatible with the local hospital system (manual screening of hospital database and 
screening through consultation requests). Some potentially eligible people with 
comorbid gout might not have been captured by manual screening. This limitation was 
not found in the derivation cohort study from New Zealand, which employed a highly 
efficient electronic ‘discharge letter word search’ algorithm to identify potential 
participants from the database. The validation study also screened for potential 
participants through rheumatology service consultation. This screening method almost 
exclusively identified people who developed gout flare and required input from a 
rheumatologist. These limitations likely explained the higher gout flare prevalence in 
the validation cohort compared to the derivation cohort (27% vs. 14%).  
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Almost all participants in the derivation cohort and the validation cohort were 
recruited from hospitals in major urban areas. These hospitals could be more likely to 
encounter people with more advanced comorbid gout who might already have higher 
chance of developing gout flare. It was therefore uncertain whether the GOUT-36 
prediction rule would perform as well as expected in primary care facilities, where the 
majority of people may have mild or early comorbid gout. 
Due to the higher prevalence of gout flare in the validation cohort, the 
performance characteristics which were dependent of the prevalence (PPV, NPV, LR+ 
and LR-) may not be directly comparable between the derivation and the validation 
cohort.(251) Most prominently, the PPV and the LR+ were higher in the validation 
cohort compared to the derivation cohort (0.47 vs. 0.21 for PPV and 2.36 vs. 1.68 for 
LR+). The high PPV and LR+ were desirable but they did not necessarily mean that the 
GOUT-36 rule performed better in the validation cohort. However, the discriminatory 
accuracy (sensitivity, specificity and the AUC) were typically considered to be 
independent of the disease prevalence in the cohort. The relatively high sensitivity 
(0.74), specificity (0.69) and AUC (0.71) in the validation cohort were therefore 
compelling indicators of the prediction model’s strong performance across different 
populations. 
5.10.3.5 The potential spectrum bias 
 Despite the general belief that sensitivity and specificity are not dependent on 
the disease prevalence, there may be some scenarios where this assumption is not true. 
Discrepancy of sensitivity and specificity between two populations of different disease 
prevalence could be the result of the difference in the underlying disease traits. This is 
known as the ‘spectrum bias’.(264) The spectrum bias can happen when testing binary 
diagnostic test (disease vs. no disease) on a condition that has continuous traits (e.g., 
result of blood test with certain cut-off). If the distribution of the continuous traits 
between two populations is different, the sensitivity and specificity of a test using the 
same cut-off may also be different. The spectrum bias typically results in a test showing 
higher sensitivity but lower specificity in the population with greater disease 
prevalence, compared to another population with lower disease prevalence.(265)  
For the current validation study, there was a possibility of a spectrum bias. The 
recruitment protocol for the validation cohort favored the identification of people with 
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gout flare which led to a higher gout flare prevalence, compared to the derivation 
cohort (27% vs. 14%). Consequently, the validation cohort might have had a higher 
proportion of people with advanced gout who were more likely to score highly in the 
GOUT-36 rule (and increasing the sensitivity). In fact, a higher percentage of tophus in 
the validation cohort supported this assumption (15% in validation cohort vs. 4% in 
derivation cohort).  
In this study, however, the GOUT-36 rule had lower sensitivity (0.74 vs. 0.84) 
and higher specificity (0.69 vs. 0.50) in the validation cohort compared to the 
derivation cohort, despite greater prevalence of flare in the validation cohort. This 
observation indicated that the spectrum bias, if it existed, did not play a significant role 
in the current study. 
5.10.3.6 Gout-36 rule cannot dictate what action should be taken 
The GOUT-36 prediction rule informs clinicians of which persons are at high 
risk of developing inpatient gout flare. It cannot, based on the existing clinical 
evidence, inform the clinician of which action should be taken in people at high risk of 
gout flare. Controlled studies for interventions for inpatient gout flare are scarce and 
recommendations for the prevention of inpatient gout flare have therefore never been 
made. It is currently not known which actions are effective for reducing the incidence 
of gout flare specifically in hospital settings. Although the efficacy of colchicine in the 
prevention of gout flare was well established in clinical trials of people starting on 
ULT,(129, 266) it is not known if the same benefit would be achieved in people 
labelled as high-risk for flare in hospital settings. These questions are beyond the scope 
of the studies in this thesis. At the current time, the decision regarding the appropriate 
action for people classified as having high risk for inpatient gout flare is entirely 
dependent on the attending doctors’ judgment. In other words, the GOUT-36 prediction 
rule only provides an early warning for the probability of inpatient gout flare. What to 
do next should be decided on an individual case basis. 
5.10.4 Future research agenda 
The inspiration for developing the GOUT-36 prediction rule was the recognition 
of the impact of inpatient gout flare as shown in the literature review, the need to 
identify factors associated with the risk of inpatient gout flare and the desire to 
accurately predict it. The most immediate research agenda is to further test the 
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performance of the GOUT-36 prediction rule in other populations, preferably by 
researchers not associated with the original studies. An independent validation study in 
countries where gout is less common than in New Zealand, as well as in community 
hospitals, would provide a compelling support for the prediction rule’s generalizability. 
Such an agenda is highly feasible because the application of the GOUT-36 prediction 
rule requires almost negligible time and resources from the evaluators. Furthermore, an 
independent validation study can be conducted retrospectively, as long as the 
investigators have reliable access to medical records and laboratory databases. 
The long-term research agenda will be more challenging. This thesis’ 
overarching aim is to develop an evidence-based, simple and reasonably accurate risk 
stratification tool for inpatient gout flare. It is therefore expected that the application of 
the proposed prediction rule would lead to clinically meaningful and measurable effects 
on health outcomes (i.e., have clinical utility). Health outcomes are defined as 
outcomes that matter to gout patients and society overall.(267) In the context of 
hospitalized people with comorbid gout, the primary health outcome is lower rates of 
inpatient gout flare. Secondary health outcomes may include a shorter hospital length of 
stay and lower hospital costs. In order to link the risk stratification tool to the rates of 
inpatient gout flare, an interventional decision model needed to be tested. Based on the 
existing literature on the prevention of gout flare in people newly initiated on ULT, 
low-dose colchicine is a safe, effective and economic choice.(129, 248, 266) A clinical 
trial could be set up to examine the difference in the rates of inpatient gout flare 
between the treatment protocol based on GOUT-36 risk stratification and a standard 
protocol (i.e., wait and see). This type of controlled study is a significant undertaking, 
but it could provide evidence informing clinicians on their decision-making for 
hospitalized people with comorbid gout. 
5.10.5 Conclusion 
 This chapter aims to develop a risk stratification tool for gout flare in 
hospitalized people with comorbid gout. This clinical tool was intended for non-
specialist clinicians who take care of adult patients in inpatient services. Using the set 
of predictors identified from the retrospective cohort study from New Zealand, the 
GOUT-36 prediction rule (no GOut prophylaxis, no Urate-lowering therapy, Tophus 
and serum urate >0.36 mmol/L) was developed. To externally validate the GOUT-36 
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prediction rule, a new cohort of people with comorbid gout was prospectively recruited 
from a hospital in Thailand (the validation cohort). The validation cohort consisted of 
184 people, 50 (27%) of whom developed inpatient gout flare. The GOUT-36 
prediction rule showed satisfactory performance in the validation cohort: sensitivity of 
0.74, specificity of 0.69 and AUC of 0.71. The GOUT-36 prediction rule has four easily 
accessible items. It requires only a single assessment to complete and subsequently 
allows very early risk stratification. Gout is a common comorbid condition among 
inpatient populations. The GOUT-36 prediction rule may help clinicians identify people 
with comorbid gout who are likely to develop inpatient gout flare, without requiring 
addition time, resources or specialist’s input. Finally, the development of GOUT-36 
prediction rule may help inform future research agenda to identify the best protocol for 




Chapter 6 Overall discussion 
6.1 Introduction 
The first half of the chapter will summarize the three studies in the thesis; where 
they fit into the current understanding of inpatient gout flare, as well as the overall 
critique of the thesis. The second half of the chapter will look to the future; how the 
results of these studies may impact clinical practice for people with comorbid gout in 
the hospital setting, what remains unknown and relevant future research priorities. 
6.2 Why does this thesis matter? 
 Literature review, as well as anecdotal observation, suggested that gout flare is a 
common inpatient complication in people with comorbid gout, affecting up to 35% of 
people with comorbid gout hospitalized for reasons other than gout.(155) Inpatient gout 
flare is associated with a longer hospital stay and higher healthcare cost.(150, 156) 
People who developed gout flare during hospitalization are also more likely to be 
exposed to more medications, which can have adverse effects, and investigation, some 
of which may be invasive (e.g., joint aspiration). Multiple factors have long been 
suspected to be associated with gout flare in the hospital setting,(1) but controlled 
studies to confirm such association were lacking. It is therefore not known how to 
identify people who are likely to develop inpatient gout flare or which actions are 
effective and safe in preventing inpatient gout flare. 
The thesis had an overarching goal of developing an evidence-based clinical 
tool for the identification of people with comorbid gout who were at high risk of 
developing gout flare during their hospital stay, informed by three research projects. 
The three studies were designed to answer the following three corresponding questions: 
(1) what are the predictors of inpatient gout flare in people with comorbid gout, (2) are 
these predictors associated with the length of hospital stay, and (3) how can people at 
high risk of developing inpatient gout flare be accurately identified? Better 
understanding of the factors associated with inpatient gout flare and accurate risk 
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stratification are key steps towards the prevention of inpatient gout flare in people with 
comorbid gout. 
6.3 What was done and what were the findings? 
 The thesis contains three consecutive studies. The protocols and main findings 
are visually summarized in Figure 6-1 along with how the studies are inter-related. 
6.3.1 The first study: predictors of inpatient gout flare 
 Determination of the predictors of inpatient gout flare is the foundation of this 
thesis. In the first study, predictors of inpatient gout flare were identified using a 
retrospective cohort study based in Wellington, New Zealand. Data of 625 hospitalized 
people with comorbid gout were collected from hospital records, with 87 (14%) having 
inpatient gout flare. Fifty-two candidate variables were explored, with inpatient gout 
flare (yes/no) as the dependent variable. Three candidate prediction models were 
developed: (1) the clinical knowledge–driven model which selected predictors based on 
clinical knowledge and estimated the regression coefficients using a regression 
analysis, (2) the statistics-driven model which selected the predictors and estimated the 
regression coefficients using the LASSO procedure and (3) a decision tree model which 
selected the predictors using a tree-based machine learning algorithm. The nine-item 
clinical knowledge-driven model was ultimately chosen for its superior discrimination 
(C-statistics 0.82), calibration (calibration slope 0.93) and practicality. To minimize 
over-optimism, the estimated regression coefficients were further shrunk by 
multiplication with a linear shrinkage factor and internally validated using a 1,000-
sample bootstrap procedure. The first study yielded nine predictors associated with 
inpatient gout flare. Four predictors were readily available at the time of hospital 
admission (pre-admission domain): no pre-admission ULT, no pre-admission gout 
prophylaxis, pre-admission serum urate >0.36 mmol/L and tophus. Five predictors 
occurred during hospital stay (in-admission domain): ULT adjustment, gout 
prophylaxis started/increased, diuretic adjustment, acute kidney injury and surgery. 
Potential limitations were the relatively small number of flares and the reliance on 
existing clinical knowledge for variable selection, which could have prevented the 




6.3.2 The second study: predictors of inpatient gout flare and the length 
of stay 
 The second study explored whether the variables associated with inpatient gout 
flare were also associated with hospital outcome, specifically the length of hospital 
stay. A population-based cohort of hospitalized people with comorbid gout was 
obtained from the New Zealand Ministry of Health’s national data collections. Data of 
36,047 people with comorbid gout who were hospitalized in the 2017 calendar year 
were analyzed using a generalized linear model, with hospital length of stay (days) set 
as the dependent variable. Twelve variables were found to be associated with the length 
of hospital stay, four with a shorter length of stay and eight with a longer length of stay. 
Regular pre-admission ULT, pre-admission serum urate testing, male gender and 
thiazide diuretics were associated with a shorter length of stay. Loop diuretics, 
potassium-sparing diuretics, surgery, corticosteroids, acute admission, age, Māori and 
Pacific ethnicity were associated with a longer stay. People who had all variables 
associated with a longer length of stay were estimated to add four days to their hospital 
admission. The interpretation of the study results was limited by the absence of record 
for inpatient gout flare episodes in the national data collections. 
6.3.3 The third study: the GOUT-36 prediction rule 
 The last study derived a risk stratification tool to help clinicians identify people 
with comorbid gout who were at high risk of developing inpatient gout flare. Three 
candidate prediction rules were developed from the previously identified nine 
predictors of inpatient gout flare: (1) the nine-item, regression coefficient-based 
prediction rule which assigned points to each item by rounding the regression 
coefficient to the closest integer, (2) the simple prediction rule which assigned all nine 
items with a single point and (3) the first-day rule which included only the four items 
(one point each) from the pre-admission domain. Cut-off for each candidate prediction 
rule was determined by the highest Youden index. The selection of the final prediction 
rule prioritized high sensitivity for predicting inpatient gout flare and practicality in the 
routine hospital setting. The first-day rule with the cut-off of two points or more was 
ultimately chosen for its high sensitivity (0.84) and practicality (only four items and 
one point for each item). The first-day rule was renamed the GOUT-36 rule, an 
acronym for “no GOut prophylaxis, no Urate-lowering therapy, Tophus and serum 
urate >0.36 mmol/L”.  
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To ensure consistent performance in a different population, the GOUT-36 
prediction rule was validated in an independent cohort of 184 Thai people with 
comorbid gout, 50 of whom had inpatient gout flare. The GOUT-36 prediction rule had 
a sensitivity of 0.74 and a specificity of 0.69 for predicting inpatient gout flare in the 
validation cohort. The GOUT-36 prediction rule is simple, does not require 
investigation or specialist input, and allows very early risk stratification (first day of 








6.4 What does the thesis add? 
 Overall this thesis provides five unique enhancements to the knowledge in the 
existing literature on gout (Table 6-1).   
• From an original 52 potential predictors of inpatient gout flare drawn from 
existing literature and pathophysiological knowledge of gout,(1, 135) the 
thesis identified nine predictors of gout flare in people with comorbid gout 
in the hospital setting. This thesis provided some evidence in support of 
these predictors as accurate and independent, as well as an estimation of the 
predictors’ regression coefficients which reflected their influence on the risk 
of inpatient gout flare.  
• The New Zealand-based retrospective cohort study provided additional 
insights into the prevalence of gout flare as a complicating condition during 
hospital stay. Previous studies which identified participants using ICD 
diagnostic coding estimated the prevalence of inpatient gout flare to be high 
(up to 35%)(154, 155) The current New Zealand cohort, which was the 
largest to date, found the prevalence of inpatient gout flare to be substantial 
(14%) but not as high as those reported by earlier studies.  
• This thesis employed two methods for patient identification (ICD-10 coding 
and electronic discharge letter word search) and identified a larger number 
of people with comorbid gout who did not have gout flare, leading to a 
lower prevalence of inpatient gout flare than initially anticipated (14%). 
This was due to the bias of ICD discharge coding in favor of people with 
comorbid gout who developed inpatient gout flare. Future research aiming 
to identify people with co-morbid gout should strongly consider applying 
more than one method for patient identification as this is likely to identify a 
more comprehensive cohort. 
• In the second study, some of the predictors of inpatient gout flare were 
found to be associated with the length of hospital stay in a population-based 
cohort study. This knowledge emphasized the importance of these predictors 
by exploring their association to the hospital length of stay, which was an 
important health system level hospital outcome. The association between 
predictors of inpatient gout flare and the hospital length of stay has not been 
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explored before. Such association may help inform future research on the 
possible impact of actions to prevent inpatient gout flare and help strengthen 
the argument for establishing protocol for people at high risk of developing 
inpatient gout flare.  
• The GOUT-36 prediction rule is a novel clinical tool for the identification of 
people with high risk of developing inpatient gout flare. The items in the 
GOUT-36 prediction rule are well known gout-related variables (tophus, 
serum urate level and gout medications) because their statistical derivation 
was guided by existing clinical knowledge and practical judgment. With 
non-specialist doctors as the target audience, the GOUT-36 prediction rule 
was designed to be as simple as possible to maximize the ease of use in real-
world hospital practice. 
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Table 6-1 What the thesis adds to the existing knowledge 
What is known What the thesis adds Chapter 
Factors associated with inpatient gout flare in people with comorbid gout 
• Some factors are associated with 
inpatient gout flare in specific 
populations: postsurgical patients 
and people admitted for stroke. 
• Nine variables are associated with 
inpatient gout flare in people with 
comorbid gout admitted for any 
reason. 
3 
Prevalence of inpatient gout flare 
• Prevalence of gout flare as an in-
hospital complication ranges from 
34% to 35% in small retrospective 
studies. 
• Prevalence of inpatient gout flare 
in the largest series to date is 
substantial but may not be as high 
as previously suggested (14%) 
3 
Identification of people with comorbid gout from a hospital database 
• Patient identification using the 
diagnostic coding is the standard 
method.  
• Electronic word search may be a 
compelling complementary 
method for identifying people with 
comorbid gout. 
3 
Impact of inpatient gout flare on hospital length of stay in people with comorbid gout 
• Inpatient gout flare is associated 
with a longer hospital length of 
stay. 
• Some predictors of inpatient gout 
flare are associated with a longer 
length of stay, including the use of 
loop diuretics and surgery. 
• Regular ULT and urate testing are 
associated with shorter length of 
stay. 
4 
Prediction of inpatient gout flare 
• No existing clinical tool or 
instrument. 
• GOUT-36 rule for the prediction 
of inpatient gout flare was 





6.5 Conceptual critique of the thesis 
   While novel findings have added to the existing knowledge of gout, there are 
also limitations and considerations around the generalizability of the results. This 
section will outline the findings of the thesis in a wider context, as well as provide some 
critical discussion where appropriate. 
6.5.1 Addressing a global problem 
 Gout is the most common form of inflammatory arthritis, predominantly 
affecting men.(2) The incidence, prevalence and number of years lived with disability 
in people with gout has been rising across the world for the past three decades.(268) 
The rates of hospitalization in people with comorbid gout also appears to be increasing 
in many countries, including Australia and New Zealand,(15) The United 
Kingdom,(153) Canada,(17) and Sweden.(16, 152) Inpatient gout flare is a problem 
commonly encountered during inpatient care. Despite the scale of the problem, studies 
on people with comorbid gout in an inpatient setting are limited. This thesis identified 
predictors of inpatient gout flare and developed a risk stratification tool for non-
specialist clinicians. The work done in this thesis is therefore relevant to the majority of 
hospital-based practicing clinicians regardless of their specialties and geographic 
locations. The items in the GOUT-36 prediction rule are specific to gout (gout 
medications, serum urate and tophus), but are not specific to any demographic 
subgroup (age, gender and ethnicity). This generalizability is desirable when 
developing a risk stratification tool for routine clinical practice. 
 It could be argued, however, that the GOUT-36 prediction rule was developed 
from a cohort based in New Zealand which has a high prevalence of gout and distinct 
population ethnic makeup of mostly European, Māori and Pacific people.(47) The high 
national prevalence coupled with the well-documented suboptimal gout management 
among Māori and Pacific people is relatively unique to New Zealand.(231) 
Consequently, there is a possibility that the GOUT-36 prediction rule may perform 
differently in another population, particularly people from a different country. To 
address this potential limitation, an external validation was conducted in Thailand, 
where the overwhelming majority of the population were Asian and the national 
prevalence of gout was much lower compared to New Zealand (less than 1% of the 
general population).(269) The performance characteristics of the GOUT-36 prediction 
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rule in the Thai cohort were comparable to those from the New Zealand cohort, which 
provided some reassurance for the prediction rule’s generalizability. Nevertheless, 
further independent validations are warranted to ensure consistent performance of the 
GOUT-36 prediction rule in populations with different gout prevalence, ethnicities and 
healthcare systems.  
6.5.2 Putting the knowledge into practice   
The thesis aimed to deepen the understanding of the risk of developing inpatient 
gout flare and subsequently proposed a practical solution. The inspiration for 
developing the thesis originated from frequent encounters with people experiencing 
inpatient gout flare during routine clinical practice. From a clinician’s perspective, a 
research that could bridge clinical knowledge to real-world practice using robust 
methodology is desirable. Practicality was one of the key priorities. In the first study to 
identify predictors of inpatient gout flare, the clinical knowledge-driven model was 
chosen for its performance and practical advantages, such as not requiring an additional 
blood test. In the third study, several candidate prediction rules were developed. The 
GOUT-36 prediction rule was subsequently chosen not only because it had the highest 
sensitivity but also because it was the most user-friendly candidate, that is, it had fewer 
items and did not require repeat assessment. On the other hand, the focus on sensitivity 
and practicality had led to a relatively low specificity for the GOUT-36 rule. This was 
an acceptable tradeoff. The consequences of misclassifying low-risk people as having 
high risk for gout flare does not seem harmful or costly, while missing out on high-risk 
people would have rendered the clinical tool less useful. For a clinician working in a 
busy hospital service, a fairly accurate and easy-to-use tool is more useful than a highly 
accurate tool that is too complicated to put into practice.  
6.5.3 Letting the best protocol win 
All three studies in this thesis explored more than one method in pursuit of their 
primary objectives and subsequently chose the most suitable method based on 
predetermined criteria. The selection criteria typically included both the performance 
indicators and practical consideration. The first study (Chapter 3) sought to identify a 
set of predictors of inpatient gout flare by exploring three statistical methods: the 
clinical knowledge-driven logistic regression, the LASSO procedure and the tree-based 
machine learning algorithm. The clinical knowledge-driven logistic regression model 
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eventually was selected because it had superior discrimination, calibration and 
practicality. There were four predictors that were selected across all three protocols (no 
pre-admission ULT, ULT adjustment, diuretic adjustment and pre-admission serum 
urate >0.36 mmol/L), suggesting robust results. The second study (Chapter 4) used two 
types of generalized linear model (the Poisson regression and the negative binomial 
model) to explore the relationship between gout flare-related variables and the hospital 
length of stay. The negative binomial model emerged as a better model according to the 
model’s goodness of fit. Nine out of the twelve variables from the negative binomial 
model were also selected by the Poisson regression model. In the last study (Chapter 5), 
the GOUT-36 prediction rule (the first-day rule) was chosen over two other candidates 
(the regression coefficient-based rule and the simple rule) for its high sensitivity and 
practical advantage.  
Exploring multiple methods could be considered one of the thesis’ strengths. 
This approach provided some evidence that the results were not derived erroneously or 
by chance, especially when there was substantial agreement between different methods. 
Using more than one protocol may also be necessary when performing analysis in areas 
where there is no well-established statistical protocol. Using more than one statistical 
method has been successfully applied in the development of the definition of gout 
flare,(256) as well as in the development of the ACR/EULAR classification criteria for 
gout.(76)  
6.5.4 Establishing the boundary of evidence 
 The understanding of the factors associated with the risk of inpatient gout flare 
has previously been based on clinical experience or clinical reasoning. Factors that 
could prime macrophages to a pro-inflammatory phenotype (e.g., acute illness) or 
factors that could alter serum urate level (e.g., diuretic adjustment, ULT withdrawal, 
acute kidney injury) have been speculated to play a role in the development of gout 
flare in hospital setting, but controlled studies to confirm such associations were 
limited.(1, 135) This gap in the knowledge means there are no evidence-based 
recommendations on how to assess the risk of inpatient gout flare, and how to prevent 
it. This thesis provided some scientific evidence in support of a set of predictors long 
suspected to be associated with inpatient gout flare. It is now clearer what is proven and 
what needs further exploration pertaining to the risk of inpatient gout flare. The 
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findings would also serve as a reference which future research could expand upon. 
Such expansion has already occurred where some of the predictors of inpatient gout 
flare were linked to hospital outcome and turned into a risk stratification tool for 
hospitalized people with comorbid gout. Major focus for future research may include an 
exploration of interventions (e.g., a course of in-admission gout prophylaxis 
medication) for the prevention of inpatient gout flare and whether these interventions 
lead to clinically meaningful hospital outcomes. 
6.6 Potential impact 
The identification of people at high risk for gout flare by the GOUT-36 
prediction rule could alert attending clinicians to the possibility of gout flare during the 
patients’ hospital stay. This may lead to further actions to prevent or mitigate effects of 
a gout flare. Examples of such actions could include close monitoring for early 
detection of flare, elimination of triggers of flare where possible (e.g., ensure 
continuation of existing ULT) or prescribing gout prophylaxis where appropriate. It is 
possible that the early risk stratification and the subsequent actions could potentially 
contribute to a lower rate of inpatient gout flare and better hospital outcomes for people 
with comorbid gout. The association between the risk of inpatient gout flare and the 
four predictors in the GOUT-36 prediction rule (pre-admission serum urate, tophus and 
pre-admission ULT and gout prophylaxis) suggests that improving pre-admission care 
for gout could also be a strategy to reduce the risk of inpatient gout flare in people with 
comorbid gout. 
However, these far-reaching impacts are only speculative and would require 
time and further research to substantiate. At a minimum, this thesis may draw more 
attention towards people with comorbid gout in the hospital setting. This is an 
understudied subgroup of people with gout, who have unique challenges compared to 
those in the outpatient or community setting. The thesis also clarifies a gap in the 
knowledge that needs further exploration regarding the risk factors that predict inpatient 




6.7 What are the next steps? 
There are several research questions prompted by this thesis (Table 6-2). The 
first priority is to further validate the GOUT-36 prediction rule by investigators not 
associated with the original studies. Validation in cohorts from community hospitals, in 
a different country would be ideal to confirm the prediction rule’s universality. The 
independent cohorts could be recruited prospectively or retrospectively, as long as 
sufficient patient data are available for review. 
For the prevention of inpatient gout flare, there are some issues that need to be 
explored further. There is currently no data in direct support of any intervention to 
prevent gout flare in the hospital setting. Low-dose colchicine appears to be the most 
suitable candidate due to its well-established safety and efficacy for gout flare 
prevention after initiation of ULT.(129, 266) It may not be necessary however to 
prescribe colchicine to every person with comorbid gout admitted to hospital due to 
contraindications or other treatment related factors such as no oral intake or acute 
illness leading to poor absorption. The GOUT-36 prediction rule may help guide this 
decision making by identifying high risk people who may benefit from prophylactic 
medications during their hospital stay.  
A pilot study to determine the benefit of GOUT-36-guided protocol to prevent 
inpatient gout flare may be feasible.  It is anticipated that the GOUT-36-guided 
protocol (in-admission gout prophylaxis for high-risk people) would result in a lower 
rate of inpatient gout flare, compared to the usual care (no intervention). The data from 
this thesis could provide some support to this hypothesis. If we undertake a post hoc 
analysis, using the New Zealand cohort (625 people), the people could be divided into 
high-risk (GOUT-36 score of two or more points) and low-risk group (GOUT-36 score 
of less than two points). The cohort could also be divided by treatment received. There 
were some people who had continued taking their existing gout prophylaxis 
medications throughout their hospital stay in the cohort. These people could be 
considered the treatment group (receiving prophylaxis during admission) and the rest 
could be considered the control group (no intervention). Twenty people who had in-
admission adjustment of gout prophylaxis medication were excluded. Using this set up, 
605 people were included in the post hoc analysis. The percentage of people who 
eventually developed inpatient gout flare were determined (Figure 6-2). Among the 
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high-risk people, none of the people who received prophylaxis during admission 
developed flare while 21% of those in the control group did. In the low-risk subgroup, 
one percent of people who received treatment and six percent of control group 
developed flare. The results suggest some benefit for the GOUT-36-guided protocol 
over the usual care, and therefore justify further exploration in a prospective, controlled 
study. A proposed design for the randomized controlled study is shown in Figure 6-3. 
The study would recruit hospitalized people with comorbid gout who are classified as 
high-risk by the GOUT-36 prediction rule. The rates of inpatient gout flare in the 
treatment group (receiving low-dose colchicine during admission) would be compared 
to the control group (receiving placebo). The results of such study may help inform 
clinicians on how to effectively and safely prevent inpatient gout flare in the hospital 
setting. 
Table 6-2 Potential future research questions 
Performance of the GOUT-36 prediction rule 
• What is the sensitivity and specificity of the GOUT-36 prediction rule in people 
with comorbid gout admitted to primary care facilities? 
Prevention of inpatient gout flare 
• Does low-dose colchicine during hospital admission lower the rates of inpatient 
gout flare in people with comorbid gout, compared to those receiving usual care? 
• Does low-dose colchicine treatment guided by GOUT-36 risk stratification lead 
to a lower rate of inpatient gout flare, compared to the usual care?   
Inpatient gout flare and hospital outcomes  
• Is the rate of inpatient gout flare associated with major hospital outcomes (e.g., 





Figure 6-2 Rates of inpatient gout flare  stratified by risk groups and treatment 




Figure 6-3 Hypothetical study design for testing the utility of the GOUT-36 




6.8 Concluding statement  
Inpatient gout flare is an important problem, but the factors associated with its 
risk have not been well understood. This thesis set out to identify the predictors of 
inpatient gout flare in people with comorbid gout, then explore the connection between 
these predictors and the hospital length of stay and eventually develop a simple clinical 
tool to identify high-risk individuals. Three separate studies were conducted in two 
countries: New Zealand and Thailand. Data were collected from a variety of sources, 
including a retrospective chart review from three hospitals in the Wellington Region, a 
population-based New Zealand national data collections and prospective patient 
recruitment from a hospital in Thailand. To answer the thesis’s questions, multiple 
statistical protocols were explored in pursuit of the most robust models, with highlights 
including the penalized logistic regression model, the machine learning algorithm and 
the generalized linear regression analysis. The wide range of methodologies allows 
results that were supported by rigorous statistical analysis, existing clinical knowledge 
and practical consideration.  
Nine predictors of inpatient gout flare and their associations with the hospital 
length of stay were reported in this thesis. The findings helped solidify the body of 
evidence pertaining to the risk of inpatient gout flare and its impact on the hospital 
outcome. The thesis also developed the first clinical tool (the GOUT-36 prediction rule) 
to help non-specialist clinicians identify people who were likely to experience gout 
flare during hospital stay. The GOUT-36 prediction rule is simple, intuitive and allows 
very early risk assessment. Most importantly, the GOUT-36 prediction rule performed 
consistently well across both the New Zealand and the Thai cohorts, a reassuring 
evidence of generalizability. It is anticipated that the knowledge and the clinical tool 
developed in this thesis would help streamline the assessment of people with comorbid 
gout admitted to hospitals. Better risk assessment may subsequently lead to actions to 
mitigate or prevent inpatient gout flare where appropriate. Future research could further 
explore which protocol is effective and safe to prevent inpatient gout flare in a 
randomized controlled trial. This thesis is the beginning of a journey towards a future 
where clinicians could easily and accurately identify people at risk of inpatient gout 
flare and people living with gout may not have to suffer from a painful flare emerging 
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Appendix A Study 1 
Appendix A.1 TRIPOD statement checklist 
Section/Topic Item  Checklist Item Chapter 
Title and abstract 
Title 1 D;V 
Identify the study as developing and/or validating a multivariable 
prediction model, the target population, and the outcome to be 
predicted. 
3.1 
Abstract 2 D;V 
Provide a summary of objectives, study design, setting, 
participants, sample size, predictors, outcome, statistical analysis, 






Explain the medical context (including whether diagnostic or 
prognostic) and rationale for developing or validating the 




Specify the objectives, including whether the study describes the 
development or validation of the model or both. 
3.4 
Methods 
Source of data 
4a D;V 
Describe the study design or source of data (e.g., randomized trial, 
cohort, or registry data), separately for the development and 
validation data sets, if applicable. 
3.5 
4b D;V 
Specify the key study dates, including start of accrual; end of 




Specify key elements of the study setting (e.g., primary care, 
secondary care, general population) including number and location 
of centres. 
3.7 
5b D;V Describe eligibility criteria for participants.  3.7 
5c D;V Give details of treatments received, if relevant.  NA 
Outcome 
6a D;V 
Clearly define the outcome that is predicted by the prediction 
model, including how and when assessed.  
3.9.2 
6b D;V 





Clearly define all predictors used in developing or validating the 




Report any actions to blind assessment of predictors for the 
outcome and other predictors.  
NA 
Sample size 8 D;V Explain how the study size was arrived at. 3.10.1 
Missing data 9 D;V 
Describe how missing data were handled (e.g., complete-case 
analysis, single imputation, multiple imputation) with details of any 





10a D Describe how predictors were handled in the analyses.  3.10.3 
10b D 
Specify type of model, all model-building procedures (including any 
predictor selection), and method for internal validation. 
3.10.3 
3.10.5 
10c V For validation, describe how the predictions were calculated.  3.10.5 
10d D;V 
Specify all measures used to assess model performance and, if 
relevant, to compare multiple models.  
3.10.4 
10e V 
Describe any model updating (e.g., recalibration) arising from the 
validation, if done. 
NA 




For validation, identify any differences from the development data 





Describe the flow of participants through the study, including the 
number of participants with and without the outcome and, if 




Describe the characteristics of the participants (basic 
demographics, clinical features, available predictors), including the 






For validation, show a comparison with the development data of the 










If done, report the unadjusted association between each candidate 





Present the full prediction model to allow predictions for individuals 
(i.e., all regression coefficients, and model intercept or baseline 
survival at a given time point). 
3.11.3 
15b D Explain how to use the prediction model. 3.12.7 
Model 
performance 
16 D;V Report performance measures (with CIs) for the prediction model.  3.11.4 
Model-updating 17 V 
If done, report the results from any model updating (i.e., model 
specification, model performance). 
NA 
Discussion 
Limitations 18 D;V 
Discuss any limitations of the study (such as non-representative 




For validation, discuss the results with reference to performance in 
the development data, and any other validation data.  
3.12.4 
19b D;V 
Give an overall interpretation of the results, considering objectives, 
l imitations, results from similar studies, and other relevant 
evidence.  
3.12.5 
Implications 20 D;V 
Discuss the potential clinical use of the model and implications for 






Provide information about the availabil ity of supplementary 




Give the source of funding and the role of the funders for the 
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Appendix B.4 List of medications and their formulation 
ID numbers 




Urate-lowering agents  
Allopurinol  1026 Tab 100 mg 102601 
  Tab 300 mg 102602 
Benzbromarone 3754 Tab 100 mg 375425 
 4003 Tab 100 mg 400325 
Febuxostat  4026 Tab 80 mg 402625 
  Tab 120 mg 402626 
Probenecid  2042 Tab 500 mg 204201 
Sulfinpyrazone  2206 Tab 100 mg 220601 
  Tab 200 mg 220602 
Gout prophylaxis  
Colchicine 1341 Tab 600 mcg 134101 
  Tab 500 mcg 134125 
Corticosteroids     
Prednisolone  2036 Tab 5 mg 203601 
Prednisone  2038 Tab 1 mg 203801 
  Tab 2.5 mg 203802 
  Tab 5 mg 203803 
  Tab 20 mg 203804 
  Tab 10 mg 203805 
  Tab 50 mg 203806 
Non-steroidal anti-inflammatory drugs  
Diclofenac  1401 Tab EC 25 mg 140101 
  Tab EC 50 mg 140102 
  Tab long-acting 75 mg 140103 
  Tab 50 mg dispersible 140111 
  Tab long-acting 100 mg 140112 
  Cap long-acting 100 mg 140113 
Diflunisal 1411 Tab 250 mg 141101 
  Tab 500 mg 141102 
Fenbufen  1489 450 mg 148901 
Fenoprofen  1490 Cap 300 mg 149001 
  Cap 600 mg 149002 
Flurbiprofen 1536 Tab 50 mg 153601 
  Tab 100 mg 153602 
  Cap long-acting 200 mg 153603 
Ibuprofen  2798 Tab 200 mg 279801 
  Tab 400 mg 279802 
  Tab 600 mg 279803 
  Tab long-acting 800 mg 279804 
Indomethacin  1645 Cap 25 mg 164501 
  Cap 50 mg 164502 
  Cap long-acting 75 mg 164503 
Ketoprofen 1697 Cap 50 mg 169701 
  Cap and tab long-acting 100 mg 169702 
  Cap long-acting 200 mg 169703 
  Tab EC 100 mg 169706 
232 
 




  Cap 100 mg 169707 
  Cap long-acting 100 mg 169708 
Mefenamic acid 1769 Cap 250 mg 176901 
Naproxen  2783 Tab 275 mg 278301 
  Tab 550 mg 278302 
 2782 Tab long-acting 750 mg 278205 
  Tab long-acting 1 gm 278206 
  Tab 250 mg 278209 
  Tab EC 250 mg 278210 
  Tab 500 mg 278211 
  Tab EC 500 mg 278212 
Sulindac 2193 Tab 100 mg 219301 
  Tab 200 mg 219302 
Tiaprofenic acid 2537 Tab 200 mg 253701 
  Tab 300 mg 253702 
  Cap long-acting 300 mg 253703 
Tenoxicam 2536 Tab 20 mg 253601 
Phenylbutazone  2494 Tab 100 mg 249401 
Piroxicam 1996 Tab dispersible 10 mg 199604 
  Cap 10 mg 199605 
  Tab dispersible 20 mg 199606 
  Cap 20 mg 199607 
Celecoxib  1271 Cap 100 mg 127101 
  Cap 200 mg 127102 
 4081 Cap 100 mg 408125 
  Cap 200 mg 408126 
Aspirin 1087 Tab dispersible 300 mg 108701 
  Tab 300 mg 108702 
  Tab EC 300 mg 108705 
  Tab 100 mg 108725 
Warfarin 2331 Tab 1 mg 233101 
  Tab 2 mg 233103 
  Tab 2.5 mg 233104 
  Tab 3 mg 233105 
  Tab 5 mg 233106 
Cyclosporine 2421 Cap 100 mg 242101 
  Cap 25 mg 242102 
  Cap 50 mg 242125 
Diuretics  
Loop diuretics    
Bumetanide 1171 Tab 1 mg 117101 
Furosemide  1544 Tab 40 mg 154401 
  Tab 500 mg 154402 
Thiazide diuretics    
Bendroflumethiazide 1116 Tab 2.5 mg 111601 
  Tab 5 mg 111602 
Chlorothiazide 1282 Tab 500 mg 128201 
Chlortalidone 1290 Tab 25 mg 129001 
Cyclopenthiazide 1367 Tab 0.5 mg 136701 
Indapamide 1643 Tab 2.5 mg 164301 
Methyclothiazide 1801 Tab 5 mg 180101 
Metolazone 4006 Tab 5 mg 400625 
Acebutolol with HCTZ 1005 Tab 200 mg with HCTZ 12.5 mg 100501 
Atenolol with 
chlorthalidone 









  Tab 50 mg with chlorthalidone 12.5 
mg 
109502 
Captopril with HCTZ 2840 Tab 25 mg with HCTZ 15 mg 284001 
  Tab 50 mg with HCTZ 25 mg 284002 
Cilazapril with HCTZ 1127 Tab 5 mg with HCTZ 12.5 mg 112701 
Enalapril with HCTZ 2708 Tab 20 mg with HCTZ 12.5 mg 270804 
Lisinopril with HCTZ 2795 Tab 20 mg with HCTZ 12.5 mg 279501 
Losartan with HCTZ 1068 Tab 50 mg with HCTZ 12.5 mg 106805 
Pindolol with clopamide 1989 Tab 10 mg with clopamide 5 mg 198901 
Quinapril with HCTZ 3749 Tab 10 mg with HCTZ 12.5 mg 374925 
  Tab 20 mg with HCTZ 12.5 mg 374926 
Potassium-sparing 
diuretics 
   
Amiloride 1050 Tab 5 mg 105001 
Spironolactone  2176 Tab 25 mg 217601 
  Tab 100 mg 217602 
Combined diuretics    
Amiloride with 
furosemide 
1051 Tab 5 mg with furosemide 40 mg 105101 
Amiloride with HCTZ 1053 Tab 5 mg with HCTZ 50 mg 105301 
Triamterene with HCTZ 2293 Tab 50 mg with HCTZ 25 mg 229301 
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Appendix C.3 Participant information sheet and 
consent form (Thai cohort) 
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